{"meta":{"query_hash":"367383d69e73","filters":{"venue":"Rheumatology and Therapy"},"cohort_total":122,"direct_labels_cover":0,"predictions_cover":122,"exported":122,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/367383d69e73","api":"https://metacan.xera.ac/api/v1/cohort?venue=Rheumatology+and+Therapy"},"results":[{"id":"W1613595294","doi":"10.1007/s40744-015-0016-9","title":"Rituximab for Rheumatoid Arthritis","year":2015,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Rituximab; Medicine; Hypogammaglobulinemia; Rheumatoid arthritis; Immunology; CD20; Progressive multifocal leukoencephalopathy; Methotrexate; Internal medicine; Lymphoma; Antibody; Virus","score_opus":0.061234917719439105,"score_gpt":0.3640471296806705,"score_spread":0.30281221196123137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1613595294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022699688,0.9961009,0.000069353104,0.00019449457,0.0003491734,0.002421605,0.00011892646,0.00016786357,0.00035066213],"genre_scores_gemma":[0.000059963008,0.99760723,0.00055612443,0.00007681192,0.000046529218,0.00094590185,0.000375188,0.00014104415,0.00019120368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717635,0.00023962221,0.00086995086,0.00069492456,0.0002766162,0.0007425576],"domain_scores_gemma":[0.9979935,0.0004866957,0.0002865483,0.0005457423,0.00022869497,0.00045879386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007033074,0.00064232777,0.00443088,0.00037351248,0.0002491571,0.00007139953,0.0002138188,0.00073343405,0.00018577525],"category_scores_gemma":[0.00017761848,0.0004907286,0.0005961015,0.00020414598,0.000483608,0.00010699105,0.00006470876,0.00056741724,0.00018422655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025745798,0.00022548954,0.00004232378,0.0027008266,0.0007358991,0.000036810667,0.000110400135,3.99373e-9,2.4937052e-7,0.004512089,0.0054585747,0.9859199],"study_design_scores_gemma":[0.008078797,0.00069242326,0.0000017114588,0.012715216,0.000011930006,0.006824269,0.000032065214,0.0000045405955,0.0000016192834,0.0026859583,0.9685294,0.00042204524],"about_ca_topic_score_codex":0.000027683926,"about_ca_topic_score_gemma":0.000008709798,"teacher_disagreement_score":0.98549783,"about_ca_system_score_codex":0.000045651133,"about_ca_system_score_gemma":0.00083364034,"threshold_uncertainty_score":0.9997544},"labels":[],"label_agreement":null},{"id":"W2307013176","doi":"10.1007/s40744-016-0025-3","title":"Chronic Diarrhea Associated with High Teriflunomide Blood Concentration","year":2016,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Teriflunomide; Diarrhea; Medicine; Chronic diarrhea; Internal medicine; Immunology; Multiple sclerosis","score_opus":0.008282392623788482,"score_gpt":0.2362358797215604,"score_spread":0.2279534870977719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307013176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801225,0.015899079,0.00010917137,0.0032514664,0.000057696532,0.00027981368,0.00000929699,0.000087583205,0.0001834002],"genre_scores_gemma":[0.8904136,0.10919338,0.00003778295,0.00010004015,0.00001872327,0.00003792718,0.000016278125,0.000018148425,0.00016415326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999006,0.00010444114,0.00018296237,0.00023342328,0.00013019213,0.00034302857],"domain_scores_gemma":[0.9993575,0.00020450873,0.00006996353,0.00016754099,0.00006862891,0.00013184581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001497335,0.00014416488,0.00033093803,0.000045193094,0.00012773882,0.00001815631,0.000051598763,0.00011448084,0.00036016927],"category_scores_gemma":[0.00006547199,0.00008000825,0.000032699998,0.00007220258,0.00038290283,0.00011768542,0.00001024091,0.00010137181,0.000022995027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017199132,0.0003094525,0.7541995,0.000025141771,0.0010941023,0.00012547761,0.00038489027,1.8749694e-7,0.07162668,0.018119311,0.000280884,0.15211444],"study_design_scores_gemma":[0.090498306,0.010402441,0.7114651,0.002839694,0.000030415966,0.003170744,0.00008066255,0.00003962227,0.14962585,0.0071155024,0.023807567,0.0009240619],"about_ca_topic_score_codex":0.000044964763,"about_ca_topic_score_gemma":0.000044923905,"teacher_disagreement_score":0.15119037,"about_ca_system_score_codex":0.000026025478,"about_ca_system_score_gemma":0.0001468699,"threshold_uncertainty_score":0.3943601},"labels":[],"label_agreement":null},{"id":"W2470479127","doi":"10.1007/s40744-016-0036-0","title":"Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil","year":2016,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Division of Graduate Education; Fundação de Amparo à Pesquisa do Estado de Minas Gerais; Universidade Federal de Minas Gerais; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Adalimumab; Etanercept; Ankylosing spondylitis; Infliximab; Cohort; Retrospective cohort study; Internal medicine; Population; Physical therapy; Disease; Rheumatoid arthritis; Environmental health","score_opus":0.006255116176306747,"score_gpt":0.24056880872538436,"score_spread":0.2343136925490776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470479127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324316,0.005654681,0.0000021843239,0.0005012173,0.00004776707,0.00033046698,0.00002808222,0.000010649056,0.00018176797],"genre_scores_gemma":[0.985828,0.013928431,0.000051303945,0.00011425743,0.0000024386086,0.000020335963,0.000013190673,0.000012597633,0.000029479703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992392,0.00005665306,0.0002158875,0.0001959555,0.00008731015,0.0002049945],"domain_scores_gemma":[0.99961036,0.00011466804,0.00006505257,0.00013294327,0.000039225753,0.000037728943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083664505,0.0001262855,0.0004049702,0.00012640149,0.000030318954,0.0000022469217,0.000030915304,0.000062387975,0.00011544737],"category_scores_gemma":[0.000012101549,0.00007167072,0.000024309173,0.00012308042,0.0001603606,0.000058266585,0.000010514385,0.00005640729,0.0000023896096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033844763,0.0003881073,0.88133603,0.0000070662154,0.00006760806,0.00002723983,0.0004202833,2.3746198e-8,0.0000521782,0.0005297174,0.000016293428,0.113771],"study_design_scores_gemma":[0.031643983,0.0009229261,0.9653752,0.0005023592,0.0000028046272,0.000028653372,0.000055753655,4.0227062e-7,0.000495863,0.00025511812,0.0006345347,0.00008239462],"about_ca_topic_score_codex":0.00029772715,"about_ca_topic_score_gemma":0.0002325904,"teacher_disagreement_score":0.1136886,"about_ca_system_score_codex":0.00003022739,"about_ca_system_score_gemma":0.000024118302,"threshold_uncertainty_score":0.29226473},"labels":[],"label_agreement":null},{"id":"W2513381414","doi":"10.1007/s40744-016-0041-3","title":"Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis","year":2016,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Tolerability; Visual analogue scale; Randomized controlled trial; McGill Pain Questionnaire; Injection site; Crossover study; Anesthesia; Surgery; Adverse effect; Placebo; Internal medicine","score_opus":0.011321142352978927,"score_gpt":0.2703180193316968,"score_spread":0.25899687697871787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513381414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232703,0.0047598733,0.0015991005,0.0002360386,0.000027952805,0.0009306718,0.000021480204,0.000028519838,0.0000693023],"genre_scores_gemma":[0.966162,0.0332568,0.00040857156,0.000025541734,0.0000021879162,0.00006839279,0.00002196179,0.000024665063,0.000029859717],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99816287,0.0003540275,0.0006517601,0.00024808946,0.00028648452,0.00029679947],"domain_scores_gemma":[0.99833405,0.00079426914,0.00031250098,0.00023905946,0.00022972026,0.0000904276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058343704,0.00020090037,0.001202168,0.00026414506,0.00008921034,0.00000998736,0.000059779202,0.00012855824,0.00018821443],"category_scores_gemma":[0.00020657077,0.00010208329,0.00006966179,0.00023361259,0.00076011935,0.00019918192,0.00001637117,0.00013204972,0.0000026484804],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28615114,0.00047110996,0.6709291,0.00003851294,0.00025692742,0.0000027441995,0.001199389,0.0000026918356,0.00017201905,0.0015693901,0.000030571515,0.03917645],"study_design_scores_gemma":[0.7740132,0.006034052,0.21160848,0.003231306,0.0000054209777,0.00012473033,0.00026828944,0.00024393667,0.0021493596,0.0014070597,0.00060821127,0.00030589502],"about_ca_topic_score_codex":0.00029123604,"about_ca_topic_score_gemma":0.00057265285,"teacher_disagreement_score":0.4878621,"about_ca_system_score_codex":0.000018754661,"about_ca_system_score_gemma":0.00012413666,"threshold_uncertainty_score":0.41628358},"labels":[],"label_agreement":null},{"id":"W2754119638","doi":"10.1007/s40744-017-0079-x","title":"Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment","year":2017,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Amgen (Canada); Centre hospitalier universitaire de Québec","funders":"Amgen","keywords":"Adalimumab; Medicine; Etanercept; Rheumatoid arthritis; Internal medicine; Clinical endpoint; Rheumatology; Adverse effect; Confidence interval; Clinical trial","score_opus":0.016428371575907753,"score_gpt":0.2667307663602153,"score_spread":0.25030239478430755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754119638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951624,0.002303869,0.000011232187,0.0005284243,0.00006000293,0.001550834,0.000019429903,0.000035180266,0.00032860698],"genre_scores_gemma":[0.9409886,0.05857937,0.000109302084,0.00006525261,0.0000041195694,0.00015212581,0.0000151222075,0.000037729755,0.000048371054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810606,0.00016015934,0.00047617801,0.0004841206,0.0003086882,0.000464769],"domain_scores_gemma":[0.9985515,0.00009204736,0.00020216045,0.00069118623,0.00023341212,0.00022970747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013282157,0.0003230729,0.0010353619,0.00022407908,0.00034973124,0.000074031115,0.00017737356,0.00012755903,0.00011570952],"category_scores_gemma":[0.000075616,0.00023329986,0.000057276407,0.0000937043,0.00025575145,0.00020586477,0.00005379747,0.00017203938,0.00001127635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009138177,0.005111339,0.8156625,0.000018170584,0.00039357843,0.0000728039,0.0074887555,0.000008156902,0.00008365144,0.00029811746,0.000029705943,0.16169505],"study_design_scores_gemma":[0.118295416,0.038116872,0.8341572,0.0017980428,0.0000058168775,0.00027318436,0.0032547833,0.00014710342,0.0017186556,0.00048992346,0.0010988839,0.0006441151],"about_ca_topic_score_codex":0.0016460577,"about_ca_topic_score_gemma":0.0036465388,"teacher_disagreement_score":0.16105093,"about_ca_system_score_codex":0.00004542779,"about_ca_system_score_gemma":0.00009167744,"threshold_uncertainty_score":0.9513692},"labels":[],"label_agreement":null},{"id":"W2757516511","doi":"10.1007/s40744-017-0080-4","title":"Chronic Disease and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment","year":2017,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Antibiotic Use and Resistance","field":"Immunology and Microbiology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"UCB Pharma","keywords":"Medicine; Context (archaeology); Empowerment; Health care; Patient experience; Nursing","score_opus":0.011672039111155144,"score_gpt":0.25060873445333554,"score_spread":0.2389366953421804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757516511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94052744,0.057616904,0.000008006831,0.001330228,0.0002555428,0.00016661754,0.0000019433737,0.000040749932,0.000052555253],"genre_scores_gemma":[0.9636744,0.03605438,0.000017969991,0.000048620943,0.000009111424,0.000032589218,0.000003536465,0.0000059126323,0.00015344976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993896,0.00008522048,0.00012330324,0.00022009319,0.00001491925,0.00016688813],"domain_scores_gemma":[0.9994668,0.00004823195,0.000100245554,0.00033725216,0.000014892512,0.000032571883],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00003848775,0.00012319424,0.0001468651,0.000031946398,0.0021948903,0.000030451569,0.00010814133,0.00010430473,0.00003060548],"category_scores_gemma":[0.0000143267725,0.00007428172,0.00003464931,0.00002681514,0.001067123,0.00007893922,0.00004047258,0.00009566973,0.000010493411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031461765,0.0002744501,0.8954242,0.00007362936,0.00083929405,0.000021408634,0.042365495,0.000003178513,0.0147987725,0.009442013,0.000072470604,0.03637051],"study_design_scores_gemma":[0.0044423747,0.0009165541,0.9234342,0.00018557366,0.00008270826,0.00043644835,0.0021754291,0.000022320533,0.027147489,0.0034324464,0.037262406,0.00046207377],"about_ca_topic_score_codex":0.00027412866,"about_ca_topic_score_gemma":0.00013343192,"teacher_disagreement_score":0.040190063,"about_ca_system_score_codex":0.000013570496,"about_ca_system_score_gemma":0.00004113906,"threshold_uncertainty_score":0.99910414},"labels":[],"label_agreement":null},{"id":"W2765105454","doi":"10.1007/s40744-017-0087-x","title":"A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States","year":2017,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Retrospective cohort study; Internal medicine; Medical record; Dermatomyositis; Rheumatoid arthritis; Polymyositis; Psoriatic arthritis; Cohort; Rheumatology; Systemic lupus erythematosus; Physical therapy; Disease","score_opus":0.016613590251796057,"score_gpt":0.2747546394899367,"score_spread":0.2581410492381407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765105454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884157,0.009939751,0.00005030288,0.00093444344,0.00002634175,0.00057306286,0.000012737225,0.000026439646,0.000021213955],"genre_scores_gemma":[0.681328,0.31826764,0.000004328235,0.00023300253,0.00000202925,0.00003497197,0.000115731615,0.000010440709,0.0000038636203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979084,0.000565036,0.00038672105,0.00027547046,0.0006342048,0.00023016242],"domain_scores_gemma":[0.99852943,0.00040082616,0.0003702371,0.0003317347,0.00020893423,0.00015883333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033975448,0.00016761562,0.00055662676,0.00012036049,0.0003034359,0.000045809116,0.00014909841,0.00015795465,0.000050115417],"category_scores_gemma":[0.00183997,0.000091562484,0.000029550249,0.00014647211,0.0010617324,0.00016871233,0.00003826208,0.0003348673,1.9548982e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092988077,0.00033585235,0.9916646,0.00022294413,0.00016776033,0.00008122568,0.00043395543,1.3370376e-7,2.4921343e-7,0.00018568823,0.00008264103,0.005895092],"study_design_scores_gemma":[0.004457001,0.0013085229,0.9809865,0.01223442,0.000009700627,0.00026095938,0.00017222129,0.00020394377,0.000004059786,0.0001076807,0.00015341694,0.00010160711],"about_ca_topic_score_codex":0.0015863484,"about_ca_topic_score_gemma":0.00077352894,"teacher_disagreement_score":0.30832788,"about_ca_system_score_codex":0.000021629645,"about_ca_system_score_gemma":0.00010125536,"threshold_uncertainty_score":0.39119974},"labels":[],"label_agreement":null},{"id":"W2796965324","doi":"10.1007/s40744-018-0109-3","title":"Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Southlake Regional Health Center; ABB (Canada); University of Toronto; St. Michael's Hospital; Université Laval","funders":"European League Against Rheumatism; AbbVie","keywords":"Ankylosing spondylitis; Adalimumab; Medicine; Spondylitis; Physical therapy; Internal medicine; Disease","score_opus":0.047056853314772704,"score_gpt":0.38990517998430324,"score_spread":0.3428483266695305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796965324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719745,0.00047523528,1.3115006e-7,0.00056906533,0.00029104136,0.0011507145,0.00014081608,0.000019903484,0.00015564726],"genre_scores_gemma":[0.99911076,0.0005850162,0.000021541126,0.00018289515,0.00001748318,0.0000330902,0.000030114092,0.0000100193165,0.000009068403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856156,0.00030046696,0.0005312315,0.0002626043,0.0001445932,0.00019953765],"domain_scores_gemma":[0.9988014,0.0005375205,0.00017704454,0.00038922846,0.000054025582,0.000040797408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002728251,0.00015384269,0.000525359,0.00002916268,0.00015166731,0.000008018051,0.00008189622,0.00008229016,0.000056864912],"category_scores_gemma":[0.000118301534,0.00006830352,0.0001488845,0.000105580606,0.00036457754,0.00002083438,0.00004759828,0.00017357475,0.0000052398805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040891976,0.003309641,0.94094,0.0000011675866,0.0005468793,0.000020248819,0.0029135575,1.2672864e-7,0.0000018313451,0.00004050737,0.0001556654,0.047981165],"study_design_scores_gemma":[0.013670669,0.012605378,0.9720837,0.00009076702,0.000028375842,0.000034291817,0.0007522902,0.000006511998,0.000015360596,0.00010804256,0.0005461164,0.000058534366],"about_ca_topic_score_codex":0.0019501937,"about_ca_topic_score_gemma":0.0005186952,"teacher_disagreement_score":0.04792263,"about_ca_system_score_codex":0.000021806227,"about_ca_system_score_gemma":0.00004986811,"threshold_uncertainty_score":0.29481223},"labels":[],"label_agreement":null},{"id":"W2897834691","doi":"10.1007/s40744-018-0129-z","title":"Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Gilead Sciences; Momenta Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Horizon Pharma; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ankylosing spondylitis; Discontinuation; Psoriatic arthritis; Internal medicine; BASDAI; Observational study; Adverse effect; Psoriasis; Physical therapy; Rheumatoid arthritis; Dermatology","score_opus":0.03990032350989552,"score_gpt":0.2904200426353766,"score_spread":0.25051971912548104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897834691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808294,0.0003857815,0.000008944968,0.00045782494,0.00013438238,0.0006971584,0.00019784055,0.000023315244,0.000011821199],"genre_scores_gemma":[0.99887884,0.000034062865,0.00015081682,0.00042536733,0.000040478124,0.000058598565,0.00038608044,0.000015286834,0.000010459845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990542,0.0001026576,0.00021878608,0.00028997826,0.00015824378,0.00017614514],"domain_scores_gemma":[0.99938834,0.00013009658,0.000107877815,0.00022793487,0.000098290846,0.00004745496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000073646974,0.0001598691,0.00029533746,0.000034866225,0.00022970623,0.000024994042,0.000052098432,0.000050972543,0.00014111043],"category_scores_gemma":[0.000032957945,0.000095176365,0.000023474213,0.00010699274,0.00021728611,0.00011099518,0.000013806237,0.00009726604,0.000003210188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002968713,0.0011313614,0.9910328,0.0000023238863,0.00009409917,0.000011371379,0.001165964,1.5707268e-7,0.000016367285,0.00004479499,0.000032747757,0.0034993137],"study_design_scores_gemma":[0.013155586,0.002781256,0.98294294,0.000119565375,0.000020192336,0.0000048660872,0.00037133152,0.00003378563,0.000078103985,0.00007857345,0.00031540383,0.00009841762],"about_ca_topic_score_codex":0.001013607,"about_ca_topic_score_gemma":0.0011909789,"teacher_disagreement_score":0.010186873,"about_ca_system_score_codex":0.000027863716,"about_ca_system_score_gemma":0.000063029154,"threshold_uncertainty_score":0.38811797},"labels":[],"label_agreement":null},{"id":"W2898156360","doi":"10.1007/s40744-018-0130-6","title":"Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; University of British Columbia; Roche (Canada); William Osler Health System; Université de Montréal","funders":"F. Hoffmann-La Roche","keywords":"Tocilizumab; Medicine; Rheumatoid arthritis; Internal medicine; Adverse effect; Observational study; Combination therapy; Clinical endpoint; Surgery; Clinical trial","score_opus":0.041763053982573115,"score_gpt":0.292740038678264,"score_spread":0.25097698469569085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898156360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973552,0.000980019,0.0000028574486,0.00037573674,0.000109646186,0.0008774279,0.00014130182,0.000027768272,0.0001300227],"genre_scores_gemma":[0.9870832,0.012035524,0.0001823854,0.0001265612,0.000011474103,0.00007908763,0.00041437143,0.000028023807,0.000039376362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975482,0.00030075756,0.000723881,0.0005508309,0.00043594564,0.00044038994],"domain_scores_gemma":[0.9987819,0.00031150196,0.00014862801,0.00038105782,0.00019306791,0.00018383066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032554005,0.0002453618,0.00063191983,0.0002609643,0.00014056155,0.000044172502,0.00013205342,0.000075840035,0.00025061308],"category_scores_gemma":[0.00010625841,0.00020540236,0.000033626187,0.00025905645,0.00024333161,0.00038791227,0.00003713738,0.00028532074,0.000006356762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010864593,0.0011673098,0.9759956,0.0000034878956,0.00014177254,0.00008136271,0.0010607803,0.0000019131037,0.000004341405,0.00045577114,0.00022646236,0.009996623],"study_design_scores_gemma":[0.034324408,0.002254823,0.96106464,0.0004889981,6.958184e-7,0.000016312413,0.00042344848,0.00011744657,0.000020814474,0.00037066286,0.00072012976,0.00019760209],"about_ca_topic_score_codex":0.88524795,"about_ca_topic_score_gemma":0.99411,"teacher_disagreement_score":0.10886203,"about_ca_system_score_codex":0.00018227327,"about_ca_system_score_gemma":0.0008258942,"threshold_uncertainty_score":0.83760655},"labels":[],"label_agreement":null},{"id":"W2899718933","doi":"10.1007/s40744-018-0131-5","title":"Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies","year":2018,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Psoriatic arthritis; Internal medicine; Dactylitis; Placebo; Enthesitis; Clinical endpoint; Psoriasis; Rheumatology; Psoriasis Area and Severity Index; Arthritis; Rheumatoid arthritis; Dermatology; Surgery; Gastroenterology; Randomized controlled trial; Pathology","score_opus":0.040418028691758666,"score_gpt":0.3785333373867725,"score_spread":0.3381153086950138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899718933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8966715,0.10236827,0.00005866162,0.00017552232,0.000098888326,0.0005034075,0.000095054835,0.0000066103917,0.000022131966],"genre_scores_gemma":[0.8886074,0.111085586,0.00016399959,0.000020973046,0.000011899964,0.0000678542,0.000018577006,0.0000060680995,0.000017673852],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992426,0.000034522454,0.0003728338,0.00014956905,0.00007041022,0.00013005803],"domain_scores_gemma":[0.99875647,0.00062626076,0.00020740496,0.00021063088,0.00017438839,0.00002485422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008609194,0.00012324232,0.0009735426,0.00011015554,0.00009200868,0.0000011796994,0.000033016182,0.00003901856,0.000057981095],"category_scores_gemma":[0.000046041037,0.00007075725,0.00022275953,0.00021363694,0.00052777136,0.000012673237,0.0000071049676,0.000016570959,5.0571094e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008748585,0.004837179,0.10935165,0.00009355065,0.08704693,0.000008200333,0.0119911665,0.000002422903,0.0009486875,0.004708557,0.00006902158,0.772194],"study_design_scores_gemma":[0.53078455,0.08873178,0.18608041,0.0011847931,0.03432922,0.00020404044,0.010257231,0.0011595376,0.12913272,0.0044344007,0.013012856,0.00068844314],"about_ca_topic_score_codex":0.00009080029,"about_ca_topic_score_gemma":0.00009231286,"teacher_disagreement_score":0.7715056,"about_ca_system_score_codex":0.0000080450345,"about_ca_system_score_gemma":0.000020012498,"threshold_uncertainty_score":0.28853968},"labels":[],"label_agreement":null},{"id":"W2912852188","doi":"10.1007/s40744-019-0145-7","title":"An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiography; Osteoarthritis; Rheumatology; Physical therapy; Internal medicine; Interphalangeal Joint; Radiological weapon; Grip strength; Radiology; Surgery; Pathology","score_opus":0.010712757509467468,"score_gpt":0.29100130488664755,"score_spread":0.28028854737718006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912852188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963886,0.0028394018,0.00012241094,0.000041715848,0.00013818688,0.0003810151,0.000018807197,0.000012303824,0.000057532434],"genre_scores_gemma":[0.9959605,0.0032809325,0.0006193767,0.00005098789,0.0000054968073,0.000012042926,0.000044031378,0.000009093609,0.000017589124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928004,0.000084020445,0.00024618846,0.00019830339,0.000097968434,0.000093498245],"domain_scores_gemma":[0.99945945,0.00010450017,0.00013073476,0.00013525761,0.00010579248,0.00006426685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019383464,0.000101417114,0.00041100947,0.00008679698,0.00005333501,0.0000057693182,0.00001875924,0.00014071763,0.000065295244],"category_scores_gemma":[0.0000053019266,0.00007965821,0.00003456276,0.00009219276,0.00029838123,0.0001023962,0.000005975617,0.000110649205,7.934769e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096744613,0.00020934967,0.9765838,0.00004502898,0.0000975182,0.000003837154,0.00015721096,6.2182136e-7,0.009587515,0.0022150667,0.000007023827,0.0101255765],"study_design_scores_gemma":[0.01618014,0.013348627,0.96501434,0.00027405442,0.000059211146,0.00018465577,0.00023572889,0.00007042686,0.004080835,0.00030352606,0.00013818231,0.00011027957],"about_ca_topic_score_codex":0.000008797783,"about_ca_topic_score_gemma":0.000010744373,"teacher_disagreement_score":0.015212695,"about_ca_system_score_codex":0.0000036880747,"about_ca_system_score_gemma":0.00008188903,"threshold_uncertainty_score":0.32483676},"labels":[],"label_agreement":null},{"id":"W2913202798","doi":"10.1007/s40744-019-0140-z","title":"Safety and Efficacy of Repeat Administration of Triamcinolone Acetonide Extended-release in Osteoarthritis of the Knee: A Phase 3b, Open-label Study","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Sanofi; Musculoskeletal Transplant Foundation","keywords":"Medicine; Osteoarthritis; WOMAC; Triamcinolone acetonide; Adverse effect; Dosing; Clinical trial; Quality of life (healthcare); Surgery; Anesthesia; Internal medicine","score_opus":0.0210760317936827,"score_gpt":0.31563577953656363,"score_spread":0.2945597477428809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913202798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930565,0.004386377,0.0000023598627,0.00017312879,0.00009265206,0.00211251,0.000018455341,0.00000653396,0.00015150284],"genre_scores_gemma":[0.9976192,0.002103497,0.00008016021,0.000021869711,0.000002291139,0.000023736426,0.000011080851,0.000010340907,0.0001278385],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998878,0.00016431039,0.000499194,0.0002259945,0.00010546234,0.00012701198],"domain_scores_gemma":[0.9991784,0.0001573832,0.0002518405,0.0003218961,0.00004793753,0.000042534368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002652,0.00012984159,0.0006801382,0.00007768299,0.000034273453,0.0000040736436,0.00007969815,0.000105337385,0.000042070988],"category_scores_gemma":[0.000051387826,0.00009237825,0.000035620793,0.00012715207,0.0001424507,0.00006738159,0.00004995256,0.000102868245,8.830762e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070621476,0.016319357,0.24439098,0.0002189506,0.00032074287,0.00007442379,0.0043757693,3.1724693e-7,0.099325515,0.0057963138,0.0000068980453,0.5585493],"study_design_scores_gemma":[0.5858706,0.090222135,0.16610457,0.0013411922,0.000192936,0.00082617404,0.0025873063,0.00003362676,0.15156882,0.00078634534,0.00017355179,0.0002926913],"about_ca_topic_score_codex":0.00006814707,"about_ca_topic_score_gemma":0.00009006516,"teacher_disagreement_score":0.55825657,"about_ca_system_score_codex":0.0000070223214,"about_ca_system_score_gemma":0.00009539028,"threshold_uncertainty_score":0.37670758},"labels":[],"label_agreement":null},{"id":"W2920976889","doi":"10.1007/s40744-019-0150-x","title":"Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"European League Against Rheumatism; F. Hoffmann-La Roche; Bristol-Myers Squibb","keywords":"Medicine; Tocilizumab; Discontinuation; Adverse effect; Rheumatoid arthritis; Internal medicine; Incidence (geometry); Biologic Agents","score_opus":0.026683295699599048,"score_gpt":0.29622415566303195,"score_spread":0.2695408599634329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920976889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877952,0.01091381,0.00004473013,0.00007757357,0.000049395443,0.00064609153,0.00045362252,0.000009042205,0.000010583199],"genre_scores_gemma":[0.93117654,0.06840479,0.00020276374,0.000011867537,0.0000020856432,0.000027399885,0.00015296166,0.000012429196,0.000009147137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851894,0.0001840902,0.0005126579,0.00030931822,0.00028531346,0.00018967502],"domain_scores_gemma":[0.99857455,0.0007266215,0.00019220215,0.00014624585,0.00030549255,0.000054908884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036378877,0.00016872444,0.0007123967,0.00015786885,0.000043547414,0.000008145467,0.00005440462,0.000095079144,0.000045251036],"category_scores_gemma":[0.00014972963,0.00013033157,0.000057445504,0.00008304138,0.00027070087,0.00016752332,0.00004323457,0.00015589038,0.0000022305362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01571479,0.00040828923,0.97215116,0.00012672898,0.00054145616,0.000004694592,0.00092320185,0.000005218781,0.00012237157,0.00048350947,0.000008200521,0.0095103625],"study_design_scores_gemma":[0.046549466,0.0013899062,0.9476327,0.0031293833,0.000001160066,0.000029509063,0.00021691852,0.00007840686,0.00033553375,0.00043748776,0.00008878442,0.00011074638],"about_ca_topic_score_codex":0.00055610255,"about_ca_topic_score_gemma":0.00026989536,"teacher_disagreement_score":0.05749098,"about_ca_system_score_codex":0.000021337639,"about_ca_system_score_gemma":0.00008471277,"threshold_uncertainty_score":0.53147674},"labels":[],"label_agreement":null},{"id":"W2922151066","doi":"10.1007/s40744-019-0149-3","title":"Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Momenta Pharmaceuticals; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Genentech; Horizon Pharma; Celgene; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Abatacept; Internal medicine; Rheumatoid arthritis; Cohort; Etanercept; Propensity score matching; Rheumatology; Serostatus; Rheumatoid factor; Oncology; Physical therapy; Immunology; Rituximab; Human immunodeficiency virus (HIV)","score_opus":0.010808186754837322,"score_gpt":0.2590551601920899,"score_spread":0.24824697343725258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922151066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930662,0.005187783,0.0000042609977,0.000115965806,0.00009745763,0.0013359329,0.00010431191,0.000019123741,0.00006897542],"genre_scores_gemma":[0.962481,0.03717245,0.000011915871,0.00005050707,0.000001940796,0.000057461875,0.00019991554,0.000021651686,0.000003134278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978214,0.00070761115,0.00039174332,0.00036834148,0.00030938446,0.00040155102],"domain_scores_gemma":[0.9979766,0.0012312452,0.00022661517,0.000303317,0.00017983306,0.00008238061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003328858,0.0002812584,0.0010646567,0.000323222,0.00008801719,0.000029362514,0.00014949542,0.00011804106,0.000054933702],"category_scores_gemma":[0.000054926622,0.00018896718,0.000059912552,0.0004944693,0.0005388115,0.00017191564,0.00003185081,0.00042823856,0.000009220125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012069706,0.000560304,0.98067254,0.00008941225,0.00018503795,0.00002866101,0.004792505,0.00001371785,0.00018330163,0.0003977719,0.000032250133,0.0009747993],"study_design_scores_gemma":[0.027009433,0.002243095,0.9615423,0.0032739437,0.0000011395805,0.000047563448,0.0031300816,0.00006609926,0.0022189417,0.000106471525,0.00015249594,0.00020843481],"about_ca_topic_score_codex":0.0010267097,"about_ca_topic_score_gemma":0.00020529515,"teacher_disagreement_score":0.03198467,"about_ca_system_score_codex":0.000038548096,"about_ca_system_score_gemma":0.000088075416,"threshold_uncertainty_score":0.77058583},"labels":[],"label_agreement":null},{"id":"W2953184093","doi":"10.1007/s40744-019-0164-4","title":"Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care","funders":"Incyte; Eli Lilly and Company","keywords":"Rheumatoid arthritis; Productivity; Work productivity; Medicine; Work (physics); Physical therapy; Physical medicine and rehabilitation; Internal medicine; Engineering; Economics; Mechanical engineering","score_opus":0.012382154287976042,"score_gpt":0.25954808196014073,"score_spread":0.2471659276721647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953184093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98886794,0.00878963,0.00001456872,0.000530535,0.00006929714,0.001589594,0.000023533625,0.000020144244,0.00009473088],"genre_scores_gemma":[0.97159636,0.028169625,0.000040253562,0.00006944097,0.000008027129,0.00004889043,0.000035532852,0.000022083104,0.000009813863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981978,0.0005316055,0.00033970998,0.00037783544,0.00024328998,0.00030975146],"domain_scores_gemma":[0.9980769,0.0012573147,0.00015879735,0.00033651586,0.00007873561,0.000091726826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069415115,0.00022688188,0.0006929406,0.000107462154,0.00009468577,0.000020251759,0.00008170202,0.00013418519,0.00014647581],"category_scores_gemma":[0.00026419366,0.00012925194,0.00007237944,0.00021966128,0.00040701835,0.00014325105,0.000025144667,0.00039838708,0.000006122345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058545843,0.0004586293,0.8818656,0.000006834713,0.00030636392,0.0000032016958,0.0014907082,0.000002709039,0.000026486874,0.00045972836,0.00008192926,0.056751948],"study_design_scores_gemma":[0.07767836,0.0077427537,0.91166544,0.0009213302,0.0000011343823,0.000012660561,0.00013853438,0.000013025917,0.000114434086,0.001286791,0.0002665049,0.00015902378],"about_ca_topic_score_codex":0.0005588933,"about_ca_topic_score_gemma":0.000050524814,"teacher_disagreement_score":0.056592926,"about_ca_system_score_codex":0.00002011741,"about_ca_system_score_gemma":0.00010108183,"threshold_uncertainty_score":0.52707416},"labels":[],"label_agreement":null},{"id":"W2955483855","doi":"10.1007/s40744-019-0165-3","title":"Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis","year":2019,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"School of Medicine; University of Utah; Genentech; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company; KU Leuven; U.S. Department of Veterans Affairs","keywords":"Ixekizumab; Medicine; Ankylosing spondylitis; Placebo; Physical therapy; Repeated measures design; Internal medicine; Clinical trial; Clinical endpoint; Secukinumab; Disease; Psoriatic arthritis; Alternative medicine","score_opus":0.040982229017327114,"score_gpt":0.39421691062771264,"score_spread":0.3532346816103855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955483855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98839647,0.007571415,0.000027406388,0.0021439139,0.00032542006,0.001229866,0.000005434274,0.000023055702,0.00027700278],"genre_scores_gemma":[0.9894413,0.007841414,0.0016857939,0.00089154183,0.000020214951,0.00005177913,0.000022104687,0.000022725832,0.000023148468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974078,0.0005552434,0.001025487,0.00052292336,0.00015501058,0.00033353743],"domain_scores_gemma":[0.997803,0.001605294,0.00022382732,0.00021674442,0.000047314887,0.00010386108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018925092,0.00023301937,0.0010750204,0.00011734142,0.00008035686,0.000019088087,0.000047490368,0.00026543753,0.00005415157],"category_scores_gemma":[0.00048748992,0.00016999421,0.00008596654,0.00013558085,0.00021663721,0.00015874812,0.00002748116,0.00044069797,0.000003776993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02956848,0.0005858122,0.66961545,0.000030481746,0.0002852412,0.00013819385,0.0006502539,1.335876e-7,0.0000018839897,0.00019023109,0.000004002282,0.2989298],"study_design_scores_gemma":[0.25371772,0.008419244,0.7329301,0.00036344957,0.000055684133,0.00019392,0.0011406414,0.00016307874,0.000003959732,0.000405264,0.00236891,0.00023804072],"about_ca_topic_score_codex":0.00046364524,"about_ca_topic_score_gemma":0.0004247829,"teacher_disagreement_score":0.29869178,"about_ca_system_score_codex":0.000023760616,"about_ca_system_score_gemma":0.00006836083,"threshold_uncertainty_score":0.69321626},"labels":[],"label_agreement":null},{"id":"W3000625420","doi":"10.1007/s40744-019-00190-7","title":"Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?","year":2020,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"AbbVie","keywords":"Nocebo Effect; Biosimilar; Nocebo; Discontinuation; Medicine; Adverse effect; Intensive care medicine; Internal medicine; Alternative medicine; Placebo; Pathology","score_opus":0.017435544185724097,"score_gpt":0.3083887121203034,"score_spread":0.2909531679345793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000625420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12573601,0.8687414,0.00006371157,0.0035830834,0.000612452,0.0011241549,0.000090543,0.000043907945,0.0000047403328],"genre_scores_gemma":[0.023720987,0.9751985,0.00021128879,0.00053262163,0.000013149619,0.00022426168,0.000042147967,0.000042092637,0.000014949756],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947062,0.0026782725,0.00082334515,0.001062427,0.0000520449,0.00067772454],"domain_scores_gemma":[0.9963916,0.002790749,0.00028665946,0.00036360644,0.000014202926,0.00015317478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006652876,0.00082331855,0.0031711399,0.00024379873,0.00025888518,0.000013197884,0.00033114743,0.0012755813,0.00012274433],"category_scores_gemma":[0.00019171942,0.00040799464,0.00024177441,0.00016912418,0.0006796285,0.000052977863,0.00023912307,0.000906606,0.000024536943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001536514,0.00019542256,0.09039634,0.0011618803,0.0026080522,0.0000922139,0.0009226011,3.4084326e-8,0.00004545147,0.0005267357,0.00022098639,0.90229374],"study_design_scores_gemma":[0.0056985742,0.0026356915,0.0019102879,0.0036432287,0.0006373339,0.0015990803,0.00019550187,0.000008114931,0.00008074304,0.0005979816,0.98230207,0.0006913985],"about_ca_topic_score_codex":0.00038172936,"about_ca_topic_score_gemma":0.0002150208,"teacher_disagreement_score":0.98208106,"about_ca_system_score_codex":0.0000486711,"about_ca_system_score_gemma":0.00007699712,"threshold_uncertainty_score":0.9998372},"labels":[],"label_agreement":null},{"id":"W3011220016","doi":"10.1007/s40744-020-00199-3","title":"Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Rheumatoid arthritis; Randomized controlled trial; Medicine; Physical therapy; Internal medicine","score_opus":0.013864430913574366,"score_gpt":0.2721957997660841,"score_spread":0.25833136885250974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011220016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9272533,0.06276298,0.0007653879,0.0017719725,0.00033598248,0.006745733,0.000016455037,0.00014914786,0.00019902475],"genre_scores_gemma":[0.698268,0.29933307,0.00015940862,0.00021440959,0.0000620044,0.0018501058,0.000031797215,0.000032289652,0.00004893259],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974782,0.00056704937,0.0008001897,0.0005021541,0.00020877965,0.000443651],"domain_scores_gemma":[0.9975587,0.0011907808,0.00053964806,0.00019624457,0.00018895335,0.0003256831],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001936604,0.0003594738,0.002602343,0.00013765506,0.00040045156,0.00006905901,0.0000723301,0.00022551676,0.000078496465],"category_scores_gemma":[0.0008305948,0.0002496768,0.00055574445,0.00011865001,0.0006004529,0.00015177939,0.000016761534,0.0002086915,0.00001005045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9245095,0.0003048735,0.0009486059,0.000020907733,0.0022087484,0.000066960536,0.002574047,0.0000013361902,0.0010419046,0.0019516943,0.00009648422,0.0662749],"study_design_scores_gemma":[0.98026043,0.010156348,0.00008956353,0.00026510874,0.000019514053,0.001255441,0.00034280683,0.0010298344,0.0029499207,0.0010625311,0.0023344057,0.00023406516],"about_ca_topic_score_codex":0.00010794659,"about_ca_topic_score_gemma":0.000014038055,"teacher_disagreement_score":0.23657008,"about_ca_system_score_codex":0.000038628245,"about_ca_system_score_gemma":0.0002660471,"threshold_uncertainty_score":0.9999955},"labels":[],"label_agreement":null},{"id":"W3019766834","doi":"10.1007/s40744-020-00207-6","title":"Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation","year":2020,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Psoriatic arthritis; Medicine; Depression (economics); Alexithymia; Population; Anxiety; Quality of life (healthcare); Disease; Anhedonia; Psoriasis; Comorbidity; Intensive care medicine; Internal medicine; Psychiatry; Immunology","score_opus":0.015603135096680794,"score_gpt":0.27557333320969546,"score_spread":0.25997019811301464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019766834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026174214,0.9725992,0.0000019937777,0.00014731372,0.00009369928,0.0008857679,0.0000061429823,0.000031320018,0.000060368555],"genre_scores_gemma":[0.02704468,0.9725773,0.00006284186,0.000024293999,0.000033790533,0.00015913582,0.000062569205,0.000027846763,0.000007539513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988664,0.00010655891,0.0003843547,0.00036602278,0.00010260979,0.00017404868],"domain_scores_gemma":[0.99943155,0.00015068807,0.00018420348,0.00012932178,0.000022673245,0.00008153464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068370005,0.00029116333,0.0016538324,0.00011549743,0.00008392366,0.000011200284,0.000027406602,0.00025663065,0.000013145588],"category_scores_gemma":[0.000021357504,0.00018794592,0.000058262835,0.00011974248,0.000081675964,0.00003826377,0.000030007477,0.00025189025,0.000011519401],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016884902,0.000027649266,0.004282962,0.0029886342,0.00035664576,0.0004640438,0.0001387914,5.494985e-8,3.7742942e-7,0.00029395655,0.000008255464,0.99126977],"study_design_scores_gemma":[0.03509914,0.0025769318,0.005471861,0.28880298,0.0009500725,0.0600973,0.0001450294,0.000044876317,0.000008154527,0.0008448256,0.60481495,0.0011438765],"about_ca_topic_score_codex":0.00002322075,"about_ca_topic_score_gemma":0.00002684787,"teacher_disagreement_score":0.9901259,"about_ca_system_score_codex":0.000025927395,"about_ca_system_score_gemma":0.00010008095,"threshold_uncertainty_score":0.7664212},"labels":[],"label_agreement":null},{"id":"W3033326213","doi":"10.1007/s40744-020-00209-4","title":"Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Toronto Western Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Psoriatic arthritis; Tolerability; Adverse effect; Discontinuation; Internal medicine; Concomitant; Incidence (geometry); Interim analysis; Surgery; Arthritis; Clinical trial; Rheumatoid arthritis","score_opus":0.024974779527172475,"score_gpt":0.3090752962793566,"score_spread":0.2841005167521841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033326213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974734,0.0015587697,0.0000060047864,0.000058338166,0.000022745531,0.0007962096,0.0000550454,0.0000075327603,0.000021955564],"genre_scores_gemma":[0.9963035,0.0034660434,0.000052443887,0.000060889248,0.0000018824677,0.000015010727,0.00008979021,0.000009365085,0.0000010704879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904585,0.00009450151,0.00033099536,0.00030283793,0.000098459706,0.00012738605],"domain_scores_gemma":[0.99947286,0.000071108276,0.00015639205,0.00015392741,0.000072833885,0.000072882314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000657607,0.00014152113,0.0009600864,0.00010707348,0.000048407994,0.0000059051195,0.00005805753,0.000050420844,0.000036140194],"category_scores_gemma":[0.000024604149,0.000104891486,0.000019423296,0.0002970385,0.00013283768,0.00008456694,0.000060691636,0.000078044875,2.711412e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015143366,0.0030072269,0.8920619,0.000018887897,0.0018384837,0.000030333003,0.0029225773,5.2279177e-7,0.000025529114,0.000038581144,6.287023e-7,0.084912],"study_design_scores_gemma":[0.051706526,0.00936245,0.9379799,0.0001667999,0.0002139162,0.0000074213945,0.0004063349,0.000028943243,0.000038507587,0.0000065744284,0.0000031658944,0.00007949165],"about_ca_topic_score_codex":0.00008856034,"about_ca_topic_score_gemma":0.00013853231,"teacher_disagreement_score":0.08483251,"about_ca_system_score_codex":0.0000069796624,"about_ca_system_score_gemma":0.000015902971,"threshold_uncertainty_score":0.4277351},"labels":[],"label_agreement":null},{"id":"W3064100784","doi":"10.1007/s40744-020-00225-4","title":"Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Memorial University of Newfoundland","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Ixekizumab; Presenteeism; Ankylosing spondylitis; Work productivity; Medicine; Absenteeism; Productivity; Internal medicine; Clinical trial; Physical therapy; Disease; Secukinumab; Psoriatic arthritis; Psychology","score_opus":0.030837431832355388,"score_gpt":0.2825535190057654,"score_spread":0.25171608717341004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3064100784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992934,0.004032267,9.113117e-7,0.0016545377,0.000051505063,0.0006955949,0.000585147,0.000014972096,0.000031060314],"genre_scores_gemma":[0.99779946,0.0018266886,0.00003533367,0.00012593862,0.000018426848,0.000015922693,0.0001576901,0.00001409022,0.000006460321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987048,0.000255451,0.000359317,0.00035559243,0.00012973283,0.00019509826],"domain_scores_gemma":[0.9988062,0.0006714091,0.00020277823,0.0001971326,0.00004684057,0.000075651624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002485037,0.00019092805,0.0007984332,0.00003268653,0.000117946336,0.000008092294,0.000038566413,0.00008459952,0.00003457806],"category_scores_gemma":[0.00031835047,0.00010204631,0.0000615028,0.00014772089,0.0002067831,0.000040647312,0.000037903545,0.00014241769,0.0000015001539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06201371,0.00032087127,0.90434676,0.000008833171,0.00047465847,0.000019406249,0.002939103,0.0000014098613,0.000013605834,0.000019638328,0.00023975261,0.029602258],"study_design_scores_gemma":[0.028766567,0.0033880852,0.9668607,0.0002419148,0.000038309496,0.000015749054,0.00013928278,0.000002460729,0.00010249234,0.000063568674,0.00029149285,0.00008938818],"about_ca_topic_score_codex":0.00082594407,"about_ca_topic_score_gemma":0.00017206947,"teacher_disagreement_score":0.06251393,"about_ca_system_score_codex":0.000026108313,"about_ca_system_score_gemma":0.000034103246,"threshold_uncertainty_score":0.41613278},"labels":[],"label_agreement":null},{"id":"W3091166611","doi":"10.1007/s40744-020-00236-1","title":"Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Placebo; Prednisone; Internal medicine; Adverse effect; Rash; Glucocorticoid; Randomized controlled trial; Population; Gastroenterology; Pathology","score_opus":0.04255996117976809,"score_gpt":0.32144535498710275,"score_spread":0.2788853938073347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091166611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97097385,0.006304962,0.0010590078,0.0009957526,0.0015513601,0.018638715,0.0000600643,0.00017114154,0.0002451418],"genre_scores_gemma":[0.9936845,0.0020915947,0.00016010723,0.00020876403,0.00025913212,0.0030704257,0.00012718506,0.000061156235,0.00033714453],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960546,0.00078621844,0.0014936315,0.00082185504,0.00037253345,0.0004711577],"domain_scores_gemma":[0.9954255,0.0027674679,0.0007568652,0.0004228653,0.00029034456,0.0003369476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060122565,0.00039992173,0.0025537766,0.00018617082,0.00026613844,0.00005907581,0.00016833092,0.00041068307,0.000026870866],"category_scores_gemma":[0.00097065576,0.00029107917,0.0005960844,0.00015534762,0.0003051425,0.00012794763,0.00004159364,0.00037226154,0.000018542636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98164535,0.00062293065,0.0009134886,0.0003889193,0.0029178385,0.000053403644,0.010456872,0.000003666365,0.0018513451,0.00015064895,0.00036916716,0.00062636234],"study_design_scores_gemma":[0.97381353,0.0026698972,6.340253e-7,0.0005845774,0.00038800793,0.009687577,0.0041127484,0.00715316,0.001113752,0.000046022287,0.00019416498,0.00023591288],"about_ca_topic_score_codex":0.00020580007,"about_ca_topic_score_gemma":0.000005081011,"teacher_disagreement_score":0.022710636,"about_ca_system_score_codex":0.00010494198,"about_ca_system_score_gemma":0.00025249305,"threshold_uncertainty_score":0.99995416},"labels":[],"label_agreement":null},{"id":"W3091964420","doi":"10.1007/s40744-020-00237-0","title":"Implementation and Evaluation of Audit and Feedback for Monitoring Treat-to-Target (T2T) Strategies in Rheumatoid Arthritis Using Performance Measures","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Research Canada; University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Audit; Family medicine; Quality management; Documentation; Rheumatoid arthritis; Session (web analytics); Medical record; Physical therapy; Internal medicine","score_opus":0.06428389117864781,"score_gpt":0.35609303158028777,"score_spread":0.29180914040163997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091964420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94687754,0.051377982,0.00032877753,0.0005672889,0.000033839253,0.0007665968,0.00000894635,0.0000155929,0.000023425666],"genre_scores_gemma":[0.80603,0.19285494,0.0009993128,0.000023597224,0.0000091358115,0.00006292398,0.000007205338,0.000012363889,5.506199e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892,0.00010353832,0.00030778084,0.0002445699,0.00020007772,0.00022399567],"domain_scores_gemma":[0.9994978,0.000090913156,0.00007790076,0.00007513717,0.0001401541,0.00011809396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004975068,0.00013605264,0.00038795275,0.0001240783,0.000115059316,0.000031585292,0.00003249949,0.00006848102,0.000025252291],"category_scores_gemma":[0.00005184972,0.00012498218,0.000022968392,0.00010888042,0.00012404546,0.00021847409,0.000017924978,0.00008555061,5.1066365e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010876773,0.0000378616,0.52637506,0.00014361167,0.000096103104,0.0000021596572,0.0048263697,0.000042297244,0.014709702,0.00050810963,0.000013355295,0.45215768],"study_design_scores_gemma":[0.05687508,0.0053391876,0.7852847,0.0026945455,0.000020011024,0.001060476,0.02679167,0.024918953,0.0876852,0.0064723734,0.0020512491,0.0008065667],"about_ca_topic_score_codex":0.00014833803,"about_ca_topic_score_gemma":0.00004664221,"teacher_disagreement_score":0.4513511,"about_ca_system_score_codex":0.000015548678,"about_ca_system_score_gemma":0.00013669128,"threshold_uncertainty_score":0.5096625},"labels":[],"label_agreement":null},{"id":"W3092509408","doi":"10.1007/s40744-020-00242-3","title":"Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Enthesitis; Dactylitis; Medicine; Psoriatic arthritis; Physical therapy; Quality of life (healthcare); Internal medicine; Disease; Nursing","score_opus":0.03384471145853712,"score_gpt":0.29172543293249303,"score_spread":0.2578807214739559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092509408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457407,0.004077543,0.000006024963,0.00023664291,0.000034266748,0.0003910958,0.0006427482,0.000018342793,0.000019243522],"genre_scores_gemma":[0.98947006,0.009742795,0.00010142377,0.00019345648,0.0000075690277,0.00002030776,0.0004486411,0.000014968865,7.820212e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990752,0.00008359273,0.00023030992,0.00035653304,0.000118491706,0.00013587119],"domain_scores_gemma":[0.9992452,0.00024319493,0.00018965056,0.00018942029,0.000045740762,0.00008678096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000024294059,0.00020404371,0.00056200847,0.000036850648,0.0001062698,0.000010389977,0.000020335126,0.00005179648,0.00001718273],"category_scores_gemma":[0.000032074215,0.0001363164,0.00003581157,0.00006608395,0.00011768665,0.00008016941,0.000023640594,0.000054355663,0.0000015202666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010595616,0.0002871564,0.66405696,0.000005265445,0.0011292434,0.000024821475,0.00097069616,4.1253176e-7,0.00004714211,0.000013659859,0.000015766367,0.3323893],"study_design_scores_gemma":[0.009502007,0.005354307,0.9843098,0.00011723208,0.00006286512,0.000035934405,0.00016122343,0.00011430562,0.00014769795,0.000052541098,0.00003353577,0.000108530214],"about_ca_topic_score_codex":0.0043847854,"about_ca_topic_score_gemma":0.0006541139,"teacher_disagreement_score":0.33228078,"about_ca_system_score_codex":0.00001855959,"about_ca_system_score_gemma":0.000031110994,"threshold_uncertainty_score":0.66285133},"labels":[],"label_agreement":null},{"id":"W3101920302","doi":"10.1007/s40744-020-00243-2","title":"Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Belimumab; Medicine; Post-hoc analysis; Internal medicine; Population; Systemic lupus erythematosus; Physical therapy; Disease; B-cell activating factor; Immunology; Antibody; Environmental health","score_opus":0.09989543768074156,"score_gpt":0.37124507036748305,"score_spread":0.2713496326867415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101920302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91979766,0.078511156,0.000024752117,0.00032093868,0.00007243536,0.0010668954,0.00017948815,0.000011852995,0.0000147907695],"genre_scores_gemma":[0.9370705,0.062648706,0.000038223505,0.000027618189,0.000009013441,0.00007069823,0.00011223401,0.000015258064,0.000007791873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970662,0.0012663947,0.00076805474,0.0003886703,0.00030904743,0.00020165465],"domain_scores_gemma":[0.99305636,0.0052908366,0.0003816151,0.0010761408,0.0001527666,0.00004229377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011272351,0.00021347628,0.0018346101,0.00018021649,0.00005135731,0.000004753149,0.00045819377,0.00010577225,0.000013106754],"category_scores_gemma":[0.00022388705,0.00010378192,0.00015177629,0.0010578565,0.00040606194,0.000043958666,0.00007997774,0.0001207635,0.0000012779834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023968935,0.00050376746,0.95524096,0.001340966,0.011475167,0.000021719334,0.02537809,0.000020137777,0.0028603885,0.0003844809,0.00003041971,0.00034698113],"study_design_scores_gemma":[0.076088995,0.0047060144,0.7136599,0.013417045,0.011028402,0.0035074498,0.14286362,0.01973824,0.013386162,0.00063026743,0.00020685003,0.0007670816],"about_ca_topic_score_codex":0.0028591466,"about_ca_topic_score_gemma":0.00092633156,"teacher_disagreement_score":0.24158111,"about_ca_system_score_codex":0.000046543802,"about_ca_system_score_gemma":0.00010615604,"threshold_uncertainty_score":0.43221936},"labels":[],"label_agreement":null},{"id":"W3111593935","doi":"10.1007/s40744-020-00254-z","title":"Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial","year":2020,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Axial spondyloarthritis; Physical therapy; Placebo; Internal medicine; Randomized controlled trial; Back pain; Low back pain; Repeated measures design; Ankylosing spondylitis; Disease; Alternative medicine","score_opus":0.018398617010719136,"score_gpt":0.2573371668712168,"score_spread":0.2389385498604977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111593935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833764,0.007837005,0.0000025192821,0.006936701,0.00048648863,0.0010799968,0.00010886559,0.000055490505,0.000116553034],"genre_scores_gemma":[0.9883908,0.009873168,0.000054707594,0.0013785937,0.000054104403,0.00010693365,0.00010790391,0.000021725295,0.000012066828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831265,0.00010624915,0.00062027987,0.00046865514,0.00017171378,0.00032044415],"domain_scores_gemma":[0.99896824,0.0003949748,0.0001890487,0.000282881,0.000039851122,0.00012502808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011168495,0.0002592938,0.0007655145,0.00006541299,0.00018560753,0.000021272925,0.000085478314,0.00016901408,0.000033989367],"category_scores_gemma":[0.00021751893,0.00016709774,0.00016003409,0.00023034085,0.00023561124,0.000060683356,0.000047853635,0.00026601276,0.000010088885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16869204,0.00090265693,0.6009417,0.000014111641,0.001731974,0.001077208,0.009753731,4.334025e-7,0.0002609638,0.00016477727,0.0013823914,0.21507798],"study_design_scores_gemma":[0.35454556,0.004894393,0.6321992,0.00014314767,0.00008625519,0.0002321782,0.0014650595,0.000037741254,0.00017762564,0.0004938584,0.005417374,0.00030755467],"about_ca_topic_score_codex":0.0014957999,"about_ca_topic_score_gemma":0.0004079737,"teacher_disagreement_score":0.21477044,"about_ca_system_score_codex":0.00001010078,"about_ca_system_score_gemma":0.000049491322,"threshold_uncertainty_score":0.68140477},"labels":[],"label_agreement":null},{"id":"W3119698067","doi":"10.1007/s40744-020-00272-x","title":"Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Cohort; Pharmacy; Internal medicine; Comorbidity; Rheumatoid arthritis; Rheumatology; Cohort study; Logistic regression; Odds ratio; Retrospective cohort study; Database; Emergency medicine; Family medicine","score_opus":0.005957307256912728,"score_gpt":0.22848344373231863,"score_spread":0.2225261364754059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119698067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203724,0.0074266545,0.00007025164,0.000049589617,0.000025478827,0.00031933322,0.000029514287,0.000017305149,0.000024622206],"genre_scores_gemma":[0.86918485,0.13031945,0.00017204131,0.000024947385,0.0000017950101,0.000042516578,0.00023968154,0.000012335423,0.0000023634366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880284,0.00014940233,0.00038187052,0.00029883752,0.00017224427,0.00019483366],"domain_scores_gemma":[0.9992682,0.000074061114,0.00019977658,0.00022096024,0.0001292544,0.00010776038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045960773,0.00016289571,0.00058042305,0.00037740363,0.00009451596,0.000019826995,0.000020059257,0.00008049435,0.000026061723],"category_scores_gemma":[0.0000200157,0.00011781727,0.000034491506,0.00046262806,0.0002352133,0.00011761036,0.00001547911,0.000118723365,4.466847e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00207788,0.0005738096,0.9556869,0.000024881325,0.00080027065,0.00006047357,0.001181258,0.000001707964,0.00014219127,0.00020938029,0.0000016453707,0.039239556],"study_design_scores_gemma":[0.008382607,0.0039027298,0.98455215,0.0004061374,0.000017382023,0.0002685588,0.0003731723,0.000056226454,0.0017583391,0.000027140566,0.00012144389,0.00013409094],"about_ca_topic_score_codex":0.0001696918,"about_ca_topic_score_gemma":0.00017835174,"teacher_disagreement_score":0.1228928,"about_ca_system_score_codex":0.00003787437,"about_ca_system_score_gemma":0.00016651633,"threshold_uncertainty_score":0.48044488},"labels":[],"label_agreement":null},{"id":"W3133061598","doi":"10.1007/s40744-021-00287-y","title":"Human Osteochondral Explants: Reliable Biomimetic Models to Investigate Disease Mechanisms and Develop Personalized Treatments for Osteoarthritis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"ReumaNederland; ZonMw; Dutch Arthritis Society; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Universiteit Leiden; Arthritis Society","keywords":"Chondrocyte; Cartilage; Downregulation and upregulation; Osteoarthritis; Catabolism; Muscle hypertrophy; Anabolism; Matrix Metalloproteinase 3; Chemistry; Cell biology; Endocrinology; Internal medicine; Medicine; Matrix metalloproteinase; Pathology; Biology; Anatomy; Biochemistry; Gene; Metabolism","score_opus":0.033478837144118465,"score_gpt":0.2733837220021514,"score_spread":0.2399048848580329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133061598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266697,0.014002029,0.0006117456,0.001205379,0.00019845866,0.0010566156,0.00008181695,0.00007846282,0.00009854607],"genre_scores_gemma":[0.97540236,0.0036163114,0.016096368,0.0013861187,0.000016415295,0.0006102721,0.00037764455,0.00005825503,0.0024362784],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9986346,0.00005827443,0.00026897746,0.00054350414,0.00011557271,0.00037908193],"domain_scores_gemma":[0.9990848,0.00005340906,0.000058846006,0.00022759533,0.00011292114,0.0004624654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008902863,0.00027692463,0.00055376906,0.00011247337,0.00030212873,0.000038175716,0.000037256752,0.00014183756,0.00007154877],"category_scores_gemma":[0.000027235517,0.000246734,0.0000725264,0.00013362848,0.000107006636,0.000120536235,0.00003823291,0.00006759609,0.0000087341605],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008592085,0.0017342373,0.020014588,0.0006502208,0.0017744411,0.0036495489,0.008547656,0.000005766311,0.45340753,0.32244763,0.0011621894,0.17801411],"study_design_scores_gemma":[0.11869561,0.017327284,0.0023555132,0.0026281015,0.0011355757,0.008317342,0.002329969,0.00031222677,0.24762909,0.5885167,0.008727714,0.0020248792],"about_ca_topic_score_codex":0.000019407282,"about_ca_topic_score_gemma":0.000022884506,"teacher_disagreement_score":0.26606905,"about_ca_system_score_codex":0.000022809329,"about_ca_system_score_gemma":0.00014675998,"threshold_uncertainty_score":0.9999985},"labels":[],"label_agreement":null},{"id":"W3135181020","doi":"10.1007/s40744-021-00294-z","title":"Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Galderma; Mallinckrodt Pharmaceuticals","keywords":"Medicine; Placebo; Systemic lupus erythematosus; Internal medicine; Post-hoc analysis; Prednisone; Adverse effect; Rheumatology; Lupus erythematosus; Rash; Quality of life (healthcare); Immunology; Disease; Pathology","score_opus":0.03281445817817048,"score_gpt":0.3216902380331188,"score_spread":0.28887577985494833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135181020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774361,0.0072314283,0.00047231856,0.00016610035,0.0023653235,0.012027993,0.000028618608,0.000078823374,0.000193277],"genre_scores_gemma":[0.99448603,0.0019868948,0.00021610902,0.000050883747,0.000050010738,0.00267179,0.00010049699,0.000052441595,0.00038535267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99584305,0.00083532097,0.0018054795,0.0006504508,0.00044849995,0.0004172251],"domain_scores_gemma":[0.9946612,0.0026800456,0.0012172633,0.0006016793,0.0006526139,0.000187211],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047321894,0.00038053334,0.0031389934,0.00025969816,0.00018371965,0.000034625413,0.000102297294,0.0003844317,0.00006054629],"category_scores_gemma":[0.00082841486,0.00027579066,0.00080892467,0.00015808515,0.00029082564,0.00011101313,0.000045632187,0.0002766209,0.000003291743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95512944,0.0017866209,0.024504617,0.0004840466,0.0068374695,0.00013025428,0.004693508,0.0000014272541,0.0053952546,0.00015527829,0.000049847215,0.00083222607],"study_design_scores_gemma":[0.96216285,0.0012603328,0.000011068481,0.00071961427,0.0006629316,0.02257398,0.0046719485,0.00072929345,0.0068802717,0.000085511856,0.000034390137,0.0002077885],"about_ca_topic_score_codex":0.00025911257,"about_ca_topic_score_gemma":0.000010307433,"teacher_disagreement_score":0.024493549,"about_ca_system_score_codex":0.000116128605,"about_ca_system_score_gemma":0.00041173433,"threshold_uncertainty_score":0.9999694},"labels":[],"label_agreement":null},{"id":"W3157970781","doi":"10.1007/s40744-021-00305-z","title":"Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Placebo; Rheumatology; Randomized controlled trial; Psoriasis Area and Severity Index; Psoriasis; Arthritis; Immunology","score_opus":0.02216772253260031,"score_gpt":0.2913959754540664,"score_spread":0.2692282529214661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157970781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680289,0.027124226,0.000015911328,0.0017733395,0.00010328924,0.002798025,0.00011768151,0.00002117112,0.000017444461],"genre_scores_gemma":[0.98479766,0.013947796,0.00013110765,0.0005979995,0.000011496761,0.000290944,0.00018290195,0.000014419387,0.000025706811],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974575,0.0012023394,0.0004493395,0.00049747806,0.00013444027,0.00025889088],"domain_scores_gemma":[0.9968389,0.0024167506,0.00012081841,0.0004466669,0.00009290745,0.00008393639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008221241,0.00023103609,0.0016079866,0.00006216976,0.00018639951,0.00002964451,0.00008973426,0.0000776112,0.00009705657],"category_scores_gemma":[0.0009440963,0.00012281112,0.000051407318,0.00017621844,0.00018739692,0.000053378037,0.00009349099,0.00015282788,0.0000070695155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7141491,0.0023101112,0.2313517,0.0000035458374,0.0019819841,0.0002487265,0.0020029922,1.5723565e-7,0.000010109113,0.000049286675,0.00008862798,0.04780365],"study_design_scores_gemma":[0.8644358,0.0034208116,0.12983033,0.0001642198,0.00015373707,0.000045593042,0.0011513784,0.00003456442,0.000012732707,0.00021771165,0.0003920634,0.00014107677],"about_ca_topic_score_codex":0.00029655354,"about_ca_topic_score_gemma":0.0005091139,"teacher_disagreement_score":0.15028667,"about_ca_system_score_codex":0.000011499356,"about_ca_system_score_gemma":0.00007621608,"threshold_uncertainty_score":0.50080925},"labels":[],"label_agreement":null},{"id":"W3164210226","doi":"10.1007/s40744-021-00310-2","title":"Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Abatacept; Rheumatoid arthritis; Internal medicine; Tofacitinib; Rheumatoid factor; Physical therapy","score_opus":0.026074776716786464,"score_gpt":0.3388522481739808,"score_spread":0.3127774714571943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164210226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952776,0.0036587117,0.000023138713,0.00048577166,0.00006928936,0.00034486272,0.000067759305,0.000047463476,0.000025403631],"genre_scores_gemma":[0.9013298,0.09772638,0.00030058826,0.00004676511,0.000009308175,0.000022204105,0.00032535743,0.000016337633,0.00022323661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973103,0.0009618783,0.00066290953,0.0004765724,0.00023546786,0.00035286997],"domain_scores_gemma":[0.99699515,0.0020439858,0.00029709277,0.00026708446,0.00022953947,0.00016713819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086272066,0.00024254785,0.0013879446,0.00038307454,0.00020321316,0.000029470468,0.000055823773,0.00019641171,0.00010137087],"category_scores_gemma":[0.00072273565,0.00015422527,0.00020223312,0.00074246206,0.00028401523,0.00011902657,0.00003391423,0.0001837143,0.0000014343958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060734823,0.00045213514,0.97475815,0.000010353931,0.006034208,0.000059184553,0.0007699171,5.319036e-7,0.0006733341,0.000025835265,0.000023936787,0.011118925],"study_design_scores_gemma":[0.010347722,0.0022565522,0.98366463,0.00017184087,0.00016799851,0.00000810054,0.00033635835,0.00006445328,0.0018634018,0.000025682404,0.0009253183,0.0001679192],"about_ca_topic_score_codex":0.0004199976,"about_ca_topic_score_gemma":0.0012510536,"teacher_disagreement_score":0.09406767,"about_ca_system_score_codex":0.000043142933,"about_ca_system_score_gemma":0.00017375092,"threshold_uncertainty_score":0.6289124},"labels":[],"label_agreement":null},{"id":"W3165653864","doi":"10.1007/s40744-021-00317-9","title":"Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Post-hoc analysis; Population; Physical therapy; Gastroenterology","score_opus":0.01965324299131082,"score_gpt":0.31472868373473734,"score_spread":0.2950754407434265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165653864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8940773,0.10240706,0.0000430079,0.0001217977,0.000036257698,0.003251423,0.000029562128,0.000023118177,0.000010469906],"genre_scores_gemma":[0.71277696,0.2867818,0.0000672413,0.000022367938,0.0000028127702,0.00021668944,0.000097101176,0.000023711731,0.000011344946],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643046,0.0008843927,0.0011197589,0.0006610497,0.00047151028,0.0004328288],"domain_scores_gemma":[0.9964703,0.0015451323,0.00058189605,0.00045322382,0.0007717628,0.00017771334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054076186,0.00046655477,0.0052747205,0.0006467104,0.00015943371,0.000027139802,0.00008043984,0.000107849075,0.000094696654],"category_scores_gemma":[0.00016646815,0.00028923005,0.00026230715,0.0006005842,0.0010633997,0.00015843207,0.000051213472,0.00021757388,6.502185e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44622493,0.007989483,0.46577692,0.000039656323,0.020734511,0.00023064262,0.005170209,0.0000027373683,0.0001955824,0.000057740148,4.169052e-7,0.053577177],"study_design_scores_gemma":[0.6145793,0.010979989,0.37089998,0.0011801455,0.00029150548,0.00008734922,0.0011384072,0.000022212113,0.0006103016,0.000021159973,4.0030494e-7,0.00018922561],"about_ca_topic_score_codex":0.0002137509,"about_ca_topic_score_gemma":0.0015165093,"teacher_disagreement_score":0.18437473,"about_ca_system_score_codex":0.000041898726,"about_ca_system_score_gemma":0.0002305417,"threshold_uncertainty_score":0.999956},"labels":[],"label_agreement":null},{"id":"W3178990742","doi":"10.1007/s40744-021-00340-w","title":"Self-Reported Weather Sensitivity is Associated with Clinical Symptoms and Structural Abnormalities in Patients with Knee Osteoarthritis: A Cross-Sectional Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Jiangxi University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; National Natural Science Foundation of China","keywords":"Osteoarthritis; Medicine; WOMAC; Cross-sectional study; Magnetic resonance imaging; Body mass index; Knee pain; Internal medicine; Cohort; Cohort study; Physical therapy; Pathology; Radiology","score_opus":0.0233569987962932,"score_gpt":0.3027387448625437,"score_spread":0.2793817460662505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178990742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99925345,0.00016201983,6.204614e-7,0.00005772388,0.00006544692,0.00031828927,0.00002205769,0.000029284583,0.00009112167],"genre_scores_gemma":[0.9994166,0.00018512778,0.00002127746,0.00029732025,0.000004880796,0.000012410456,0.000022323138,0.000011063607,0.000029026505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986716,0.0002508975,0.0003014848,0.00033574598,0.00016973744,0.0002705323],"domain_scores_gemma":[0.99943876,0.0001845496,0.00012979966,0.000120112556,0.000029782323,0.00009699131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035344728,0.00014161211,0.00029904905,0.000023212537,0.00018296416,0.00003935113,0.000023231027,0.00012560336,0.00026322858],"category_scores_gemma":[0.000029424122,0.00010412357,0.000015956486,0.00011122101,0.0002544837,0.0001661911,0.000043543547,0.00017805675,0.0000037010807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040481857,0.00027141327,0.9953429,0.0000054285365,0.00009701492,0.000078334844,0.0020791816,0.000001302503,9.598822e-7,0.000006924644,0.0000050349795,0.0017066611],"study_design_scores_gemma":[0.006426798,0.0011897881,0.9916714,0.000026749964,0.000008484536,0.00019111848,0.00021088212,0.00003795901,0.0000046054415,0.000080357364,0.000016746071,0.00013513159],"about_ca_topic_score_codex":0.0002894649,"about_ca_topic_score_gemma":0.0022818572,"teacher_disagreement_score":0.0060219797,"about_ca_system_score_codex":0.000033209308,"about_ca_system_score_gemma":0.000025195017,"threshold_uncertainty_score":0.42460358},"labels":[],"label_agreement":null},{"id":"W3180838433","doi":"10.1007/s40744-021-00337-5","title":"Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Placebo; Internal medicine; Psoriasis; Tumor necrosis factor alpha; TNF inhibitor; Certolizumab pegol; Arthritis; Oncology; Immunology; Etanercept; Pathology; Alternative medicine","score_opus":0.03344847966845219,"score_gpt":0.31787157241101904,"score_spread":0.28442309274256683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180838433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944474,0.0044865985,0.0000031870686,0.000111317044,0.00013755649,0.0006499745,0.00012986985,0.000027698043,0.000006358716],"genre_scores_gemma":[0.9900244,0.009365591,0.00018401425,0.00021375531,0.000007866924,0.00006252567,0.00008054084,0.00002775044,0.00003355826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834263,0.000103090584,0.00051458017,0.0004667652,0.0002509073,0.00032203223],"domain_scores_gemma":[0.9986613,0.00044660733,0.00025488733,0.00031195988,0.00022612004,0.000099149394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006564358,0.0003181062,0.0016285891,0.00034219603,0.00015580378,0.000015915377,0.000044216707,0.00009128312,0.00011276151],"category_scores_gemma":[0.00017924629,0.00021010524,0.00015246992,0.0008063584,0.0002025396,0.00008387071,0.000030208526,0.00016199352,0.0000025577392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010985753,0.0029874481,0.94666004,0.00005324642,0.0096419705,0.00033568867,0.0019936915,0.0000013566246,0.00006265863,0.000065798704,0.00002500683,0.02718734],"study_design_scores_gemma":[0.08179993,0.0046610585,0.91003454,0.00079574925,0.0009022555,0.00007463957,0.0005697588,0.000024224326,0.00066523446,0.000029662318,0.0001833557,0.0002595902],"about_ca_topic_score_codex":0.00008773955,"about_ca_topic_score_gemma":0.00068069017,"teacher_disagreement_score":0.07081418,"about_ca_system_score_codex":0.000048960956,"about_ca_system_score_gemma":0.00008754569,"threshold_uncertainty_score":0.8567843},"labels":[],"label_agreement":null},{"id":"W3182483969","doi":"10.1007/s40744-021-00339-3","title":"Nurse-Led Care for Stable Patients with Rheumatoid Arthritis: Quality of Care in Routine Practice Compared to the Traditional Rheumatologist-Led Model","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Calgary","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"Medicine; Rheumatoid arthritis; Clinical Practice; Family medicine; Internal medicine; Nursing; Intensive care medicine","score_opus":0.02428735887086365,"score_gpt":0.30719682648317587,"score_spread":0.2829094676123122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182483969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93734074,0.056697465,0.00073012244,0.0028290327,0.00010083626,0.0015671349,0.00031697602,0.00004481649,0.0003728665],"genre_scores_gemma":[0.95337194,0.04242317,0.0028953855,0.00033434862,0.000005279574,0.0003797808,0.0005401973,0.00003668878,0.000013202228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997331,0.00043059696,0.00075563695,0.0005161928,0.0004369216,0.0005296566],"domain_scores_gemma":[0.9969879,0.0009237642,0.0002455693,0.00047352668,0.0011817947,0.00018747943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044839975,0.00029823586,0.0011166035,0.000141877,0.00030351293,0.00004157271,0.00017288688,0.00016650332,0.000061963496],"category_scores_gemma":[0.0006097616,0.00021553495,0.00012463424,0.00030467825,0.00033991731,0.00020161296,0.00003402669,0.00031131192,0.0000041040644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046391264,0.0030095228,0.7847649,0.00090253644,0.0012575908,0.000054046563,0.046917394,0.0009432605,0.00037855035,0.075777695,0.0008824614,0.038720828],"study_design_scores_gemma":[0.24146983,0.010477345,0.4912775,0.009284833,0.000044036755,0.0019316367,0.17376277,0.0049062464,0.008835508,0.008043277,0.047085542,0.0028814839],"about_ca_topic_score_codex":0.0002549371,"about_ca_topic_score_gemma":0.0016136849,"teacher_disagreement_score":0.29348737,"about_ca_system_score_codex":0.000064938205,"about_ca_system_score_gemma":0.0005797287,"threshold_uncertainty_score":0.878926},"labels":[],"label_agreement":null},{"id":"W3183606991","doi":"10.1007/s40744-021-00331-x","title":"Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto; Alberta Health Services; Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Alberta Innovates; Arthritis Society; Children's Hospital Foundation; Alberta Children's Hospital Foundation; ZonMw; Canadian Institutes of Health Research; Genome Canada","keywords":"Medicine; Cohort; Health care; Emergency medicine; Emergency department; Retrospective cohort study; Pediatrics; Physical therapy; Internal medicine","score_opus":0.025759305721385566,"score_gpt":0.31591480354515916,"score_spread":0.2901554978237736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183606991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97807175,0.019886125,6.588556e-7,0.00048149336,0.000009797687,0.0010616741,0.0000069238154,0.0000119364595,0.00046963018],"genre_scores_gemma":[0.9889626,0.010800324,0.000002407294,0.000056138677,0.0000020485174,0.00006551177,0.0000722753,0.000011955137,0.000026747684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982636,0.0006853302,0.0002950732,0.0002474335,0.0003225368,0.00018605443],"domain_scores_gemma":[0.9992084,0.00002420474,0.00010592414,0.00016019997,0.00042476493,0.0000765114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001805059,0.00009262195,0.000490433,0.0002036333,0.0001075015,0.000008189755,0.00002626047,0.00010136456,0.000039354058],"category_scores_gemma":[0.00019040509,0.00008452104,0.000013704356,0.00038484758,0.00008784275,0.00004621609,0.000010976603,0.00021141068,5.1711726e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108748536,0.00014682362,0.97729915,0.000009963918,0.00019636536,0.000013625714,0.0011208473,9.3189414e-7,0.000010139857,0.00023084736,0.000014838625,0.02084769],"study_design_scores_gemma":[0.005344548,0.00047694446,0.9922999,0.0002591063,0.00002819923,0.00007835818,0.0010106799,0.00019773898,0.00005657415,0.0001560117,0.000022480766,0.000069423964],"about_ca_topic_score_codex":0.07656922,"about_ca_topic_score_gemma":0.46029046,"teacher_disagreement_score":0.38372123,"about_ca_system_score_codex":0.00022504065,"about_ca_system_score_gemma":0.0010957074,"threshold_uncertainty_score":0.92958},"labels":[],"label_agreement":null},{"id":"W3184531276","doi":"10.1007/s40744-021-00346-4","title":"Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eli Lilly and Company","keywords":"Medicine; Renal function; Rheumatoid arthritis; Kidney disease; Internal medicine; Population; Retrospective cohort study; Cohort; Creatinine; Surgery; Environmental health","score_opus":0.010194751418540569,"score_gpt":0.2729724678159526,"score_spread":0.262777716397412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184531276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9406513,0.058131155,0.00006613171,0.0006245057,0.000046505178,0.0002801071,0.000026133637,0.000028567536,0.00014560058],"genre_scores_gemma":[0.6653832,0.33425084,0.00021331315,0.000058737773,0.0000032598246,0.000028208144,0.0000310284,0.0000095226815,0.0000219041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815744,0.0002929017,0.0005652156,0.00037810378,0.0002835816,0.00032272693],"domain_scores_gemma":[0.9990799,0.00012248324,0.00014879102,0.00032951552,0.00019325188,0.00012607343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038839143,0.00017805665,0.0008809139,0.00035890902,0.000098070486,0.000018539034,0.00007771175,0.0001465077,0.00052351505],"category_scores_gemma":[0.00012236467,0.00016555072,0.00017329986,0.00077404553,0.00023002441,0.00010394747,0.00004309141,0.00024886598,0.0000034374034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006464336,0.00041609327,0.9831484,0.000055296794,0.00084388553,0.00011168465,0.00086911727,0.0000063985412,0.0007176103,0.0025445197,0.00002700417,0.010613574],"study_design_scores_gemma":[0.0051084924,0.000443773,0.98996496,0.00043274643,0.0000073257374,0.00055844476,0.00009804734,0.00016820115,0.00113163,0.0017393591,0.00020886477,0.00013814642],"about_ca_topic_score_codex":0.0006261171,"about_ca_topic_score_gemma":0.0009316319,"teacher_disagreement_score":0.27611968,"about_ca_system_score_codex":0.000038705264,"about_ca_system_score_gemma":0.00016004192,"threshold_uncertainty_score":0.6750963},"labels":[],"label_agreement":null},{"id":"W3193683700","doi":"10.1007/s40744-021-00355-3","title":"Patient-Reported Outcome Measures in Takayasu Arteritis: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Physical therapy; Anxiety; Strictly standardized mean difference; Cochrane Library; Mood; MEDLINE; Randomized controlled trial; Observational study; Quality of life (healthcare); Psychiatry","score_opus":0.10513623567748936,"score_gpt":0.3555354420390121,"score_spread":0.25039920636152274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193683700","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038782375,0.99727947,0.000009491595,0.00044404564,0.000039182953,0.002070334,0.00003582169,0.000029644814,0.0000532241],"genre_scores_gemma":[0.00030232038,0.9978617,0.00003179829,0.0005060027,0.0000019044002,0.0008907483,0.00022871206,0.000028369986,0.00014846888],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99641144,0.0008327085,0.0018360725,0.0005201033,0.00017038028,0.0002292834],"domain_scores_gemma":[0.9983204,0.0002464254,0.00064717827,0.000569139,0.00009711343,0.00011971873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000490008,0.0004310274,0.012841755,0.00039353626,0.00007539946,0.000024842335,0.00006104209,0.0004643172,0.00042285395],"category_scores_gemma":[0.00021148802,0.00025586816,0.0019943668,0.00066249765,0.00010186877,0.000035449277,0.000026125606,0.00046849297,0.000007993717],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022239278,0.00011994126,0.0001281018,0.5591208,0.42585242,0.0006470453,0.0000996064,2.8465037e-8,1.9926986e-8,0.00037152655,0.000066856555,0.013591479],"study_design_scores_gemma":[0.00050435006,0.00006123978,0.000021368458,0.09084562,0.87517023,0.01018656,0.000030005025,6.072568e-7,3.1529385e-8,0.000040467476,0.022851538,0.00028799035],"about_ca_topic_score_codex":0.000042406144,"about_ca_topic_score_gemma":0.000020236992,"teacher_disagreement_score":0.46827513,"about_ca_system_score_codex":0.000019608196,"about_ca_system_score_gemma":0.00010018716,"threshold_uncertainty_score":0.99998933},"labels":[],"label_agreement":null},{"id":"W3197844272","doi":"10.1007/s40744-021-00367-z","title":"Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Incyte; Horizon Pharma; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Medicine; Psoriatic arthritis; Family medicine; Physical therapy; Internal medicine; Rheumatoid arthritis","score_opus":0.08832795041247882,"score_gpt":0.32570483340535006,"score_spread":0.23737688299287124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197844272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862077,0.01293951,0.0000042272172,0.0003432036,0.000027055175,0.00014336227,0.00030446696,0.0000053813887,0.000025080473],"genre_scores_gemma":[0.955709,0.04391636,0.00013841326,0.000024973884,0.000002804381,0.00000837992,0.00019442251,0.000003929929,0.0000017235922],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992026,0.00023004308,0.00027665735,0.0001190012,0.00008925058,0.0000824454],"domain_scores_gemma":[0.9990771,0.00036221772,0.00016032114,0.0002287659,0.00015281011,0.000018827846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001752816,0.00007617709,0.00040211793,0.000008756794,0.00007498708,0.0000024951592,0.00003016444,0.000027403918,0.000001436524],"category_scores_gemma":[0.000096048476,0.00004999212,0.000022464179,0.00011513761,0.00020101153,0.000038668306,0.000028354323,0.000052941905,1.4553386e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006919323,0.000241218,0.8671986,0.000018330069,0.00029325453,7.245696e-7,0.00043300042,7.461804e-8,0.000002438818,0.00029708896,0.000004654153,0.13081871],"study_design_scores_gemma":[0.008959542,0.0003351739,0.9896802,0.0003031612,0.000019402236,0.0000053502145,0.0003154724,6.469707e-7,0.0000928645,0.00021208628,0.000035708596,0.000040405866],"about_ca_topic_score_codex":0.0010735695,"about_ca_topic_score_gemma":0.0015287179,"teacher_disagreement_score":0.1307783,"about_ca_system_score_codex":0.000006118568,"about_ca_system_score_gemma":0.000020512987,"threshold_uncertainty_score":0.20386194},"labels":[],"label_agreement":null},{"id":"W3203140217","doi":"10.1007/s40744-021-00372-2","title":"Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Department of Health and Social Care; National Institute for Health and Care Research; Leeds Biomedical Research Centre; Pfizer; Eli Lilly and Company","keywords":"Osteoarthritis; Composite number; Medicine; Internal medicine; Materials science; Pathology; Composite material; Alternative medicine","score_opus":0.008219133328378626,"score_gpt":0.2202051131008637,"score_spread":0.21198597977248507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203140217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294996,0.0063050976,0.0000027090125,0.00009941924,0.00007433722,0.0004470817,0.000036756155,0.000010314648,0.00007430459],"genre_scores_gemma":[0.9985174,0.0006499523,0.00043966807,0.000115551564,0.0000017942826,0.000015458836,0.00023452485,0.000013485016,0.000012197102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989915,0.000058429803,0.00031814334,0.0003316868,0.00012290326,0.00017734991],"domain_scores_gemma":[0.9994374,0.000043773078,0.0001007388,0.00030393223,0.00005522576,0.000058921854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000723116,0.00014264991,0.00043221712,0.000096946525,0.000027690068,0.000009876114,0.000044247456,0.0000862608,0.000020042142],"category_scores_gemma":[0.000013791752,0.00011748622,0.000013020532,0.000105577725,0.00009091696,0.00011318526,0.00006938087,0.0001019002,7.6678674e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002026485,0.0011290329,0.7665399,0.000051285355,0.00009039192,0.00017439423,0.0011077226,2.3821933e-7,0.011405894,0.00037017587,0.0000021899475,0.21710232],"study_design_scores_gemma":[0.19288304,0.053882353,0.47518387,0.0037437049,0.00018195329,0.0012754247,0.001639824,0.00007998145,0.2682795,0.0015159314,0.00043047062,0.0009039523],"about_ca_topic_score_codex":0.000044556033,"about_ca_topic_score_gemma":0.00029204608,"teacher_disagreement_score":0.291356,"about_ca_system_score_codex":0.000018506344,"about_ca_system_score_gemma":0.000049642775,"threshold_uncertainty_score":0.4790949},"labels":[],"label_agreement":null},{"id":"W3205906452","doi":"10.1007/s40744-021-00386-w","title":"Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19","year":2021,"lang":"en","type":"letter","venue":"Rheumatology and Therapy","topic":"Vagus Nerve Stimulation Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rheumatoid arthritis; Tumor necrosis factor alpha; Tumor necrosis factor α; Medicine; Internal medicine; Oncology","score_opus":0.053915058923763234,"score_gpt":0.3057772729268409,"score_spread":0.2518622140030777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205906452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68698174,0.00332288,0.000041627325,0.30793485,0.00026930522,0.001020873,0.00021370828,0.000049908158,0.00016508764],"genre_scores_gemma":[0.70672363,0.0984714,0.00019130923,0.19382346,0.000015124589,0.0003397056,0.00021237333,0.0001311679,0.00009185991],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958411,0.001018393,0.000971017,0.0010593004,0.00045712997,0.00065310247],"domain_scores_gemma":[0.9965315,0.0020250862,0.0005676782,0.0006852174,0.00009150961,0.00009899655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022046681,0.0006540989,0.0014317551,0.00043267274,0.00026476244,0.00018681234,0.00022846583,0.00039765975,0.00088388525],"category_scores_gemma":[0.00009613101,0.00055525696,0.00015935008,0.00032625804,0.00054514525,0.00019606255,0.00008263746,0.0010536218,0.000017077678],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009143129,0.009376379,0.31565073,0.002172119,0.003846545,0.019390464,0.02708102,0.004003766,0.0744768,0.019896934,0.44647214,0.06848997],"study_design_scores_gemma":[0.033790275,0.0035724463,0.0029727416,0.0071476307,0.000017504974,0.004204051,0.00083024683,0.0014539429,0.1716196,0.0015073448,0.7698977,0.0029865098],"about_ca_topic_score_codex":0.0009484894,"about_ca_topic_score_gemma":0.00021953958,"teacher_disagreement_score":0.32342556,"about_ca_system_score_codex":0.00016775411,"about_ca_system_score_gemma":0.0004545933,"threshold_uncertainty_score":0.9996899},"labels":[],"label_agreement":null},{"id":"W3207340776","doi":"10.1007/s40744-021-00379-9","title":"Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"AbbVie","keywords":"Medicine; Adalimumab; Placebo; Minimal clinically important difference; Psoriatic arthritis; Internal medicine; Psoriasis Area and Severity Index; Ankylosing spondylitis; Physical therapy; Randomized controlled trial; Rheumatoid arthritis; Psoriasis; Immunology","score_opus":0.011917436474358637,"score_gpt":0.2431157939151935,"score_spread":0.23119835744083486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207340776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968702,0.0016287866,0.0000011751006,0.00026851447,0.00011886836,0.00083614537,0.00009575211,0.000037306414,0.00014325303],"genre_scores_gemma":[0.99548554,0.0035436659,0.00021900202,0.00012328244,0.000004056754,0.00013784657,0.00040730642,0.000027094144,0.000052217783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998273,0.000082242135,0.0005366936,0.0005254865,0.00021127178,0.00037131656],"domain_scores_gemma":[0.9990545,0.0002844684,0.00018455683,0.0002790963,0.00011009599,0.000087293134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005513238,0.0002900891,0.0008065437,0.00010864196,0.00008418715,0.000014166822,0.00003259456,0.00012520932,0.00009339913],"category_scores_gemma":[0.00008907536,0.00018527677,0.00003484553,0.0002920212,0.000089614754,0.00006651823,0.000022212591,0.0001679501,0.0000032354696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07386985,0.0011725937,0.8719022,0.00000909068,0.00096676056,0.0014490816,0.00084787206,0.0000011855168,0.000008981266,0.000015493075,0.00002159659,0.04973527],"study_design_scores_gemma":[0.2463341,0.0066889743,0.74458194,0.00044462795,0.000058017107,0.00008147647,0.00068791106,0.000009232654,0.0006042987,0.0000272535,0.00023081413,0.0002513455],"about_ca_topic_score_codex":0.0016758423,"about_ca_topic_score_gemma":0.0070904647,"teacher_disagreement_score":0.17246427,"about_ca_system_score_codex":0.0000657883,"about_ca_system_score_gemma":0.00013192241,"threshold_uncertainty_score":0.75553674},"labels":[],"label_agreement":null},{"id":"W3208988466","doi":"10.1007/s40744-021-00388-8","title":"Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Adalimumab; Psoriatic arthritis; Psoriasis; Post-hoc analysis; Dermatology; Drug; Arthritis; Pharmacology; Internal medicine; Disease; Secukinumab","score_opus":0.02560367786290212,"score_gpt":0.26404507703939595,"score_spread":0.23844139917649382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208988466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93993574,0.05715401,0.0000021134254,0.0009337621,0.0007145474,0.000597912,0.0005095977,0.00005023363,0.00010209108],"genre_scores_gemma":[0.91899896,0.07982613,0.00029370235,0.00010498965,0.000015536945,0.00004576112,0.0006715319,0.000028632474,0.000014732787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722606,0.00031372634,0.0009768319,0.0007340546,0.00025553574,0.00049377064],"domain_scores_gemma":[0.9976485,0.0010435885,0.00035928213,0.0004885448,0.00025923678,0.00020086198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016941573,0.00040805698,0.0013576403,0.0001532621,0.00021824663,0.000028433378,0.00010575923,0.00020799797,0.00006144724],"category_scores_gemma":[0.000578496,0.00035740566,0.00021210978,0.0002867107,0.00039190706,0.00009405162,0.00008837464,0.00024075207,0.000015200346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035246715,0.0064231907,0.5642689,0.0003580994,0.0033018717,0.0014735542,0.003633074,0.000008706914,0.00012561074,0.0006648503,0.00014269492,0.38435274],"study_design_scores_gemma":[0.12383323,0.0018432308,0.8661678,0.0028271961,0.00027645216,0.00013758353,0.0022538458,0.00008503375,0.000819609,0.00083855743,0.000361656,0.000555827],"about_ca_topic_score_codex":0.0006942812,"about_ca_topic_score_gemma":0.00045053833,"teacher_disagreement_score":0.3837969,"about_ca_system_score_codex":0.000060575636,"about_ca_system_score_gemma":0.00021131933,"threshold_uncertainty_score":0.99988776},"labels":[],"label_agreement":null},{"id":"W4200209300","doi":"10.1007/s40744-021-00351-7","title":"Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Placebo; Biomarker; Internal medicine; Immunology; Gastroenterology; Post-hoc analysis; Pathology","score_opus":0.05249104156641909,"score_gpt":0.36216949100233553,"score_spread":0.30967844943591644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200209300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9658145,0.0226513,0.00070380076,0.00018970761,0.0017152386,0.008614182,0.000057826222,0.00006360881,0.00018986446],"genre_scores_gemma":[0.99235576,0.0047891214,0.00024625374,0.00004616131,0.00007244496,0.0017440151,0.00015112245,0.000051705432,0.0005434373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960406,0.0010712143,0.0014171185,0.0006586299,0.00039578986,0.0004166671],"domain_scores_gemma":[0.994808,0.002804983,0.000858507,0.0005565662,0.00078268524,0.00018925457],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005595145,0.00037620155,0.0028896532,0.00036139498,0.00022553693,0.000044304827,0.0001346385,0.00039468205,0.00007108754],"category_scores_gemma":[0.00059049943,0.00027468163,0.0008590858,0.000218847,0.0004071295,0.00012130311,0.000045499393,0.00023865658,0.000004616085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9287575,0.0014333022,0.0027103855,0.00060018105,0.007228524,0.000089986395,0.002574083,0.0000010828368,0.05559353,0.00012485629,0.00005385581,0.00083271065],"study_design_scores_gemma":[0.95397276,0.0014193826,0.0000058255546,0.0008578779,0.0008557432,0.021496166,0.0053751953,0.0015376655,0.01418767,0.00005511255,0.000026561247,0.00021001662],"about_ca_topic_score_codex":0.0003702451,"about_ca_topic_score_gemma":0.000019484087,"teacher_disagreement_score":0.04140586,"about_ca_system_score_codex":0.00011357222,"about_ca_system_score_gemma":0.0004145105,"threshold_uncertainty_score":0.99997056},"labels":[],"label_agreement":null},{"id":"W4200357740","doi":"10.1007/s40744-021-00405-w","title":"Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib","year":2021,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Pfizer (Canada)","funders":"Celgene; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Tofacitinib; Discontinuation; Janus kinase inhibitor; Nausea; Adverse effect; Internal medicine; Placebo; Rheumatoid arthritis; Vomiting; Incidence (geometry); Gastroenterology","score_opus":0.005117525276364914,"score_gpt":0.21830132155952292,"score_spread":0.213183796283158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200357740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98057836,0.01856297,0.000019828638,0.00014779446,0.000024039153,0.000563527,0.000025521165,0.000023563578,0.000054375432],"genre_scores_gemma":[0.7783167,0.22129732,0.00023346343,0.000028028127,0.000001896615,0.00004190162,0.00005410214,0.000020974809,0.0000056372273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985369,0.00013016546,0.00041910497,0.00037435014,0.00022308758,0.00031639592],"domain_scores_gemma":[0.99923384,0.00008665741,0.00014245303,0.00019917198,0.00018110703,0.00015675052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012790838,0.00023151805,0.0006734213,0.00016251975,0.00011323084,0.000011372786,0.000035774767,0.00013188017,0.000067600784],"category_scores_gemma":[0.000040877923,0.00018262205,0.000027037073,0.00021580161,0.00034204195,0.00023752518,0.000017137305,0.00019228396,0.0000018790083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015442525,0.00024462465,0.93359333,0.000045739172,0.00019059467,0.000084580795,0.001172821,2.9462868e-7,0.00020846663,0.00037090824,0.0000017994837,0.06254261],"study_design_scores_gemma":[0.027166251,0.0021251114,0.96584564,0.0017140581,0.0000024960848,0.0007253104,0.00032865806,0.000017350343,0.0011453059,0.00069600943,0.00002888357,0.00020490302],"about_ca_topic_score_codex":0.00031704962,"about_ca_topic_score_gemma":0.0004073472,"teacher_disagreement_score":0.20273435,"about_ca_system_score_codex":0.000010376441,"about_ca_system_score_gemma":0.00011670057,"threshold_uncertainty_score":0.7447111},"labels":[],"label_agreement":null},{"id":"W4206718482","doi":"10.1007/s40744-021-00415-8","title":"Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Gilead Sciences; Sanofi; Amgen; Pfizer; Canadian Rheumatology Association; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Post-hoc analysis; Rheumatoid arthritis; Post hoc; Medicine; Physical therapy; Internal medicine; Phase (matter); Clinical trial","score_opus":0.028062979523669526,"score_gpt":0.3322063269093806,"score_spread":0.3041433473857111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206718482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886761,0.008616677,0.000033755165,0.00041863017,0.000085799016,0.001441583,0.0006100392,0.000056631052,0.000060811144],"genre_scores_gemma":[0.9725113,0.02620994,0.00022380691,0.00028207316,0.00000289714,0.00027673357,0.00043662035,0.000043340155,0.000013313583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964349,0.00082076434,0.0011392155,0.00057769206,0.00050529646,0.0005220905],"domain_scores_gemma":[0.9977685,0.0007542177,0.00052371743,0.00040321331,0.00032306154,0.00022726522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043621994,0.0003638501,0.0019150181,0.00049367896,0.00025652963,0.00002594872,0.00014632955,0.000090115514,0.0007139462],"category_scores_gemma":[0.00043585812,0.0002685452,0.00016059128,0.0004724831,0.00023695074,0.00017155016,0.0000873921,0.00038785595,0.000004686959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07738074,0.0027764637,0.7838406,0.000014024575,0.0023240172,0.00024790486,0.0041358895,0.00009820242,0.00223031,0.00031065405,0.00009869971,0.12654252],"study_design_scores_gemma":[0.4342435,0.0304588,0.48625666,0.0020742037,0.000052027935,0.0010415732,0.012002617,0.000616775,0.02296408,0.0045631574,0.0036727353,0.0020538687],"about_ca_topic_score_codex":0.0022485123,"about_ca_topic_score_gemma":0.00025998408,"teacher_disagreement_score":0.35686275,"about_ca_system_score_codex":0.000054934328,"about_ca_system_score_gemma":0.00020231352,"threshold_uncertainty_score":0.9999767},"labels":[],"label_agreement":null},{"id":"W4212822641","doi":"10.1007/s40744-022-00429-w","title":"Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Post-hoc analysis; Internal medicine; Rheumatoid arthritis; Erythrocyte sedimentation rate; Placebo; Post hoc; Demographics; Clinical trial; Osteoarthritis; Gastroenterology; Pathology","score_opus":0.015913924057114205,"score_gpt":0.306031817797459,"score_spread":0.2901178937403448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212822641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857549,0.012941884,0.000011775951,0.00051434734,0.00022134368,0.0004153796,0.000060579026,0.000022755408,0.000057048474],"genre_scores_gemma":[0.9195991,0.08013881,0.000054112545,0.000073528194,0.0000040373116,0.00006614763,0.000025924297,0.000012389442,0.00002595339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695235,0.0010964078,0.000994446,0.0003562568,0.00034182955,0.0002586822],"domain_scores_gemma":[0.998448,0.0006095847,0.00030382402,0.00031449928,0.00016404742,0.00016003106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074312923,0.00014509415,0.0010986021,0.0009810189,0.00014751806,0.0000061447777,0.000113831724,0.000108618966,0.00018087379],"category_scores_gemma":[0.00034027515,0.0001394921,0.0002781786,0.00086460845,0.00035024504,0.00006855178,0.000079400175,0.00035094467,0.0000010846097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062251855,0.00078196696,0.8805341,0.000017353093,0.002357763,0.000058635065,0.005410064,0.000072192386,0.0097044045,0.00025478858,0.000053832227,0.03850302],"study_design_scores_gemma":[0.007512807,0.010663311,0.97157496,0.00015590846,0.000019502844,0.0005789292,0.0051065776,0.0002818227,0.0017393095,0.000049214646,0.002153977,0.00016369844],"about_ca_topic_score_codex":0.0005542875,"about_ca_topic_score_gemma":0.00012939375,"teacher_disagreement_score":0.09104081,"about_ca_system_score_codex":0.000041126474,"about_ca_system_score_gemma":0.00025126405,"threshold_uncertainty_score":0.5688322},"labels":[],"label_agreement":null},{"id":"W4220972031","doi":"10.1007/s40744-022-00433-0","title":"Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Hospital for Sick Children; University of Toronto","funders":"Swedish Orphan Biovitrum; OPKO Health; F. Hoffmann-La Roche","keywords":"Granulomatosis with polyangiitis; Rituximab; Microscopic polyangiitis; Medicine; Immunology; Antibody; Vasculitis; Dermatology; Pathology; Disease","score_opus":0.011317587977648548,"score_gpt":0.2596496005984515,"score_spread":0.24833201262080296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220972031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495775,0.0033957227,0.000120577984,0.00019791067,0.00011951354,0.0010934636,0.00006663131,0.0000261463,0.000022310456],"genre_scores_gemma":[0.9966486,0.0025344559,0.00023359008,0.00004866413,0.0000064097426,0.0003576229,0.00012794686,0.000022882987,0.000019810514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988698,0.00017120536,0.00027591322,0.00022529262,0.00025652145,0.00020126608],"domain_scores_gemma":[0.9993771,0.00009774504,0.00016058254,0.0001406413,0.00018684022,0.00003713858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000319126,0.00013414447,0.00036518642,0.00024926843,0.00023423861,0.0000076153606,0.00003833952,0.00009402639,0.00022785844],"category_scores_gemma":[0.00003631566,0.00009821679,0.00004800786,0.0003702901,0.00006576881,0.00007261561,0.000014589072,0.00016457468,9.1929877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011649717,0.000704504,0.97363335,0.00010438968,0.00027139328,0.000005391486,0.00070252136,0.00004007744,0.000108423985,0.000071756986,0.000030590894,0.023162613],"study_design_scores_gemma":[0.0278611,0.0021061683,0.96840805,0.00018455679,0.00022681906,0.00032016338,0.00007480004,0.00013944457,0.0003213752,0.00017880989,0.00003808154,0.0001406274],"about_ca_topic_score_codex":0.00034968316,"about_ca_topic_score_gemma":0.00018566905,"teacher_disagreement_score":0.026696127,"about_ca_system_score_codex":0.0000706113,"about_ca_system_score_gemma":0.0001912443,"threshold_uncertainty_score":0.40051645},"labels":[],"label_agreement":null},{"id":"W4220985222","doi":"10.1007/s40744-022-00435-y","title":"Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Psoriatic arthritis; Disease; Health care; Family medicine; Demography; Patient satisfaction; Internal medicine; Surgery","score_opus":0.012206181359198718,"score_gpt":0.2621634408837821,"score_spread":0.24995725952458336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220985222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97661114,0.021211758,0.000005218878,0.00032235787,0.00015554247,0.00041358414,0.0012461593,0.000008949142,0.00002528888],"genre_scores_gemma":[0.96639276,0.032612458,0.000088347464,0.00017037561,0.000003991344,0.000087076325,0.00063717447,0.0000068386807,0.0000010075175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989459,0.00017042893,0.00031513514,0.00024031155,0.00018792135,0.00014028499],"domain_scores_gemma":[0.99952376,0.0001582728,0.000100622405,0.00010368165,0.00005296478,0.000060674363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007011661,0.00010007748,0.00039042925,0.00003233563,0.00012077769,0.0000029257726,0.000029192934,0.00004519355,0.00006814167],"category_scores_gemma":[0.00011103417,0.00008628798,0.00002881835,0.00013180879,0.0000990899,0.000013951208,0.000057119592,0.00008319471,8.318484e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026684445,0.00022515537,0.5096492,0.000013158063,0.00008524793,0.00004233468,0.0064445394,0.0000012695132,0.0000015790113,0.00001837731,0.00013344632,0.4807172],"study_design_scores_gemma":[0.015029759,0.0034525183,0.9701452,0.00007791145,0.000011952946,0.0001054446,0.0048151533,0.00006875977,0.0000026183004,0.000050985655,0.0061446964,0.00009495805],"about_ca_topic_score_codex":0.0043684267,"about_ca_topic_score_gemma":0.0036379574,"teacher_disagreement_score":0.48062226,"about_ca_system_score_codex":0.000028509752,"about_ca_system_score_gemma":0.000049325303,"threshold_uncertainty_score":0.66037834},"labels":[],"label_agreement":null},{"id":"W4223530465","doi":"10.1007/s40744-022-00445-w","title":"Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Internal medicine; Enthesitis; Rheumatology; Randomized controlled trial; Physical therapy; Body mass index; Arthritis; Secukinumab","score_opus":0.04814159111236015,"score_gpt":0.3781690111166092,"score_spread":0.33002742000424906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223530465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97841793,0.018241227,0.000008022651,0.001071444,0.00026923654,0.001590868,0.0003097606,0.000022100321,0.00006943703],"genre_scores_gemma":[0.98155975,0.017150577,0.000323598,0.0004177221,0.000022090637,0.00030389157,0.00011896713,0.000017140652,0.00008628264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99645853,0.0017486835,0.0009332366,0.0004581089,0.00016496675,0.0002364562],"domain_scores_gemma":[0.9960688,0.0033128934,0.00022801397,0.00022169198,0.000038531944,0.00013010915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002162182,0.00018882733,0.001650046,0.0001311962,0.00021720109,0.00001314656,0.00004607023,0.00006362253,0.00017967084],"category_scores_gemma":[0.00127094,0.0001355481,0.00009427415,0.00012907281,0.000197048,0.00003896863,0.00006260568,0.00020494063,0.000005910281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60703427,0.00084643904,0.23149015,0.0000041678923,0.0005002438,0.00020526498,0.0012455485,6.622098e-7,0.0000015483783,0.000121441415,0.00014744433,0.15840285],"study_design_scores_gemma":[0.93102485,0.0037081295,0.061383516,0.00015647092,0.0000812136,0.00016932115,0.00053932564,0.000020119824,0.000011108789,0.00045146135,0.0022855434,0.0001689251],"about_ca_topic_score_codex":0.0005712646,"about_ca_topic_score_gemma":0.00016018013,"teacher_disagreement_score":0.3239906,"about_ca_system_score_codex":0.000019045945,"about_ca_system_score_gemma":0.00005579994,"threshold_uncertainty_score":0.5527491},"labels":[],"label_agreement":null},{"id":"W4229007735","doi":"10.1007/s40744-022-00447-8","title":"Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”","year":2022,"lang":"en","type":"letter","venue":"Rheumatology and Therapy","topic":"Shoulder Injury and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Capsulitis; Adhesive; Medicine; Orthodontics; Materials science; Radiology; Composite material","score_opus":0.015271759486481155,"score_gpt":0.27891443279883865,"score_spread":0.2636426733123575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229007735","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040194593,0.013509264,0.0000075670296,0.93805075,0.005719167,0.001032846,0.00015351137,0.000054467582,0.0012778474],"genre_scores_gemma":[0.047873776,0.004731925,0.00010187347,0.9359601,0.007028536,0.00034100335,0.00036670754,0.00007171937,0.00352435],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985279,0.00022357481,0.00027674125,0.00039602732,0.00026535493,0.00031040833],"domain_scores_gemma":[0.99855626,0.00071187306,0.00015178528,0.00048724713,0.000041674808,0.000051165145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016148464,0.00029500888,0.0006983258,0.0001260921,0.00022111916,0.000014341647,0.000170667,0.0005079677,0.0006469174],"category_scores_gemma":[0.00005427655,0.00018315487,0.00017630901,0.000105748884,0.0001704765,0.000023962077,0.000048901366,0.0013440703,0.000012199948],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043514272,0.0000414577,0.0013402217,0.00008455157,0.0008203349,0.00024722857,0.00089974224,2.2415644e-7,0.00007248043,0.00012668205,0.9944715,0.0014604466],"study_design_scores_gemma":[0.0011510643,0.0006272098,0.0009816266,0.00007407337,0.00015297296,0.0016050094,0.00009029532,7.27939e-8,0.0013569591,0.00022465552,0.9935735,0.00016260135],"about_ca_topic_score_codex":0.00013566388,"about_ca_topic_score_gemma":0.0000060662396,"teacher_disagreement_score":0.008777339,"about_ca_system_score_codex":0.00003502951,"about_ca_system_score_gemma":0.000069987356,"threshold_uncertainty_score":0.74688387},"labels":[],"label_agreement":null},{"id":"W4281252987","doi":"10.1007/s40744-022-00454-9","title":"Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review","year":2022,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline","keywords":"Belimumab; Medicine; Observational study; Prednisone; Internal medicine; Randomized controlled trial; Systematic review; Clinical trial; Meta-analysis; MEDLINE; Immunology; Antibody; B-cell activating factor; B cell","score_opus":0.033347838248144676,"score_gpt":0.3527322264854972,"score_spread":0.3193843882373525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281252987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009977088,0.9867557,0.0000023018777,0.000016167778,0.000488368,0.0111513715,0.000039305858,0.00007962741,0.00046941653],"genre_scores_gemma":[0.00035891257,0.9949824,0.000016111884,0.00002039613,0.000014792826,0.0039052234,0.00018150217,0.00015158192,0.00036904294],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9891476,0.0060688504,0.0026257008,0.0009144209,0.00063890347,0.00060454756],"domain_scores_gemma":[0.99211895,0.00487088,0.0012973067,0.0013912801,0.00014907324,0.0001725323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005004916,0.000845475,0.011732746,0.0014755911,0.00009856223,0.00002223625,0.00049945776,0.00059955154,0.00013567801],"category_scores_gemma":[0.00048805104,0.00057453633,0.00082456705,0.002163065,0.00019589263,0.000073662566,0.0001866543,0.0012960288,0.000024903646],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023435347,0.00018194366,0.0026327723,0.98236054,0.0010685235,0.00051503204,0.0004095526,5.2311293e-8,0.0000010833629,0.0014912018,0.00008742118,0.011017525],"study_design_scores_gemma":[0.0020499297,0.00018299157,0.0000025201305,0.7510992,0.0004906248,0.228214,0.00007460911,0.0000024568935,5.6318595e-7,0.000056420253,0.017535413,0.00029127026],"about_ca_topic_score_codex":0.00005290287,"about_ca_topic_score_gemma":0.0000091687925,"teacher_disagreement_score":0.23126133,"about_ca_system_score_codex":0.00042272502,"about_ca_system_score_gemma":0.0007121193,"threshold_uncertainty_score":0.9996706},"labels":[],"label_agreement":null},{"id":"W4281385143","doi":"10.1007/s40744-022-00449-6","title":"Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"Gilead Sciences; AbbVie; Sanofi; Sun Pharma; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Post-hoc analysis; Medicine; Placebo; Internal medicine; Post hoc; Disease; Oncology; Pathology; Alternative medicine","score_opus":0.006328893737726416,"score_gpt":0.24811055344896543,"score_spread":0.24178165971123902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281385143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97528124,0.02070135,0.000012424372,0.00056848576,0.000045561505,0.003163525,0.00019713602,0.000011206465,0.000019081062],"genre_scores_gemma":[0.9949751,0.0037893327,0.000017921211,0.0002560997,0.0000035250503,0.0008711514,0.000057089732,0.0000132236,0.00001657829],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977774,0.00097496127,0.0005414908,0.00027123137,0.00022528495,0.0002096457],"domain_scores_gemma":[0.9981954,0.001075745,0.00037084054,0.00019324615,0.00008274944,0.00008200138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072430243,0.00020286128,0.002452135,0.00021385886,0.00022859938,0.000009083459,0.000046837344,0.000035791334,0.0001710918],"category_scores_gemma":[0.00023143213,0.00010332232,0.00019911489,0.00038724387,0.0002750051,0.00003304238,0.000020207042,0.0001313595,2.0744146e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7078291,0.0008284963,0.27657706,0.000011361474,0.007820267,0.000026217052,0.00048234436,0.00001198465,0.0000018590233,0.0002238605,0.0000061120472,0.006181303],"study_design_scores_gemma":[0.92170584,0.0025289345,0.07247276,0.00007922636,0.0024810547,0.000025320098,0.00022207107,0.00025714413,0.0000030138488,0.00007160941,0.00004312865,0.000109895016],"about_ca_topic_score_codex":0.00009597969,"about_ca_topic_score_gemma":0.00011242266,"teacher_disagreement_score":0.21387671,"about_ca_system_score_codex":0.00001710817,"about_ca_system_score_gemma":0.00008861307,"threshold_uncertainty_score":0.4213362},"labels":[],"label_agreement":null},{"id":"W4289912960","doi":"10.1007/s40744-022-00474-5","title":"Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie; Boehringer Ingelheim","keywords":"Medicine; Placebo; Internal medicine; Rheumatology; Psoriatic arthritis; Randomized controlled trial; Adverse effect; Clinical endpoint; Psoriasis Area and Severity Index; Psoriasis; Gastroenterology; Arthritis; Physical therapy; Dermatology; Pathology","score_opus":0.010314349004259685,"score_gpt":0.2628086861174515,"score_spread":0.2524943371131918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289912960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98935336,0.007978597,0.000004719109,0.00013743815,0.0001677681,0.0020385091,0.0002450518,0.000015164453,0.000059377842],"genre_scores_gemma":[0.98786557,0.011561554,0.00004655448,0.000041407115,0.000008794968,0.00018178008,0.000271588,0.000014120102,0.000008622364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985334,0.0003045722,0.000490571,0.00032165032,0.00016294121,0.00018685662],"domain_scores_gemma":[0.99880266,0.00070054637,0.00023973502,0.00016857371,0.000031598407,0.00005690346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019789126,0.00017644951,0.0011132299,0.000098694,0.0001604482,0.0000048376282,0.000038141654,0.00006103023,0.00010476273],"category_scores_gemma":[0.000096649805,0.0001315154,0.000058659676,0.00010856208,0.00024707682,0.000041764186,0.00004072162,0.00017247834,6.600493e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8500456,0.0028852466,0.022011183,0.000007602017,0.0008228141,0.0000619481,0.0021477733,3.9444402e-7,0.0000012608922,0.000063135034,0.000007662782,0.12194535],"study_design_scores_gemma":[0.87724376,0.005787279,0.11626075,0.00014996954,0.000075018084,0.000029945097,0.00013528219,0.000005306343,0.000021016243,0.00015720684,0.00003454557,0.000099937715],"about_ca_topic_score_codex":0.00027732833,"about_ca_topic_score_gemma":0.000051330262,"teacher_disagreement_score":0.12184542,"about_ca_system_score_codex":0.000026125997,"about_ca_system_score_gemma":0.000045330045,"threshold_uncertainty_score":0.5363042},"labels":[],"label_agreement":null},{"id":"W4294123158","doi":"10.1007/s40744-022-00485-2","title":"Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada)","funders":"","keywords":"Medicine; Apremilast; Golimumab; Tofacitinib; Secukinumab; Tocilizumab; Abatacept; Psoriatic arthritis; Ustekinumab; Internal medicine; Adalimumab; Rheumatoid arthritis; Rituximab","score_opus":0.012558214626956528,"score_gpt":0.2444003840956414,"score_spread":0.23184216946868488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294123158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98264354,0.01647632,0.0002208359,0.00015250323,0.000040353458,0.0004271043,0.000019904515,0.0000074601144,0.000011977812],"genre_scores_gemma":[0.94540447,0.054032806,0.0003510316,0.000029037576,0.0000010944334,0.00015599915,0.0000055108167,0.000011692928,0.000008343921],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999227,0.00007547868,0.00023197052,0.000152468,0.00013964868,0.00017346445],"domain_scores_gemma":[0.99954414,0.00016173936,0.00010947719,0.00010257373,0.00003665595,0.000045398596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016466365,0.00009715832,0.0003893232,0.000089572255,0.00009071182,0.0000026845462,0.000046493184,0.000026917342,0.000056877332],"category_scores_gemma":[0.0000142117115,0.00008216617,0.000019224279,0.000076116994,0.00011757945,0.0000578091,0.000023276014,0.0001215724,2.9663575e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008793872,0.00018012935,0.39809898,0.00038589168,0.0003796018,0.000044054996,0.004524809,0.000040925337,0.10065191,0.0110506015,0.00001692168,0.4758323],"study_design_scores_gemma":[0.083027914,0.018014833,0.58098984,0.0026736776,0.000012661864,0.0034955225,0.04620218,0.001752653,0.20965892,0.046181466,0.006767192,0.0012231093],"about_ca_topic_score_codex":0.03531625,"about_ca_topic_score_gemma":0.12698467,"teacher_disagreement_score":0.4746092,"about_ca_system_score_codex":0.000027673606,"about_ca_system_score_gemma":0.00030266907,"threshold_uncertainty_score":0.97110766},"labels":[],"label_agreement":null},{"id":"W4294970515","doi":"10.1007/s40744-022-00482-5","title":"Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Enthesitis; Medicine; Psoriasis Area and Severity Index; Internal medicine; Psoriatic arthritis; Psoriasis; Arthritis; Placebo; Dermatology; Gastroenterology; Rheumatoid arthritis; Pathology","score_opus":0.011728116135810375,"score_gpt":0.24505841220178645,"score_spread":0.23333029606597608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294970515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595475,0.0032420037,0.00006499143,0.00012733082,0.000016664964,0.0005630486,0.000015462609,0.0000099639365,0.0000057780953],"genre_scores_gemma":[0.99755424,0.0019335541,0.000093928975,0.000008072519,0.0000031439465,0.00025754518,0.00014057421,0.0000073924775,0.0000015390457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993492,0.00011316935,0.00018578947,0.00014831427,0.00010433498,0.00009923756],"domain_scores_gemma":[0.999605,0.00011220439,0.00014199594,0.00007523788,0.00004929886,0.000016256028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002296237,0.00008057663,0.00027512878,0.00015217983,0.00020786354,0.000006117783,0.000015923306,0.000025942458,0.000014483345],"category_scores_gemma":[0.000019837502,0.0000526214,0.000024934174,0.00029879826,0.000060083952,0.00005130893,0.000006980754,0.00005603445,4.9406154e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012595758,0.000088487686,0.9077422,0.000017630555,0.00057746895,0.0000014687645,0.002383842,0.000017772622,0.000054130272,0.0002741433,5.473366e-7,0.08758272],"study_design_scores_gemma":[0.018260894,0.0025537098,0.96572703,0.00011230867,0.0002729129,0.00007008313,0.009604949,0.0016085972,0.0005392699,0.0010077523,0.00009949484,0.00014302046],"about_ca_topic_score_codex":0.00014746339,"about_ca_topic_score_gemma":0.0001721215,"teacher_disagreement_score":0.0874397,"about_ca_system_score_codex":0.000014782859,"about_ca_system_score_gemma":0.0000126604755,"threshold_uncertainty_score":0.21458384},"labels":[],"label_agreement":null},{"id":"W4296161978","doi":"10.1007/s40744-022-00487-0","title":"Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren’s","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Physical therapy; Internal medicine; Perspective (graphical); Patient-reported outcome; Clinical psychology; Quality of life (healthcare)","score_opus":0.4302436541809335,"score_gpt":0.43518523397959574,"score_spread":0.004941579798662221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296161978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954068,0.001129406,0.0000194656,0.0027181304,0.000054165124,0.00048508903,0.000019226853,0.000011122816,0.00015659865],"genre_scores_gemma":[0.99705076,0.0016939689,0.000037234757,0.0009626512,0.000006204449,0.00018650423,0.000016606215,0.000010085095,0.00003600706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892086,0.0003748421,0.00010800629,0.00026538587,0.00014873545,0.00018219238],"domain_scores_gemma":[0.99937433,0.00037955577,0.00003181467,0.00008620954,0.000055102293,0.000073014715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004422434,0.0000989724,0.00026585776,0.00015003321,0.00027838172,0.000012386743,0.000024068893,0.000039641513,0.000018976018],"category_scores_gemma":[0.000039549035,0.00007464624,0.000008938896,0.0001423396,0.0001552551,0.000047663074,0.000047580994,0.00023075208,5.4452175e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020485625,0.00036740853,0.9493882,0.000032117227,0.000045291203,0.000010142451,0.038307633,2.3898906e-7,0.000029137585,0.0035672865,0.00015638523,0.006047591],"study_design_scores_gemma":[0.006519855,0.0046646423,0.9579273,0.00008681187,0.000009624708,0.00004792929,0.027979653,0.000039846054,0.000029495443,0.0014684595,0.0010913789,0.00013502981],"about_ca_topic_score_codex":0.00054265646,"about_ca_topic_score_gemma":0.00012731296,"teacher_disagreement_score":0.01032798,"about_ca_system_score_codex":0.000014377079,"about_ca_system_score_gemma":0.000016786835,"threshold_uncertainty_score":0.30439854},"labels":[],"label_agreement":null},{"id":"W4296929673","doi":"10.1007/s40744-022-00489-y","title":"Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Novartis Pharma","keywords":"Content validity; Medicine; Population; Qualitative research; Physical therapy; Psychology; Family medicine; Clinical psychology; Psychometrics","score_opus":0.04063145435845555,"score_gpt":0.2585249252789308,"score_spread":0.21789347092047523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296929673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555284,0.0033038757,0.00019179021,0.000218226,0.00019633895,0.00041051256,0.000039885505,0.000012489961,0.00007405077],"genre_scores_gemma":[0.99730736,0.002328373,0.000026308397,0.00009133236,0.0000037245454,0.00010297785,0.00010828932,0.000011768898,0.00001986174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990062,0.00016061087,0.0002803524,0.0002152911,0.00019138584,0.00014612339],"domain_scores_gemma":[0.99942666,0.00016903838,0.00014103067,0.0001562289,0.00005822465,0.000048788042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002212498,0.00013303524,0.00044752329,0.00014243471,0.00012584055,0.0000027938324,0.000037902548,0.00006003032,0.000417004],"category_scores_gemma":[0.000007696337,0.0000973822,0.00004168329,0.00013019111,0.00017732091,0.00004884021,0.000031263447,0.00017033683,1.5429426e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011173814,0.0010128361,0.99248916,0.000052942512,0.00019460777,0.0000053414924,0.00027431658,0.000025469833,0.000037129754,0.0011156616,0.00004574947,0.0036293862],"study_design_scores_gemma":[0.011079568,0.002899975,0.984817,0.00004917996,0.000017796463,0.00011910679,0.00030037903,0.0001623541,0.000028534632,0.00021725796,0.0002012746,0.00010752743],"about_ca_topic_score_codex":0.00020547051,"about_ca_topic_score_gemma":0.000019371317,"teacher_disagreement_score":0.009962187,"about_ca_system_score_codex":0.000034867357,"about_ca_system_score_gemma":0.00013600742,"threshold_uncertainty_score":0.45659015},"labels":[],"label_agreement":null},{"id":"W4303859853","doi":"10.1007/s40744-022-00498-x","title":"Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Post-hoc analysis; Post hoc; Medicine; Internal medicine; Oncology","score_opus":0.007263990919716048,"score_gpt":0.2490476914079439,"score_spread":0.24178370048822784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303859853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645376,0.0013983671,0.0000020063871,0.0006471666,0.00001675722,0.0013049535,0.00016672093,0.0000061587193,0.0000040807618],"genre_scores_gemma":[0.9965818,0.0032256073,0.00003905096,0.0000414507,5.537004e-7,0.00007352115,0.000015359952,0.000012126344,0.000010521495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775475,0.0010172853,0.00045506886,0.00024615065,0.0003307061,0.00019601952],"domain_scores_gemma":[0.9986709,0.00060671906,0.0002395386,0.00027541944,0.0001395973,0.000067833185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008462714,0.00013467603,0.00078404974,0.0004654399,0.00013596618,0.000004175625,0.00013541251,0.000041923013,0.00010567897],"category_scores_gemma":[0.00021840303,0.00008657098,0.00006692521,0.0009826814,0.0002571208,0.000032761567,0.00011650984,0.00020224015,1.5675467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082642354,0.0014230745,0.8937865,0.000019035866,0.0017158074,0.0000032022801,0.006573463,0.000033431872,0.0001924372,0.00007184611,0.000007882452,0.0135309445],"study_design_scores_gemma":[0.01615883,0.009600744,0.97237915,0.00009356257,0.000047758585,0.0000051270754,0.001208456,0.000041739346,0.00030070022,0.000022560489,0.000064474894,0.000076877724],"about_ca_topic_score_codex":0.00090206246,"about_ca_topic_score_gemma":0.0003175531,"teacher_disagreement_score":0.07859265,"about_ca_system_score_codex":0.000013799211,"about_ca_system_score_gemma":0.00008709458,"threshold_uncertainty_score":0.3530262},"labels":[],"label_agreement":null},{"id":"W4306294863","doi":"10.1007/s40744-022-00499-w","title":"Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group; McMaster University","funders":"AbbVie","keywords":"Psoriatic arthritis; Medicine; Dermatology; Phase (matter); Internal medicine; Oncology; Arthritis; Chemistry","score_opus":0.009607918117707422,"score_gpt":0.2528416980567992,"score_spread":0.24323377993909176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306294863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929122,0.0055392594,6.419973e-7,0.0002763582,0.000060225822,0.00097270514,0.00016813545,0.0000119026345,0.00005859073],"genre_scores_gemma":[0.9959706,0.0037514432,0.000029292689,0.000073592855,0.000004984851,0.00006171281,0.00008953866,0.000010798777,0.000008010315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989996,0.0001639134,0.00029067154,0.00024672312,0.0001457623,0.0001533156],"domain_scores_gemma":[0.99933594,0.00031462262,0.00010515608,0.00018065068,0.000029579765,0.00003402403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015755103,0.00012235685,0.00040587614,0.00004031166,0.0002222891,0.0000043143655,0.000043664153,0.000028362034,0.00007484861],"category_scores_gemma":[0.000041113595,0.000078851175,0.0000178024,0.00013905017,0.00011148698,0.000022582673,0.000042185813,0.00015313158,9.2505104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031794492,0.0027424933,0.910847,0.00000355456,0.00046868183,0.00003295409,0.0050398833,8.2844673e-7,0.0000023787707,0.00009266696,0.00006836893,0.048906717],"study_design_scores_gemma":[0.1611972,0.005980977,0.82979786,0.00006653166,0.000032243446,0.00002277207,0.001967724,0.0000037016175,0.000008905405,0.00006983992,0.00077559263,0.0000766361],"about_ca_topic_score_codex":0.0003634431,"about_ca_topic_score_gemma":0.00011279207,"teacher_disagreement_score":0.12940271,"about_ca_system_score_codex":0.000011711581,"about_ca_system_score_gemma":0.000026287975,"threshold_uncertainty_score":0.32154575},"labels":[],"label_agreement":null},{"id":"W4311927297","doi":"10.1007/s40744-022-00511-3","title":"Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate","year":2022,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Montreal Clinical Research Institute","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Rheumatoid arthritis; Methotrexate; Erythrocyte sedimentation rate; Internal medicine; Gastroenterology","score_opus":0.012924978512339091,"score_gpt":0.2704188013543953,"score_spread":0.2574938228420562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311927297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395365,0.0040929033,0.00010065301,0.00007935216,0.000022327364,0.0014672625,0.00016461012,0.00006276308,0.000056483997],"genre_scores_gemma":[0.9841909,0.015077941,0.00010480826,0.000029225755,0.0000012100398,0.0003953636,0.00013614091,0.00004685752,0.000017558315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632543,0.0011601574,0.00052748213,0.0006827716,0.0007620987,0.0005420651],"domain_scores_gemma":[0.99818635,0.00042147317,0.00034622318,0.00052147725,0.00019791392,0.0003265666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077974505,0.0003838769,0.001614826,0.001633478,0.00031814852,0.000029016735,0.0001718261,0.00006946379,0.00041617328],"category_scores_gemma":[0.00008551023,0.00028552784,0.00014530703,0.003150421,0.00048393698,0.00021340349,0.0000782752,0.00051004795,8.866412e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022179974,0.0024044134,0.95377696,0.000020623787,0.0041746283,0.00021119571,0.0022946286,0.00021363674,0.000020532189,0.00008430413,0.0000034191728,0.014615686],"study_design_scores_gemma":[0.02505435,0.0047863014,0.9668195,0.00010716492,0.000079551595,0.000037214555,0.0013563696,0.0011843576,0.00012497618,0.000060549053,0.000068221925,0.00032139788],"about_ca_topic_score_codex":0.001725321,"about_ca_topic_score_gemma":0.00074793975,"teacher_disagreement_score":0.014294288,"about_ca_system_score_codex":0.00006854485,"about_ca_system_score_gemma":0.00022280532,"threshold_uncertainty_score":0.9999597},"labels":[],"label_agreement":null},{"id":"W4317567968","doi":"10.1007/s40744-022-00529-7","title":"Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Chugai Pharmaceutical; Genentech; Astellas Pharma; National Institute for Health and Care Research; Biogen; Celgene; Gilead Sciences; Nordic Pharma Group; Eisai; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Rheumatoid arthritis; Medicine; Disease; Dermatology; Arthritis; Internal medicine; Physical therapy","score_opus":0.037912512539651305,"score_gpt":0.3451770614039854,"score_spread":0.3072645488643341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317567968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684716,0.029686116,0.000001847868,0.00066879415,0.00012896377,0.0008346809,0.000031564403,0.00013013725,0.000046307894],"genre_scores_gemma":[0.6233025,0.3763398,0.000018425326,0.00008705877,0.000004881708,0.00015988783,0.000053003852,0.000024669496,0.000009742257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973598,0.00039662706,0.000795295,0.0005264341,0.00029385285,0.00062795694],"domain_scores_gemma":[0.9986126,0.0005904509,0.0000912669,0.00027115954,0.00013924704,0.0002952746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004419808,0.00030408273,0.0009934555,0.000469217,0.00013968893,0.000024876894,0.00007772664,0.00013879957,0.000053939835],"category_scores_gemma":[0.00040481708,0.0002273249,0.00008801941,0.00065313175,0.0005931421,0.00016055634,0.000044638713,0.00038046352,0.000029644298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056083966,0.0009091351,0.8832953,0.00003615874,0.00020670918,0.00066978973,0.0014209703,0.0000014354994,0.000016889526,0.0002995805,0.00023547711,0.10730017],"study_design_scores_gemma":[0.0464327,0.0038678227,0.94189125,0.0015224998,0.0000021439341,0.00013265396,0.0012291999,0.00016757887,0.00011305492,0.001033572,0.0032454217,0.00036208925],"about_ca_topic_score_codex":0.00014156739,"about_ca_topic_score_gemma":0.000309006,"teacher_disagreement_score":0.3466537,"about_ca_system_score_codex":0.00003125561,"about_ca_system_score_gemma":0.00014346464,"threshold_uncertainty_score":0.92700404},"labels":[],"label_agreement":null},{"id":"W4321016164","doi":"10.1007/s40744-023-00531-7","title":"Patient Experience of Sjögren’s Disease and its Multifaceted Impact on Patients’ Lives","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Active listening; Quality of life (healthcare); Social media; Medicine; Disease; Throat; Dry mouth; Perspective (graphical); Physical therapy; Psychology; Clinical psychology; Internal medicine; Nursing; Surgery","score_opus":0.017198325909339094,"score_gpt":0.28498128328159084,"score_spread":0.2677829573722517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321016164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970533,0.0023576852,0.0000019824747,0.00015976062,0.0000903,0.00020559656,0.000020767988,0.00003825085,0.000072349794],"genre_scores_gemma":[0.99367,0.006103225,0.0000049567484,0.00012256729,0.0000026143202,0.000025054309,0.000034090568,0.0000069559765,0.00003056357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951875,0.000027065003,0.00012284104,0.00014684793,0.00006469492,0.000119771525],"domain_scores_gemma":[0.99962723,0.00009188887,0.000041340296,0.000096769174,0.000032846852,0.000109893794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000022892295,0.000091249494,0.00018568864,0.00008393005,0.00007002728,0.000003098639,0.000016507702,0.000038414542,0.000089998466],"category_scores_gemma":[0.00005106939,0.00005947338,0.000036867346,0.0000968584,0.00007085238,0.00003047587,0.000012588319,0.000048217218,0.000009203323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001485742,0.00025196598,0.9852063,0.000026501622,0.000065268745,0.0000063694465,0.0038933817,0.0000036569236,0.000107164145,0.00021176417,0.00022697636,0.008514882],"study_design_scores_gemma":[0.0024629445,0.0010033154,0.9946081,0.000057125813,0.000009666774,0.000008902031,0.0006351128,0.0006266372,0.00018566292,0.0001548901,0.00017350358,0.00007414656],"about_ca_topic_score_codex":0.000032025804,"about_ca_topic_score_gemma":6.6044015e-7,"teacher_disagreement_score":0.009401766,"about_ca_system_score_codex":0.0000030666044,"about_ca_system_score_gemma":0.00001752832,"threshold_uncertainty_score":0.2425254},"labels":[],"label_agreement":null},{"id":"W4321611533","doi":"10.1007/s40744-023-00533-5","title":"Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Golimumab; Infliximab; Observational study; Rheumatoid arthritis; Medicine; Phase (matter); Physical therapy; Internal medicine; Adalimumab; Tumor necrosis factor alpha","score_opus":0.043906529844289936,"score_gpt":0.32960152492120626,"score_spread":0.2856949950769163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321611533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893116,0.0013008672,0.0000049157766,0.0062341406,0.00007947532,0.0026056143,0.00027547116,0.00014803089,0.000039915954],"genre_scores_gemma":[0.90537506,0.0931052,0.000071338865,0.00026481802,0.000012161182,0.00064298895,0.00030843675,0.000042887725,0.00017713704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715894,0.0006115105,0.0006656656,0.0006021229,0.0004000761,0.0005617039],"domain_scores_gemma":[0.9972504,0.0016980113,0.00012806455,0.0005431476,0.00015705294,0.00022335211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006992713,0.00033459155,0.0007512106,0.00034045536,0.0003335849,0.000066647845,0.00017033714,0.000095547846,0.0001166218],"category_scores_gemma":[0.00031148843,0.00019245737,0.00005376176,0.0008863828,0.00021889922,0.00013332407,0.00005454014,0.00023977384,0.000063401734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18518719,0.0040393174,0.6057324,0.0000066369184,0.00051567354,0.0005493392,0.026360132,0.000008956089,0.00015138205,0.00014061817,0.00079421955,0.17651416],"study_design_scores_gemma":[0.1267158,0.02259112,0.81554747,0.0007700044,0.0000038679896,0.00010976746,0.00430064,0.00017961208,0.00024050512,0.00033137648,0.02881855,0.00039128776],"about_ca_topic_score_codex":0.003874465,"about_ca_topic_score_gemma":0.010547194,"teacher_disagreement_score":0.2098151,"about_ca_system_score_codex":0.000106685926,"about_ca_system_score_gemma":0.0004230743,"threshold_uncertainty_score":0.78481835},"labels":[],"label_agreement":null},{"id":"W4322496507","doi":"10.1007/s40744-023-00541-5","title":"Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Barrie Urology Group","funders":"UCB Pharma","keywords":"Certolizumab pegol; Rheumatoid arthritis; Medicine; Term (time); Pooled analysis; Clinical trial; Internal medicine; Arthritis; Meta-analysis; Adalimumab","score_opus":0.045446736948720104,"score_gpt":0.360959686237571,"score_spread":0.31551294928885093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322496507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961589,0.002713507,0.000008855459,0.00011690055,0.000087361295,0.00073202193,0.0001294908,0.00004240815,0.0000105773415],"genre_scores_gemma":[0.89797616,0.10127711,0.00003569531,0.000010874693,0.0000054306397,0.000019654191,0.00065172254,0.0000200101,0.0000033554943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722064,0.00046609298,0.0010162088,0.000558136,0.00038462324,0.0003542875],"domain_scores_gemma":[0.99792963,0.00043824536,0.00027680254,0.0010562002,0.0001312146,0.00016792433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062547345,0.00018773197,0.0014013629,0.00058786245,0.000044803684,0.0000139548765,0.000283482,0.00020060856,0.00027274],"category_scores_gemma":[0.00025716456,0.00015003925,0.00013721772,0.0008711702,0.000647408,0.0002279791,0.00010687356,0.000257465,0.0000046258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044240773,0.0012682294,0.89889747,0.000028993583,0.001428355,0.000052084757,0.0003690887,8.0384933e-7,0.0000154857,0.0001459688,0.00001935628,0.05353339],"study_design_scores_gemma":[0.081422195,0.0023147238,0.9153052,0.00019462979,0.000018416187,0.000028056074,0.00006240718,0.0003711037,0.000019207768,0.0001031537,0.000035287674,0.00012560042],"about_ca_topic_score_codex":0.00034563692,"about_ca_topic_score_gemma":0.0006554,"teacher_disagreement_score":0.09856361,"about_ca_system_score_codex":0.000011086778,"about_ca_system_score_gemma":0.00015820918,"threshold_uncertainty_score":0.6118423},"labels":[],"label_agreement":null},{"id":"W4360983727","doi":"10.1007/s40744-023-00545-1","title":"A Narrative Review of Acthar Gel for the Treatment of Myositis","year":2023,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Polymyositis; Medicine; Dermatomyositis; Myositis; Refractory (planetary science); Proximal muscle weakness; Internal medicine; Immunology; Muscle biopsy","score_opus":0.06468238412892124,"score_gpt":0.3852631856699987,"score_spread":0.32058080154107743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360983727","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029791507,0.9964524,0.000011560104,0.00030526205,0.00017966576,0.0025764168,0.0001006383,0.000023008723,0.00005314794],"genre_scores_gemma":[0.000013628358,0.9988613,0.00004710975,0.000118933596,0.000025244028,0.0006525362,0.00008893191,0.00003782347,0.00015450032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860287,0.00014125473,0.0007684605,0.00021567802,0.000094668736,0.00017708994],"domain_scores_gemma":[0.997943,0.0009659964,0.0005761837,0.00035991272,0.00011078,0.00004417016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022244903,0.00029121083,0.0028765702,0.00008776444,0.00009671068,0.000002908479,0.00009086815,0.00024320965,0.000055145832],"category_scores_gemma":[0.000037303016,0.00015133746,0.0006383787,0.00015027593,0.0002222389,0.000017023076,0.000011796357,0.000097100245,0.000006096465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102351325,0.00009749171,0.000028795392,0.1671697,0.0018431991,0.000019562936,0.0017461738,6.1500645e-9,3.622195e-7,0.0012928345,0.00185477,0.82584476],"study_design_scores_gemma":[0.000985742,0.0007513405,0.000012595768,0.09060231,0.0007688995,0.00078798295,0.00011835764,0.0000016940697,0.00001128439,0.00006312263,0.9057853,0.00011132952],"about_ca_topic_score_codex":0.000028003886,"about_ca_topic_score_gemma":0.0000024785602,"teacher_disagreement_score":0.9039306,"about_ca_system_score_codex":0.000021531572,"about_ca_system_score_gemma":0.00020926367,"threshold_uncertainty_score":0.61713624},"labels":[],"label_agreement":null},{"id":"W4366160578","doi":"10.1007/s40744-023-00546-0","title":"Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Gout, Hyperuricemia, Uric Acid","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Genentech; LG Chem; Sun Pharma; University of British Columbia; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company","keywords":"Tolerability; Dosing; Uric acid; Pharmacology; Medicine; Gout; Chemistry; Internal medicine; Adverse effect","score_opus":0.034541394054713535,"score_gpt":0.30171768839830554,"score_spread":0.267176294343592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366160578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974796,0.00038804748,0.000033957454,0.00017645059,0.00009225147,0.0015678329,0.000011715767,0.00022903735,0.000021101223],"genre_scores_gemma":[0.99923575,0.00012503203,0.00025909138,0.00014308136,0.000008552176,0.000069701506,0.00004719114,0.000075467455,0.000036128808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764866,0.00016044854,0.00053453515,0.0006292199,0.00035686023,0.0006702831],"domain_scores_gemma":[0.99881744,0.00018419765,0.00022713731,0.0004444073,0.000113832764,0.00021296061],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035616662,0.0004051613,0.0008662992,0.00038491326,0.00025038558,0.000032350177,0.00013658668,0.00019239406,0.000039500534],"category_scores_gemma":[0.000047283975,0.00029263936,0.00005053083,0.0012387254,0.0002020633,0.00016610778,0.00005958312,0.00037296946,0.000023227594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008854725,0.0056011397,0.97255635,0.00005249732,0.00078864506,0.000384717,0.0046288953,0.0000474222,0.005461254,0.000050266546,0.000023437251,0.0015506257],"study_design_scores_gemma":[0.21556024,0.018546298,0.7480204,0.0005544703,0.00051114406,0.0011725379,0.0033053586,0.0074040764,0.0036797067,0.000059924478,0.00012205392,0.0010637483],"about_ca_topic_score_codex":0.00017176721,"about_ca_topic_score_gemma":0.000050590894,"teacher_disagreement_score":0.22453594,"about_ca_system_score_codex":0.00007331716,"about_ca_system_score_gemma":0.00015798747,"threshold_uncertainty_score":0.99995255},"labels":[],"label_agreement":null},{"id":"W4375856191","doi":"10.1007/s40744-023-00548-y","title":"Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Psoriatic arthritis; Medicine; Dermatology; Interleukin; Immunology; Psoriasis; Cytokine","score_opus":0.006998237075083139,"score_gpt":0.22879227441581781,"score_spread":0.22179403734073466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375856191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974765,0.0019017045,0.0000022244842,0.00017105276,0.000054748598,0.00023756038,0.0000051892966,0.000025548015,0.00012544752],"genre_scores_gemma":[0.99415815,0.0056523597,0.000036163376,0.000055795565,0.0000027251576,0.000029812696,0.000035305664,0.000008643594,0.000021060761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999458,0.000022440498,0.00017030229,0.00013055743,0.00007528668,0.00014341976],"domain_scores_gemma":[0.999767,0.000032188807,0.00004726554,0.0000909941,0.00003316749,0.000029362443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049090886,0.00008283854,0.00029201218,0.00010648847,0.00003381865,0.000002343374,0.000011988051,0.000050606373,0.000032530384],"category_scores_gemma":[0.000011730784,0.00006221777,0.0000234793,0.00017161357,0.00008806053,0.000031429427,0.000011536727,0.000052390595,0.000010653714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006091262,0.00022114169,0.9660001,0.000024269899,0.00011617557,0.000057013116,0.0006858683,5.52354e-7,0.000030257454,0.00031084346,0.00010107981,0.031843595],"study_design_scores_gemma":[0.016300617,0.0012182543,0.98051906,0.00042133778,0.000010156756,0.000034323824,0.00015251023,0.000009228837,0.00050292496,0.000508719,0.00025263464,0.00007023529],"about_ca_topic_score_codex":0.00004781877,"about_ca_topic_score_gemma":0.00004865603,"teacher_disagreement_score":0.031773362,"about_ca_system_score_codex":0.0000083762625,"about_ca_system_score_gemma":0.000011203511,"threshold_uncertainty_score":0.2537167},"labels":[],"label_agreement":null},{"id":"W4377091353","doi":"10.1007/s40744-023-00560-2","title":"Patient–Physician Communication and Perception of Treatment Goals in Rheumatoid Arthritis: An Online Survey of Patients and Physicians","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Rheumatoid arthritis; Perception; Medicine; Family medicine; Physical therapy; Psychology; Internal medicine","score_opus":0.032642556881457334,"score_gpt":0.3037722516472685,"score_spread":0.27112969476581117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377091353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877195,0.011615499,0.0000015955349,0.00011869977,0.0000187904,0.00037464133,0.0001127529,0.00002343356,0.000015112284],"genre_scores_gemma":[0.6130031,0.38659203,0.00004324644,0.000022563148,7.5600775e-7,0.000014982695,0.0003119916,0.000009775494,0.0000016077047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879336,0.00034180787,0.00036684514,0.00020626755,0.00010410627,0.00018761425],"domain_scores_gemma":[0.9992764,0.00019885688,0.00013641613,0.00021376151,0.00011026222,0.00006432514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000213856,0.00014139354,0.0005463488,0.00019163934,0.000075965174,0.000008024274,0.000041547268,0.000084762796,0.000008310169],"category_scores_gemma":[0.000039621038,0.00011972022,0.000026937414,0.0002023924,0.00038376177,0.00013058877,0.000029552632,0.00008959887,0.0000012219311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004293392,0.0005082385,0.63080674,0.000020710982,0.00004980718,8.7125545e-7,0.0036956253,6.6283394e-7,0.0013340384,0.00013543839,0.000010301069,0.36300823],"study_design_scores_gemma":[0.004290783,0.0021272518,0.99018264,0.00035398873,8.954519e-7,0.000010624041,0.0016489692,0.00029502015,0.00038075255,0.0005042963,0.00011172973,0.000093062816],"about_ca_topic_score_codex":0.0020489036,"about_ca_topic_score_gemma":0.0011329771,"teacher_disagreement_score":0.37497652,"about_ca_system_score_codex":0.000013548762,"about_ca_system_score_gemma":0.00003327211,"threshold_uncertainty_score":0.4882049},"labels":[],"label_agreement":null},{"id":"W4378195026","doi":"10.1007/s40744-023-00552-2","title":"Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Leeds Biomedical Research Centre; Department of Health and Social Care; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Abatacept; Medicine; Rheumatoid arthritis; Spear; Internal medicine; Population; Surgery; Rituximab","score_opus":0.035263739205698995,"score_gpt":0.33111069432484824,"score_spread":0.29584695511914927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378195026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654475,0.033111114,0.000008400411,0.00053260627,0.00008281414,0.0006543195,0.000056970057,0.000051857813,0.000054424865],"genre_scores_gemma":[0.6909024,0.30892706,0.000044289365,0.00001887119,0.0000018099765,0.000041928313,0.000033163007,0.000015380107,0.000015078362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680436,0.0005276695,0.0014497666,0.0003787221,0.0003538379,0.00048562625],"domain_scores_gemma":[0.9975525,0.0015262534,0.0003427959,0.00036964272,0.00008973954,0.00011908162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019692555,0.0002475727,0.0026493142,0.002146072,0.00004663313,0.000013538559,0.00015207642,0.00019967457,0.00013651431],"category_scores_gemma":[0.00062086975,0.00020056729,0.00033204467,0.0018368956,0.00024259157,0.00010464784,0.000053249496,0.00023981115,0.000011938473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011382276,0.00045887232,0.9517372,0.000036680158,0.0023165348,0.0000342073,0.002198341,0.00008269073,0.0011726335,0.0033778336,0.000024413339,0.03742236],"study_design_scores_gemma":[0.013136901,0.00046460424,0.9831055,0.00052639394,0.000015115566,0.000029834751,0.00029541578,0.0002837148,0.0012044706,0.00068891986,0.00009263589,0.0001565299],"about_ca_topic_score_codex":0.00077269686,"about_ca_topic_score_gemma":0.0003725416,"teacher_disagreement_score":0.27581593,"about_ca_system_score_codex":0.000016633498,"about_ca_system_score_gemma":0.000096589385,"threshold_uncertainty_score":0.81788963},"labels":[],"label_agreement":null},{"id":"W4380869940","doi":"10.1007/s40744-023-00556-y","title":"Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"Janssen Scientific Affairs","keywords":"Ankylosing spondylitis; Golimumab; Medicine; Spondylitis; Physical therapy; Phase (matter); Psychology; Internal medicine; Physics","score_opus":0.032301350799224554,"score_gpt":0.3684574879036627,"score_spread":0.33615613710443815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380869940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634683,0.00096894044,0.0000012047396,0.0009472936,0.000024771192,0.0016253171,0.000018167158,0.000013132035,0.00005435367],"genre_scores_gemma":[0.99784696,0.001887669,0.000005383668,0.00006203734,0.0000044274975,0.00016291905,0.000013720721,0.000011045603,0.0000058480814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745053,0.0017491127,0.00026725125,0.00024049623,0.00012042269,0.00017218881],"domain_scores_gemma":[0.9923295,0.007328735,0.00009773039,0.00019409937,0.000022630602,0.000027306472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00149487,0.00014780316,0.0005291725,0.00012262915,0.00013063938,0.0000065652803,0.00004521,0.000071524235,0.0000047211856],"category_scores_gemma":[0.00028890738,0.000064926455,0.000027467328,0.00032642705,0.00049391104,0.000029443307,0.000013134973,0.00027686573,0.000001364554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32119244,0.0006906717,0.6342335,0.00002391475,0.00020418786,0.00044320937,0.024164462,0.000001254575,7.153186e-7,0.00046417504,0.0000031960474,0.018578265],"study_design_scores_gemma":[0.09447798,0.030704057,0.86687666,0.0005741479,0.000043736123,0.0003183943,0.0067508295,0.000026343323,0.000019397079,0.00013233448,0.000012505674,0.00006359334],"about_ca_topic_score_codex":0.00023682286,"about_ca_topic_score_gemma":0.00033723333,"teacher_disagreement_score":0.23264317,"about_ca_system_score_codex":0.000013641859,"about_ca_system_score_gemma":0.000032011692,"threshold_uncertainty_score":0.2647624},"labels":[],"label_agreement":null},{"id":"W4381104181","doi":"10.1007/s40744-023-00564-y","title":"Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Pfizer (Canada)","funders":"Pfizer","keywords":"Ankylosing spondylitis; Tofacitinib; Medicine; Spondylitis; Surgery; Internal medicine; Rheumatoid arthritis","score_opus":0.033452515047247895,"score_gpt":0.32996713202599093,"score_spread":0.29651461697874304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381104181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525315,0.00272718,2.6288433e-7,0.0010573542,0.00018466303,0.00048175876,0.00020503096,0.000036921778,0.000053671778],"genre_scores_gemma":[0.9922477,0.007035471,0.00005549339,0.00005533257,0.000026267142,0.000051776933,0.0004987985,0.000009262108,0.000019901181],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987955,0.000093620336,0.00046945794,0.00029423184,0.00008629474,0.00026087862],"domain_scores_gemma":[0.9996749,0.00008630174,0.000086500004,0.00008936345,0.0000151022305,0.000047802165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021650648,0.00014745106,0.00043241036,0.0002075326,0.00008181706,0.000021303906,0.000025507645,0.00009998971,0.00003233927],"category_scores_gemma":[0.000064793894,0.00012865641,0.000028202654,0.00009644751,0.00008549068,0.00011680991,0.00002874257,0.00011098579,0.0000056112085],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32079908,0.00048036195,0.4385494,0.000042232034,0.00030908125,0.0009802538,0.01063107,3.1454823e-7,0.002280741,0.00019964778,0.00006800381,0.2256598],"study_design_scores_gemma":[0.55743366,0.0042163585,0.42979646,0.00087156583,0.00002451598,0.00019944986,0.0012668527,0.00030280117,0.0017983878,0.002406098,0.0014263819,0.00025745804],"about_ca_topic_score_codex":0.00051253464,"about_ca_topic_score_gemma":0.00032643141,"teacher_disagreement_score":0.23663458,"about_ca_system_score_codex":0.000018508907,"about_ca_system_score_gemma":0.000020653695,"threshold_uncertainty_score":0.52464557},"labels":[],"label_agreement":null},{"id":"W4384560180","doi":"10.1007/s40744-023-00576-8","title":"Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Tofacitinib; Psoriatic arthritis; Rheumatoid arthritis; Medicine; Dermatology; Arthritis; Internal medicine","score_opus":0.004905192711362207,"score_gpt":0.22037863563510987,"score_spread":0.21547344292374768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384560180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833169,0.015851531,6.4351934e-7,0.00016671747,0.00008590793,0.00035198094,0.00010587245,0.000039784194,0.000080675476],"genre_scores_gemma":[0.8620898,0.13768864,0.000049857903,0.00005320253,0.000002893116,0.000019603509,0.00006860166,0.000017582628,0.000009795067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888957,0.00009405121,0.00033054096,0.00027228825,0.00013695768,0.00027658555],"domain_scores_gemma":[0.9993633,0.0002635424,0.00010642423,0.00014368523,0.00005976415,0.00006326356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025386826,0.00015972508,0.00059731846,0.00013454066,0.000079408775,0.0000067902606,0.000028894956,0.000092134724,0.00008296299],"category_scores_gemma":[0.000091958704,0.0001371656,0.000033814496,0.00021767386,0.00018497002,0.000042281667,0.000032174616,0.000103584345,0.000005037828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015444445,0.000089192465,0.7960385,0.000027864267,0.00012009846,0.000045833847,0.0003729276,2.81492e-7,0.0000070403858,0.00013397245,0.000023025712,0.2015968],"study_design_scores_gemma":[0.018149067,0.00055035844,0.97965705,0.00068355165,0.000002342555,0.000083512066,0.00016563381,0.00000883176,0.000013710032,0.00007862138,0.0004854305,0.00012186305],"about_ca_topic_score_codex":0.00017345125,"about_ca_topic_score_gemma":0.00024697013,"teacher_disagreement_score":0.20147493,"about_ca_system_score_codex":0.000010077156,"about_ca_system_score_gemma":0.000025667632,"threshold_uncertainty_score":0.55934507},"labels":[],"label_agreement":null},{"id":"W4385064820","doi":"10.1007/s40744-023-00573-x","title":"Is the Rate of Responders to Hyaluronic Acid Injection for Patients with Knee Osteoarthritis Stable Over Time? Post hoc Analyses of a 6-Month Follow-Up Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Post-hoc analysis; Internal medicine; Hyaluronic acid; Sodium hyaluronate; Population; Physical therapy; Body mass index; Surgery","score_opus":0.017844555350789697,"score_gpt":0.2877707440129409,"score_spread":0.2699261886621512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385064820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970558,0.0008091309,0.000008264529,0.00017460906,0.00010639283,0.0017160004,0.000073535564,0.000029764022,0.000026481091],"genre_scores_gemma":[0.99892086,0.00018006239,0.00004304499,0.000119104385,0.000003893117,0.00013546986,0.0000620603,0.000021467287,0.0005140333],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991118,0.00010043239,0.00023820101,0.00022479924,0.00012051242,0.00020429707],"domain_scores_gemma":[0.99928135,0.00016415826,0.00011981215,0.00023316189,0.00015255975,0.00004897176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018842454,0.0001445659,0.00043388587,0.00018192233,0.00010986868,0.000006847631,0.000047568992,0.00006888462,0.00006435211],"category_scores_gemma":[0.000036894256,0.00009164927,0.000075792894,0.00031864722,0.00006574521,0.00005982354,0.0000194212,0.000054508662,0.0000073092797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09275573,0.0019900878,0.62566787,0.00016515363,0.002397861,0.000023732073,0.016765684,0.000008657491,0.035602298,0.00043045846,0.00089256966,0.22329994],"study_design_scores_gemma":[0.16405413,0.48596781,0.2673539,0.00075279566,0.000841172,0.000065021544,0.008976853,0.000083563435,0.06846225,0.0011269618,0.0016563433,0.00065922993],"about_ca_topic_score_codex":0.0000877108,"about_ca_topic_score_gemma":0.00014677062,"teacher_disagreement_score":0.4839777,"about_ca_system_score_codex":0.000011349208,"about_ca_system_score_gemma":0.0000614594,"threshold_uncertainty_score":0.3737349},"labels":[],"label_agreement":null},{"id":"W4386001822","doi":"10.1007/s40744-023-00582-w","title":"Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Genentech; Janssen Scientific Affairs; Janssen Research and Development; Novavax; Jazz Pharmaceuticals; Sun Pharma; Regeneron Pharmaceuticals; University of Pennsylvania; Gilead Sciences; Childhood Arthritis and Rheumatology Research Alliance; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Pfizer; CSL Behring; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Psoriasis; Visual analogue scale; Arthritis; Population; Psoriasis Area and Severity Index; Confidence interval; BASDAI; Physical therapy; Dermatology","score_opus":0.030470400480237355,"score_gpt":0.28420683598653346,"score_spread":0.2537364355062961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386001822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91749734,0.08036073,0.000013428692,0.0004359109,0.00017206627,0.0010322182,0.00035221738,0.0000630245,0.000073054376],"genre_scores_gemma":[0.77833813,0.22071661,0.00037234646,0.000047049787,0.000018725072,0.00013456894,0.00032852223,0.000031568954,0.000012480334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976402,0.00042429112,0.0005035143,0.00075468846,0.00023569372,0.00044162403],"domain_scores_gemma":[0.9976087,0.0011702193,0.00024318437,0.00079569366,0.00007078487,0.000111366935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006144475,0.00034495574,0.0011353948,0.00014491382,0.00024142639,0.000024997502,0.00020742799,0.00012185911,0.00003052001],"category_scores_gemma":[0.00016403639,0.00024886784,0.000060633927,0.0005483088,0.0008116808,0.00014572612,0.00014371023,0.00026894355,0.000010868098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006407122,0.00043124598,0.8367505,0.00032132133,0.00065138197,0.00084776344,0.0020591354,0.0000012537888,0.000049571387,0.0008767197,0.00015327185,0.1514507],"study_design_scores_gemma":[0.03907865,0.001354724,0.94603395,0.008469488,0.00006975793,0.00048339076,0.0028966614,0.00020160395,0.000063144,0.0007050285,0.00033511195,0.000308509],"about_ca_topic_score_codex":0.003975504,"about_ca_topic_score_gemma":0.022706872,"teacher_disagreement_score":0.15114218,"about_ca_system_score_codex":0.000028644914,"about_ca_system_score_gemma":0.00008295889,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W4386438083","doi":"10.1007/s40744-023-00590-w","title":"Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses","year":2023,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Gilead Sciences","keywords":"Medicine; Rheumatoid arthritis; Placebo; Internal medicine; Post-hoc analysis; Methotrexate; Radiography; Surgery; Pathology","score_opus":0.13131910439501193,"score_gpt":0.4747900576888363,"score_spread":0.3434709532938244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386438083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25074503,0.7467875,0.0000012181134,0.000012226437,0.000059461487,0.002338387,0.000038202765,0.000013826926,0.00000416424],"genre_scores_gemma":[0.0048095235,0.9944926,0.00011917686,0.000008593589,0.0000048727857,0.00022219929,0.00028439274,0.000049658975,0.0000089790165],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959394,0.0010064756,0.0017671366,0.00053089485,0.00040604742,0.00035008672],"domain_scores_gemma":[0.99703676,0.0006796535,0.0014754891,0.00040948426,0.00032225208,0.00007638947],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009985397,0.0004227299,0.0046961852,0.0010237044,0.0000587748,0.0000041316252,0.00014295391,0.00033315376,0.00005656719],"category_scores_gemma":[0.00027797546,0.00027686506,0.00031508922,0.0018214332,0.00053181,0.00008291609,0.00006790821,0.00047454916,0.0000012974538],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017496839,0.0011565299,0.0032772887,0.1515296,0.0023973258,0.00008844407,0.0014409058,6.2621416e-7,9.4639097e-7,0.000022623295,0.000052445623,0.8382836],"study_design_scores_gemma":[0.056295898,0.0031059422,0.00020063708,0.93441224,0.00029437957,0.00021660715,0.00038682416,0.00003332378,0.00000610388,0.00004669218,0.0046641286,0.00033721197],"about_ca_topic_score_codex":0.00029616794,"about_ca_topic_score_gemma":0.00009534727,"teacher_disagreement_score":0.83794636,"about_ca_system_score_codex":0.0006135101,"about_ca_system_score_gemma":0.0024897298,"threshold_uncertainty_score":0.99996835},"labels":[],"label_agreement":null},{"id":"W4386591807","doi":"10.1007/s40744-023-00589-3","title":"Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada)","funders":"","keywords":"Psoriatic arthritis; Medicine; Observational study; Clinical Practice; Arthritis; Internal medicine; Physical therapy","score_opus":0.09776755823014459,"score_gpt":0.37334026600450426,"score_spread":0.27557270777435966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386591807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932465,0.0018527429,2.8165135e-7,0.001987038,0.000119479504,0.0026564097,0.00010741648,0.000011081982,0.000019078674],"genre_scores_gemma":[0.9854109,0.014193314,0.000043560492,0.00012913393,0.000010248127,0.000114262955,0.00008275491,0.000010852913,0.000004920739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835914,0.00036495397,0.00051896425,0.0003958462,0.00018819986,0.00017289746],"domain_scores_gemma":[0.9968061,0.002456479,0.00019803691,0.00045145457,0.000054749453,0.00003322197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032117803,0.00016442107,0.00052487425,0.000036484485,0.00016242589,0.000008771408,0.00010566555,0.000055037643,0.00001007004],"category_scores_gemma":[0.0003900768,0.000083569306,0.000024700197,0.00024247033,0.0001630151,0.00008896227,0.00013275663,0.00015976705,0.0000025631728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005770425,0.006196383,0.910759,0.0000035732999,0.000769132,0.00006520814,0.0089795375,0.0000010078852,8.4304034e-8,0.000021822409,0.000017760536,0.067416064],"study_design_scores_gemma":[0.06029404,0.0028766403,0.9253295,0.00016228593,0.0000866084,0.000015432053,0.010395119,0.000060450388,7.207795e-7,0.000023477787,0.00069022964,0.00006548077],"about_ca_topic_score_codex":0.0024396037,"about_ca_topic_score_gemma":0.010306506,"teacher_disagreement_score":0.06735058,"about_ca_system_score_codex":0.000027926893,"about_ca_system_score_gemma":0.000067298766,"threshold_uncertainty_score":0.57512724},"labels":[],"label_agreement":null},{"id":"W4387529687","doi":"10.1007/s40744-023-00592-8","title":"Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"Janssen Research and Development","keywords":"Psoriatic arthritis; Medicine; Placebo; Dermatology; Randomized controlled trial; Physical therapy; Phase (matter); Placebo-controlled study; Psoriasis; Internal medicine; Alternative medicine; Double blind; Pathology","score_opus":0.009355531925551755,"score_gpt":0.2923530906948628,"score_spread":0.28299755876931104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387529687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924513,0.0016196319,0.0000018980821,0.00051684293,0.00014942723,0.005075633,0.000011063251,0.000027608923,0.0001466123],"genre_scores_gemma":[0.9918942,0.0071569034,0.000005329825,0.00009321652,0.000006111114,0.00077964587,0.000018511604,0.000018300478,0.000027802094],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99833894,0.00042057582,0.00047045687,0.00031171893,0.0001910636,0.00026723102],"domain_scores_gemma":[0.9983236,0.001256417,0.0001303136,0.00023019974,0.000024490228,0.000034939898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041529266,0.0002075145,0.0013517459,0.0001902382,0.00006614908,0.000007818832,0.00007331399,0.00008213352,0.000026877806],"category_scores_gemma":[0.00016802027,0.00011946069,0.00009211555,0.00047221835,0.00014998949,0.00004622897,0.000018051604,0.00018142659,0.000017386812],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8739298,0.0024092824,0.009981321,0.000013890643,0.0013667997,0.00039589693,0.06227353,0.00001965905,0.0000029425366,0.00078692817,0.00003052798,0.048789397],"study_design_scores_gemma":[0.94694734,0.004788528,0.040800728,0.0006592771,0.00006753611,0.000060202197,0.0061848057,0.000035135185,0.000023161776,0.00029694565,0.000021434764,0.00011492883],"about_ca_topic_score_codex":0.00054251467,"about_ca_topic_score_gemma":0.0004820746,"teacher_disagreement_score":0.07301749,"about_ca_system_score_codex":0.00002172196,"about_ca_system_score_gemma":0.000039771174,"threshold_uncertainty_score":0.48714656},"labels":[],"label_agreement":null},{"id":"W4388792712","doi":"10.1007/s40744-023-00625-2","title":"Cross-Sectional and Longitudinal Associations of Comorbidities with Knee Symptoms and Radiographic Abnormalities of Osteoarthritis","year":2023,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Comorbidity; Odds ratio; Internal medicine; Confidence interval; Physical therapy; Knee pain; Diabetes mellitus; Cross-sectional study; Pathology","score_opus":0.022430055463650674,"score_gpt":0.2754877570209315,"score_spread":0.2530577015572808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388792712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925039,0.0069456277,0.0000031298155,0.00006268748,0.00006866029,0.00017438029,0.00007737422,0.000035442652,0.00012880214],"genre_scores_gemma":[0.9924834,0.007208062,0.000056495395,0.000012648797,0.000007258885,0.000023039744,0.000059682898,0.000009212354,0.00014025073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940413,0.0000306669,0.0001941331,0.00014003515,0.00009827208,0.0001327671],"domain_scores_gemma":[0.99956393,0.00015695246,0.00009386628,0.00007309664,0.00006708748,0.000045092416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107614214,0.00010045981,0.00033190812,0.00017248548,0.00011448262,0.000010539107,0.000015769958,0.00009564622,0.00003006489],"category_scores_gemma":[0.000009708818,0.00008197661,0.000033861947,0.00012811879,0.0005081169,0.00007431885,0.000012983782,0.000063523185,5.5073065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024527442,0.00003392567,0.98425376,0.00006166237,0.0001620839,0.000012403044,0.0004997986,2.0172844e-7,0.0002930334,0.009887215,0.00000560612,0.004545022],"study_design_scores_gemma":[0.005610959,0.0028282786,0.9877671,0.0000996625,0.000026283122,0.00077194953,0.00025132074,0.000004255865,0.0012801908,0.0012436165,0.000042570333,0.000073796735],"about_ca_topic_score_codex":0.000073111594,"about_ca_topic_score_gemma":0.000056132052,"teacher_disagreement_score":0.008643598,"about_ca_system_score_codex":0.000003210027,"about_ca_system_score_gemma":0.000026156556,"threshold_uncertainty_score":0.3342909},"labels":[],"label_agreement":null},{"id":"W4389273395","doi":"10.1007/s40744-023-00615-4","title":"Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis","year":2023,"lang":"en","type":"erratum","venue":"Rheumatology and Therapy","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Tofacitinib; Psoriatic arthritis; Rheumatoid arthritis; Medicine; Dermatology; Psoriasis; Internal medicine","score_opus":0.06315086854079685,"score_gpt":0.3904287381111574,"score_spread":0.32727786957036054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389273395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9429027,0.038954988,0.0000012575348,0.0006099922,0.014842999,0.00077821,0.0009116576,0.00010606814,0.00089217385],"genre_scores_gemma":[0.5725615,0.42440128,0.00001212937,0.0006739706,0.000106944855,0.00006970064,0.0006408189,0.00008299565,0.0014506779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959856,0.0014921292,0.0009308959,0.0006640282,0.00022431278,0.00070301845],"domain_scores_gemma":[0.997022,0.0017822604,0.0004923269,0.0002353021,0.00018119728,0.00028692666],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014248795,0.00047784785,0.0012653113,0.0002712712,0.0002651124,0.000020358819,0.00018598665,0.0019436231,0.0009896923],"category_scores_gemma":[0.0003668496,0.00047399083,0.00007953617,0.0003617626,0.00065765274,0.0000938592,0.000093906565,0.0033903243,0.000016202435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004942448,0.0002754037,0.5923335,0.00035717193,0.00042977542,0.000077084995,0.00071436,0.000008343155,0.0000040364125,0.00023188061,0.05160613,0.34901986],"study_design_scores_gemma":[0.011753178,0.0005559806,0.76565516,0.0020946811,0.000016483538,0.00013922233,0.00018787102,0.00030014248,0.000023288016,0.00019379987,0.21838091,0.00069931376],"about_ca_topic_score_codex":0.00023418176,"about_ca_topic_score_gemma":0.0006103461,"teacher_disagreement_score":0.3854463,"about_ca_system_score_codex":0.00004566711,"about_ca_system_score_gemma":0.00025667378,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W4390839319","doi":"10.1007/s40744-023-00629-y","title":"Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; McMaster University","funders":"Pfizer","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Rheumatoid arthritis; Health care; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Virology; Economic growth; Immunology; Economics; Disease; Outbreak; Internal medicine; Infectious disease (medical specialty)","score_opus":0.029639278951661466,"score_gpt":0.3618202045383068,"score_spread":0.33218092558664536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390839319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86891454,0.12949929,0.000009539533,0.0010895946,0.00006792975,0.00033269802,0.000017736535,0.000051341965,0.000017324368],"genre_scores_gemma":[0.67161214,0.32817447,0.00000874985,0.00011114586,0.000003562418,0.000069733556,0.000002001457,0.000010979685,0.000007212955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985007,0.00023338136,0.0003054535,0.0003475718,0.00022580907,0.0003871028],"domain_scores_gemma":[0.998644,0.0008737548,0.0000838929,0.0001851137,0.000047791116,0.00016544554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044006322,0.00020204803,0.0005087775,0.0001230916,0.00031808266,0.00011464425,0.00011572599,0.00012347323,0.000080004655],"category_scores_gemma":[0.00015322695,0.00011049812,0.000059745435,0.00026449072,0.00085224566,0.00020586899,0.000049538467,0.00032531927,0.0000012966218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000555712,0.00004584625,0.8972781,0.00015184359,0.00010468504,0.000012957417,0.08178263,0.0000031317368,0.000033515862,0.0006611648,0.00002794167,0.01934253],"study_design_scores_gemma":[0.004045668,0.0023109396,0.9401739,0.0072755087,0.0000014127301,0.003883197,0.039096568,0.000210845,0.00011491956,0.0019240824,0.00065018015,0.0003127741],"about_ca_topic_score_codex":0.0029211687,"about_ca_topic_score_gemma":0.0036656626,"teacher_disagreement_score":0.19867519,"about_ca_system_score_codex":0.00004321711,"about_ca_system_score_gemma":0.00058699725,"threshold_uncertainty_score":0.45059827},"labels":[],"label_agreement":null},{"id":"W4391109334","doi":"10.1007/s40744-023-00631-4","title":"Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Tofacitinib; Psoriatic arthritis; Discontinuation; Dactylitis; Internal medicine; Enthesitis; BASDAI; Psoriasis Area and Severity Index; Leflunomide; Apremilast; Rheumatoid arthritis; Psoriasis; Dermatology","score_opus":0.015451302178369384,"score_gpt":0.2735925287782496,"score_spread":0.2581412265998802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391109334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83180684,0.16423108,0.000028961551,0.00033911888,0.00070264883,0.0016492282,0.0010860291,0.00005767149,0.000098450444],"genre_scores_gemma":[0.8811673,0.11746241,0.0001816291,0.00012368153,0.000048913986,0.00039339258,0.0005714329,0.000043973854,0.000007282335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975615,0.0003438631,0.0008361863,0.0006170953,0.00021864785,0.00042266792],"domain_scores_gemma":[0.9961153,0.0030738697,0.00021075904,0.00039788726,0.00012440607,0.00007776499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006911627,0.00034822506,0.0010131046,0.00011645445,0.00020602737,0.00004623246,0.00011693961,0.00022984746,0.00004400259],"category_scores_gemma":[0.0004705148,0.00025926833,0.00019707264,0.00027733916,0.00029348384,0.00012983289,0.000035723864,0.00027973723,0.000007745982],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009220292,0.00066514255,0.16533357,0.00036077452,0.0010727518,0.00012850363,0.0023336625,0.0000012518217,0.00009382882,0.0036317909,0.0003246705,0.8168338],"study_design_scores_gemma":[0.13997991,0.005982055,0.79966295,0.020991918,0.00011811778,0.0003054336,0.0009725781,0.0001359757,0.0024386765,0.018526666,0.0100875385,0.00079816894],"about_ca_topic_score_codex":0.00037004295,"about_ca_topic_score_gemma":0.00009264345,"teacher_disagreement_score":0.81603557,"about_ca_system_score_codex":0.0000367318,"about_ca_system_score_gemma":0.00010856796,"threshold_uncertainty_score":0.99998593},"labels":[],"label_agreement":null},{"id":"W4391749966","doi":"10.1007/s40744-024-00643-8","title":"Safety and Efficacy of Hybrid Cooperative Complexes of Sodium Hyaluronate and Sodium Chondroitin for the Treatment of Patients with Symptomatic Knee Osteoarthritis","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sodium hyaluronate; Osteoarthritis; Sodium; Hyaluronic acid; Chondroitin sulphate; Medicine; Chemistry; Surgery; Anatomy; Pathology; Alternative medicine; Glycosaminoglycan; Organic chemistry","score_opus":0.00844465405434613,"score_gpt":0.23928414783507942,"score_spread":0.2308394937807333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391749966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97218716,0.026033232,0.000062568426,0.00016856373,0.00007529222,0.0012617257,0.00016093504,0.000015289881,0.000035260924],"genre_scores_gemma":[0.99200875,0.007574684,0.00019358446,0.000015536092,0.000004830375,0.00005483642,0.000061720195,0.000016369298,0.000069672096],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992752,0.000040721246,0.00028248268,0.00019187847,0.000078042714,0.00013167894],"domain_scores_gemma":[0.9991382,0.0005295772,0.000092399685,0.00012370232,0.00007386847,0.00004228446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006111829,0.0001626987,0.00055086694,0.00006263643,0.00007601373,0.000007305294,0.000023089522,0.000042193285,0.000019543206],"category_scores_gemma":[0.000009069918,0.00009292336,0.000048362923,0.000049964503,0.000381839,0.00003843951,0.000008929247,0.00003612933,3.2511755e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016032232,0.0015005177,0.07512719,0.00095797534,0.0017589544,0.000024160257,0.0065529784,0.00000130199,0.0037437284,0.016180554,0.00001961039,0.8781008],"study_design_scores_gemma":[0.26361337,0.27232036,0.17857507,0.004925163,0.0019788733,0.0013144863,0.0019581714,0.0011269236,0.26228496,0.0031677792,0.0077490723,0.0009857564],"about_ca_topic_score_codex":0.00001772298,"about_ca_topic_score_gemma":0.000013088633,"teacher_disagreement_score":0.877115,"about_ca_system_score_codex":0.000007206617,"about_ca_system_score_gemma":0.00003796518,"threshold_uncertainty_score":0.37893045},"labels":[],"label_agreement":null},{"id":"W4392084347","doi":"10.1007/s40744-024-00642-9","title":"Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto; Memorial University of Newfoundland","funders":"Janssen Biotech; Janssen Research and Development; Janssen Scientific Affairs; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Medicine; Randomized controlled trial; Dermatology; Physical therapy; Internal medicine; Psoriasis","score_opus":0.012672494572725464,"score_gpt":0.29787496165604904,"score_spread":0.2852024670833236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392084347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96641034,0.031294607,0.000008223777,0.00030994628,0.0001440497,0.0017724745,0.000030936462,0.0000116792135,0.0000177727],"genre_scores_gemma":[0.9562655,0.043317888,0.00019942736,0.000012759814,0.000010468821,0.00014792316,0.00002270895,0.000010693155,0.000012637287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990858,0.00014897047,0.00030258944,0.00023367487,0.00008603534,0.00014296739],"domain_scores_gemma":[0.9995469,0.00017972868,0.000109009154,0.00010673948,0.000024866573,0.000032768752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012594639,0.00012889184,0.0010432844,0.00007194097,0.000030227127,0.0000035747787,0.000012915036,0.00004980218,0.0000115900075],"category_scores_gemma":[0.000026217971,0.00008669742,0.000057250472,0.00013544105,0.00023762874,0.00004831659,0.000007714854,0.000058506223,3.0693016e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54262716,0.0016833966,0.010273665,0.000054880016,0.0008911163,0.000019390558,0.0042926935,1.7971621e-7,0.0000017113782,0.00040930804,0.000007561848,0.43973896],"study_design_scores_gemma":[0.97484833,0.0066661164,0.01690826,0.0004242691,0.000057831818,0.00002445279,0.00007116362,0.000004689039,0.00013342938,0.00055205927,0.0002374482,0.00007196045],"about_ca_topic_score_codex":0.00048430145,"about_ca_topic_score_gemma":0.000083095496,"teacher_disagreement_score":0.439667,"about_ca_system_score_codex":0.00002851735,"about_ca_system_score_gemma":0.00008851261,"threshold_uncertainty_score":0.35354182},"labels":[],"label_agreement":null},{"id":"W4392234510","doi":"10.1007/s40744-024-00644-7","title":"Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Pharmaceuticals; Janssen Research and Development; Asia Pacific League of Associations for Rheumatology","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Internal medicine; Odds ratio; Population; Psoriasis Area and Severity Index; Psoriasis; Dermatology; Arthritis; Rheumatoid arthritis; Adalimumab","score_opus":0.13589997253204683,"score_gpt":0.3501018757925874,"score_spread":0.21420190326054056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392234510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95025945,0.04852794,0.000011257641,0.000058374455,0.0003063362,0.0006232653,0.00018411652,0.000019970954,0.0000093041945],"genre_scores_gemma":[0.99600667,0.0033153764,0.00017282166,0.000020978852,0.000015855752,0.000011455636,0.00043798666,0.000018434524,4.1208165e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984811,0.000241828,0.0005144254,0.0003801749,0.00018899629,0.00019350213],"domain_scores_gemma":[0.9985984,0.00080332527,0.00015272092,0.0003659967,0.000026861575,0.000052718424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024163844,0.00019134255,0.0008767516,0.00007190185,0.00010878081,0.000041134983,0.00009941322,0.00008329471,0.00002582088],"category_scores_gemma":[0.000081946615,0.0001151994,0.000030436435,0.0001334072,0.00018225369,0.0001574795,0.00010025277,0.0001656174,0.0000011516942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065339445,0.00060225977,0.90467334,0.000027997747,0.0014539186,0.000018562807,0.0029346028,0.000008878987,0.000003200471,0.00013911072,0.00004723389,0.08355693],"study_design_scores_gemma":[0.046817042,0.0018911015,0.94647497,0.0012019482,0.00038337862,0.000018074139,0.0014036789,0.0013694075,0.000030656967,0.00005538515,0.00018911836,0.00016523093],"about_ca_topic_score_codex":0.0009761624,"about_ca_topic_score_gemma":0.0008529147,"teacher_disagreement_score":0.083391696,"about_ca_system_score_codex":0.000016844075,"about_ca_system_score_gemma":0.00005053479,"threshold_uncertainty_score":0.46976954},"labels":[],"label_agreement":null},{"id":"W4392237848","doi":"10.1007/s40744-024-00641-w","title":"Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); Memorial University of Newfoundland; Université Laval; Vancouver Island University; McGill University; Windsor Regional Hospital; Arthritis Research Centre of Canada; Toronto Western Hospital","funders":"UCB Pharma; Gilead Sciences; Sanofi; Amgen Canada; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Psoriatic arthritis; Tolerability; Observational study; Discontinuation; Dactylitis; Internal medicine; Nausea; Adverse effect; Physical therapy; Enthesitis; Visual analogue scale; Psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Arthritis; Dermatology; Nursing","score_opus":0.03489463385291654,"score_gpt":0.30566172438908634,"score_spread":0.2707670905361698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392237848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916355,0.0059457375,3.5707205e-7,0.0011682278,0.00012213706,0.0008246565,0.000029082168,0.0000136271265,0.00026069247],"genre_scores_gemma":[0.9734936,0.026132414,0.000034144512,0.00008185186,0.000008447595,0.000111950525,0.000008320009,0.000010542247,0.00011877684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928546,0.00008397577,0.00017888112,0.00021180577,0.0000744106,0.00016548422],"domain_scores_gemma":[0.99955297,0.00018724012,0.00002260666,0.00014369287,0.000013464174,0.00008003229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009759148,0.00012409218,0.00032346277,0.00016872109,0.00012457684,0.000020927584,0.000017629452,0.000047406746,0.00003527492],"category_scores_gemma":[0.000012196018,0.00008050889,0.000028150605,0.00016002532,0.000060687482,0.000036704674,0.000010837543,0.000061818224,0.000009114164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033092816,0.00010893584,0.9046587,0.000013501911,0.0002641793,0.00014543405,0.0057637626,5.005595e-7,0.000015189154,0.0009505953,0.00018229095,0.08756599],"study_design_scores_gemma":[0.0029874265,0.0019015549,0.9891825,0.00015202328,0.000038805054,0.00017635268,0.00074321975,0.000008308392,0.000023539293,0.0001156446,0.0045961365,0.000074510055],"about_ca_topic_score_codex":0.18240756,"about_ca_topic_score_gemma":0.8042954,"teacher_disagreement_score":0.62188786,"about_ca_system_score_codex":0.00008467218,"about_ca_system_score_gemma":0.00005072043,"threshold_uncertainty_score":0.82303685},"labels":[],"label_agreement":null},{"id":"W4392641843","doi":"10.1007/s40744-024-00651-8","title":"Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Hôpital Maisonneuve-Rosemont; McMaster University; University of British Columbia; Lakeridge Health; Université de Montréal; Université Laval","funders":"AbbVie Canada","keywords":"Medicine; Rheumatoid arthritis; Interim analysis; Internal medicine; Observational study; Clinical endpoint; Adverse effect; Population; Interim; Clinical trial; Physical therapy","score_opus":0.033180781732463305,"score_gpt":0.32875538963207657,"score_spread":0.29557460789961326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392641843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832865,0.012953874,0.0000057041643,0.0003822111,0.00022893115,0.0023266803,0.00064640614,0.000020713584,0.00014898661],"genre_scores_gemma":[0.9050839,0.09421182,0.000040600888,0.000012508783,0.000008276543,0.00037596945,0.00022973692,0.000020532865,0.000016664373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983352,0.00030046326,0.00055570784,0.0003560396,0.00015983083,0.00029278378],"domain_scores_gemma":[0.99735796,0.0020397173,0.000090439884,0.0002358688,0.00017468097,0.00010133968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056617433,0.00018353519,0.000666412,0.00022507754,0.00009292042,0.00002030976,0.00008531551,0.00007622064,0.000035025303],"category_scores_gemma":[0.00018739373,0.00012330904,0.00009604617,0.00025194627,0.0002592826,0.000089235706,0.00001307732,0.00009152001,0.0000017432419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072613726,0.0007170452,0.93834454,0.00004553811,0.0006313353,0.000013484782,0.007215137,5.692654e-7,0.00019471625,0.010932575,0.00007122848,0.034572456],"study_design_scores_gemma":[0.019337563,0.0036779842,0.96389306,0.0014229887,0.0000029807538,0.000013411512,0.0008203337,0.00007951479,0.0018840772,0.0054216906,0.0033252202,0.00012116961],"about_ca_topic_score_codex":0.21255766,"about_ca_topic_score_gemma":0.21794008,"teacher_disagreement_score":0.08125795,"about_ca_system_score_codex":0.00011402019,"about_ca_system_score_gemma":0.00044790178,"threshold_uncertainty_score":0.79633045},"labels":[],"label_agreement":null},{"id":"W4392910954","doi":"10.1007/s40744-024-00658-1","title":"Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"AbbVie","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Adverse effect; Internal medicine; Rheumatology; Randomized controlled trial","score_opus":0.019400903406484527,"score_gpt":0.28559850141689924,"score_spread":0.2661975980104147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392910954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8820017,0.11654379,0.000057057103,0.0003891695,0.00009169387,0.0006013816,0.00016570617,0.000103433624,0.000046068093],"genre_scores_gemma":[0.81254303,0.18650544,0.00014508014,0.00003972567,0.000017513723,0.000016726413,0.0006825095,0.00004365096,0.0000063154257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978282,0.00015931886,0.000451482,0.0007827508,0.00028161274,0.0004966416],"domain_scores_gemma":[0.9986453,0.0005618978,0.000057064153,0.00045335924,0.000038978997,0.0002433674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032400747,0.000323619,0.0008431962,0.00021582033,0.00021651135,0.00014712547,0.00016318259,0.00015469974,0.00009700522],"category_scores_gemma":[0.000055669218,0.0002554511,0.000035990255,0.00021490389,0.00031134838,0.00037845058,0.00013579453,0.00046507077,0.000012567284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016835576,0.00010988388,0.88702494,0.000055255547,0.00058455236,0.00007654474,0.0007719031,6.3587414e-8,0.00002444905,0.00020475412,0.00009133385,0.10937278],"study_design_scores_gemma":[0.020345254,0.00056953466,0.9734091,0.0028068384,0.000007616884,0.00014026424,0.00012082715,0.000056033063,0.000044146607,0.0003864148,0.0018086123,0.00030537145],"about_ca_topic_score_codex":0.00027789193,"about_ca_topic_score_gemma":0.00030096716,"teacher_disagreement_score":0.10906741,"about_ca_system_score_codex":0.000017828623,"about_ca_system_score_gemma":0.00012068057,"threshold_uncertainty_score":0.99998975},"labels":[],"label_agreement":null},{"id":"W4392911023","doi":"10.1007/s40744-024-00654-5","title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Placebo; Internal medicine; Psoriatic arthritis; Rheumatology; Cohort; Rheumatoid arthritis; Randomized controlled trial; Gastroenterology; Physical therapy; Pathology; Alternative medicine","score_opus":0.046767378464928115,"score_gpt":0.3733697934603381,"score_spread":0.32660241499541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392911023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9194191,0.07450208,0.00014163052,0.0020492817,0.00090430566,0.0024782326,0.00035584584,0.000038645165,0.00011087677],"genre_scores_gemma":[0.86000156,0.13925922,0.000192766,0.00011282552,0.000108724176,0.00016207,0.00011427581,0.000016115118,0.00003242469],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981735,0.0003633312,0.00079998956,0.00038031663,0.000095039955,0.00018786883],"domain_scores_gemma":[0.98919445,0.010326175,0.00016076589,0.00020800726,0.0000438625,0.00006673022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008917762,0.00018260455,0.0012185855,0.000038272847,0.00016838803,0.000016864662,0.00004738455,0.00016381826,0.000038522056],"category_scores_gemma":[0.0009767008,0.00010651823,0.00023473633,0.00006935755,0.00057258236,0.00003787372,0.000023311823,0.00018101398,0.000003449611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6148525,0.00050552184,0.000052190626,0.000012356009,0.0017647495,0.00001778129,0.0011081374,3.2051513e-8,0.0000030667095,0.0011447298,0.00031397294,0.38022497],"study_design_scores_gemma":[0.9819361,0.003467791,0.0008850323,0.00043578265,0.00030471754,0.000078351266,0.00023193368,0.00013012944,0.000060680533,0.0032855433,0.009085897,0.0000980257],"about_ca_topic_score_codex":0.00013252477,"about_ca_topic_score_gemma":0.000028116801,"teacher_disagreement_score":0.38012695,"about_ca_system_score_codex":0.000008112752,"about_ca_system_score_gemma":0.000074759395,"threshold_uncertainty_score":0.43436873},"labels":[],"label_agreement":null},{"id":"W4392911057","doi":"10.1007/s40744-024-00657-2","title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Placebo; Psoriatic arthritis; Tolerability; Rheumatology; Randomized controlled trial; Psoriasis; Gastroenterology; Arthritis; Adverse effect; Dermatology; Pathology","score_opus":0.040045974397428304,"score_gpt":0.3479623500081854,"score_spread":0.3079163756107571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392911057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9124634,0.081391424,0.00009553943,0.0023752744,0.00094693375,0.0023075887,0.00022606077,0.000038073715,0.00015568401],"genre_scores_gemma":[0.8422732,0.1570334,0.00020056224,0.000114777715,0.000103238206,0.00014345105,0.000077935154,0.000015300178,0.000038136714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982471,0.00035474083,0.00075694354,0.00036693306,0.00009299199,0.00018130567],"domain_scores_gemma":[0.9887013,0.010847548,0.00014868466,0.00020177983,0.000041734154,0.000058996506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008778373,0.00017314623,0.0011723333,0.00003526167,0.00016080546,0.00001616772,0.000046748195,0.00016806781,0.000031243297],"category_scores_gemma":[0.0009496586,0.00010004769,0.00022634339,0.00006600034,0.00055748783,0.000034255463,0.000025215413,0.00017814348,0.0000036367428],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65398854,0.00025790205,0.0001471937,0.000013751782,0.0018663579,0.000014555113,0.001179623,4.6736435e-8,0.0000017288769,0.0018335106,0.00033043034,0.34036633],"study_design_scores_gemma":[0.979062,0.0022880351,0.003949366,0.000486853,0.00028038587,0.00007968525,0.00024869438,0.000092048664,0.00004000085,0.004708552,0.0086637465,0.000100632045],"about_ca_topic_score_codex":0.00016561257,"about_ca_topic_score_gemma":0.000038905353,"teacher_disagreement_score":0.34026572,"about_ca_system_score_codex":0.000007859449,"about_ca_system_score_gemma":0.00006974179,"threshold_uncertainty_score":0.40798265},"labels":[],"label_agreement":null},{"id":"W4394911994","doi":"10.1007/s40744-024-00660-7","title":"Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Ankylosing spondylitis; Post-hoc analysis; Medicine; Randomized controlled trial; Physical therapy; Inflammation; Clinical trial; Spondylitis; Internal medicine; Arthritis","score_opus":0.02612725016961004,"score_gpt":0.285099333464549,"score_spread":0.258972083294939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394911994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99612194,0.002213792,0.0000680943,0.00015242714,0.00021552586,0.0011137121,0.00006569374,0.000015483085,0.00003331637],"genre_scores_gemma":[0.997957,0.0016675886,0.000033029028,0.000056922276,0.000017048449,0.00014606229,0.00010968951,0.000011146625,0.000001495901],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978346,0.0011018025,0.00047098208,0.00025263027,0.00020258916,0.00013737309],"domain_scores_gemma":[0.9939176,0.005652594,0.00013606352,0.00018672923,0.000076985416,0.000030038833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011450263,0.00015169366,0.0010565106,0.00024321335,0.000061065744,0.000007727431,0.000035306683,0.00007103886,0.000027045515],"category_scores_gemma":[0.0005892091,0.00008301974,0.00023063604,0.0003240774,0.000163805,0.00004194695,0.000008626367,0.00015345022,6.607639e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76461244,0.00059229025,0.13198322,0.00006264848,0.003494507,0.00003694832,0.0013393867,0.000003958558,0.000003202935,0.0004751765,0.0000013508613,0.09739488],"study_design_scores_gemma":[0.7229864,0.0122651905,0.26169604,0.0013507279,0.0005857925,0.0000010958554,0.00016837064,0.00045095148,0.00018053099,0.00015179916,0.000061901854,0.00010116807],"about_ca_topic_score_codex":0.00017088401,"about_ca_topic_score_gemma":0.00007330406,"teacher_disagreement_score":0.12971282,"about_ca_system_score_codex":0.00001946234,"about_ca_system_score_gemma":0.000043938166,"threshold_uncertainty_score":0.33854467},"labels":[],"label_agreement":null},{"id":"W4396596535","doi":"10.1007/s40744-024-00662-5","title":"Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data","year":2024,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; Pfizer (Canada)","funders":"Celgene; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Biogen","keywords":"Medicine; Tofacitinib; Psoriatic arthritis; Ankylosing spondylitis; Rheumatoid arthritis; Internal medicine; Psoriasis; Mace; Risk factor; Dermatology","score_opus":0.10360238364189833,"score_gpt":0.4160644502500809,"score_spread":0.31246206660818254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396596535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009744792,0.9806458,0.000018258832,0.000025428772,0.00012303924,0.0028238518,0.0065966835,0.00001344057,0.000008742582],"genre_scores_gemma":[0.00086114305,0.99417007,0.00031750914,0.000007519622,0.00001516831,0.00025729925,0.004331694,0.00003587886,0.0000037293903],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979859,0.00016811378,0.0009670139,0.0005765215,0.00013246042,0.00016997088],"domain_scores_gemma":[0.99820864,0.0003215218,0.00073229073,0.0005330211,0.00013022717,0.00007431776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000259498,0.00036175543,0.0028738785,0.000082416846,0.00006479739,0.000007264865,0.000067106106,0.00013745116,0.000024041477],"category_scores_gemma":[0.00005619871,0.00019970926,0.00015506762,0.00012906163,0.0002831934,0.000045772627,0.00002555265,0.0001234031,8.1781127e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039469928,0.00046481105,0.009357163,0.046809446,0.0019999242,0.0000057786547,0.000051113147,9.689942e-10,1.901658e-9,0.00023188857,0.00003752867,0.94064766],"study_design_scores_gemma":[0.010752926,0.008360006,0.0012372383,0.33234903,0.006860434,0.00025051043,0.000029807778,0.0000027320887,3.8203225e-7,0.00014795602,0.63971984,0.0002891551],"about_ca_topic_score_codex":0.00001713503,"about_ca_topic_score_gemma":0.000018086488,"teacher_disagreement_score":0.9403585,"about_ca_system_score_codex":0.000016265938,"about_ca_system_score_gemma":0.00020941142,"threshold_uncertainty_score":0.8143907},"labels":[],"label_agreement":null},{"id":"W4399435000","doi":"10.1007/s40744-024-00672-3","title":"Regional Differences in Diagnosis Journey and Healthcare Utilization: Results from the International Map of Axial Spondyloarthritis (IMAS)","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"Novartis Pharma; Celgene; UCB Pharma; Pfizer; Eli Lilly and Company","keywords":"Axial spondyloarthritis; Medicine; Health care; Sample (material); Physical therapy; Cartography; Ankylosing spondylitis; Political science; Geography; Internal medicine; Physics; Sacroiliitis","score_opus":0.06497558158008217,"score_gpt":0.31370339809962555,"score_spread":0.2487278165195434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399435000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84123427,0.12316745,0.0000028432848,0.034898177,0.0003560588,0.00013760904,0.00013568386,0.00001356809,0.000054341082],"genre_scores_gemma":[0.8397404,0.15978585,0.000037582515,0.00026095664,0.000035315632,0.000028179418,0.00007435636,0.0000057570523,0.000031604675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99925095,0.00005375836,0.00025338,0.00021917239,0.00011426954,0.00010849891],"domain_scores_gemma":[0.9993067,0.00048513332,0.000047184756,0.000088190485,0.000035324323,0.000037459333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010431092,0.000098704775,0.00025590503,0.00006062034,0.00007605111,0.000018840772,0.000047818936,0.000076966615,0.00009638526],"category_scores_gemma":[0.000037002395,0.0000641393,0.000034592245,0.000068067406,0.00019262999,0.000044369357,0.000026658174,0.000117231015,0.0000029130726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089397456,0.00008733499,0.91385907,0.000024716459,0.00021748323,0.00010001913,0.0024781926,3.9076383e-8,0.0000074582335,0.006395607,0.0014860528,0.074450076],"study_design_scores_gemma":[0.0076051005,0.00044744625,0.94650316,0.0012916405,0.000020020649,0.0004091748,0.0009792146,0.00009722325,0.00008334601,0.0060053216,0.036448758,0.000109583365],"about_ca_topic_score_codex":0.00094961846,"about_ca_topic_score_gemma":0.0007207984,"teacher_disagreement_score":0.07434049,"about_ca_system_score_codex":0.000010739693,"about_ca_system_score_gemma":0.000039446084,"threshold_uncertainty_score":0.26155245},"labels":[],"label_agreement":null},{"id":"W4399671356","doi":"10.1007/s40744-024-00686-x","title":"Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial","year":2024,"lang":"en","type":"erratum","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"","keywords":"Ixekizumab; Ankylosing spondylitis; Medicine; Post-hoc analysis; Randomized controlled trial; Physical therapy; Spondylitis; Alternative medicine; Post hoc; Clinical trial; Internal medicine; Secukinumab; Pathology; Arthritis","score_opus":0.01737343005230877,"score_gpt":0.2766401411234276,"score_spread":0.2592667110711188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399671356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827311,0.0063071684,0.000030048406,0.00013438234,0.008196604,0.002067419,0.00021127514,0.00002403271,0.00029797663],"genre_scores_gemma":[0.99033237,0.007569431,0.000017530174,0.00009095731,0.00015085618,0.0004093238,0.0012255339,0.00003779393,0.00016623839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99612874,0.0018863544,0.0008795808,0.00049351255,0.00039365434,0.00021817799],"domain_scores_gemma":[0.99274194,0.0061415615,0.0005066473,0.00036175366,0.00019972584,0.000048382506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001412979,0.00036103587,0.0025315944,0.0004999413,0.000109015564,0.000013252882,0.00007100815,0.00033884836,0.000054732736],"category_scores_gemma":[0.0012469814,0.00020939899,0.000517913,0.0004933796,0.00027781955,0.00003513023,0.000020208596,0.000684228,0.0000013591495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8972008,0.00097319897,0.032377906,0.00018479564,0.0089224,0.00006405504,0.0011289526,0.0000033950396,2.3123405e-7,0.000082387494,0.0006723202,0.058389507],"study_design_scores_gemma":[0.87950313,0.023758259,0.08464341,0.006405925,0.002461651,0.0000034750353,0.00025864187,0.000458064,0.000028582432,0.00012304887,0.002075898,0.00027990268],"about_ca_topic_score_codex":0.00034269286,"about_ca_topic_score_gemma":0.00029190586,"teacher_disagreement_score":0.058109604,"about_ca_system_score_codex":0.000055201886,"about_ca_system_score_gemma":0.00015705214,"threshold_uncertainty_score":0.8539043},"labels":[],"label_agreement":null},{"id":"W4400007994","doi":"10.1007/s40744-024-00684-z","title":"Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma","keywords":"Secukinumab; Ixekizumab; Medicine; Axial spondyloarthritis; Matching (statistics); Radiography; Internal medicine; Radiology; Arthritis; Psoriatic arthritis; Pathology","score_opus":0.03613181706726756,"score_gpt":0.30800036190621094,"score_spread":0.2718685448389434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400007994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84339064,0.15470995,0.000014321416,0.0003461201,0.00053698325,0.00084317767,0.000089413064,0.00002143473,0.000047979203],"genre_scores_gemma":[0.9506188,0.049151514,0.00007296663,0.0000081210965,0.000018207347,0.00006951159,0.000016570573,0.000021031587,0.000023268098],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99890774,0.00007371665,0.00042103746,0.00025408654,0.00013796636,0.00020543413],"domain_scores_gemma":[0.9984194,0.0010520997,0.00016249981,0.00026962694,0.00005575475,0.000040625488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100063226,0.00021499283,0.00083562825,0.00013255142,0.00018292766,0.00000855651,0.00007649223,0.00012374582,0.000024129036],"category_scores_gemma":[0.000019071307,0.00011783904,0.00026279024,0.00026896078,0.00058846275,0.000027266737,0.000021876023,0.000092425704,4.87066e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02124593,0.002459891,0.066288255,0.0005045788,0.007133297,0.000028119104,0.020078788,0.000005265881,0.00060111005,0.0071279765,0.00015660877,0.87437016],"study_design_scores_gemma":[0.22552393,0.06032071,0.6081955,0.0035193276,0.003860195,0.001895112,0.00946002,0.0011156407,0.037516534,0.0041943924,0.043427225,0.0009714384],"about_ca_topic_score_codex":0.00034130272,"about_ca_topic_score_gemma":0.00015650764,"teacher_disagreement_score":0.8733987,"about_ca_system_score_codex":0.000018764784,"about_ca_system_score_gemma":0.000059685713,"threshold_uncertainty_score":0.48053363},"labels":[],"label_agreement":null},{"id":"W4400281428","doi":"10.1007/s40744-024-00677-y","title":"Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Amgen; Pfizer; AstraZeneca; Taichung Veterans General Hospital; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Internal medicine; Placebo; Post-hoc analysis; Erythrocyte sedimentation rate; Janus kinase inhibitor; Odds ratio; Rheumatology; Abatacept; Physical therapy; Pathology; Rituximab","score_opus":0.04824780470720594,"score_gpt":0.403260588564786,"score_spread":0.35501278385758006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400281428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89156836,0.10667901,0.000019962805,0.0008998368,0.000056909725,0.00052780757,0.00015783677,0.000017083741,0.0000732184],"genre_scores_gemma":[0.59599906,0.40391514,0.000016680631,0.000022443108,0.0000029297369,0.000009256524,0.000020519314,0.000009847844,0.000004143273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963471,0.0012978509,0.0015523797,0.0003176259,0.00022854142,0.00025644654],"domain_scores_gemma":[0.9918325,0.007280506,0.00030735316,0.00034195554,0.00012296677,0.000114695395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00441217,0.00020229118,0.002107231,0.0005919262,0.00004914741,0.000015615105,0.00010890849,0.00019810219,0.00046664473],"category_scores_gemma":[0.0016356067,0.000118617645,0.0005215196,0.00065909256,0.00081234344,0.000062967774,0.000032880947,0.00035180466,0.0000023690557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02805853,0.001014543,0.49136057,0.00013243414,0.014432992,0.000041591175,0.003107456,0.00001160142,0.004664606,0.023454374,0.00016480051,0.4335565],"study_design_scores_gemma":[0.025488108,0.008741791,0.9539307,0.0038421366,0.00010281747,0.00029482003,0.00086227857,0.0012761932,0.0020212934,0.001887099,0.0012390001,0.00031380213],"about_ca_topic_score_codex":0.00023859521,"about_ca_topic_score_gemma":0.000048474492,"teacher_disagreement_score":0.4625701,"about_ca_system_score_codex":0.0000098442015,"about_ca_system_score_gemma":0.00020596424,"threshold_uncertainty_score":0.51094323},"labels":[],"label_agreement":null},{"id":"W4400297889","doi":"10.1007/s40744-024-00678-x","title":"Gender Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Medac; Celltrion; Genentech; Celgene; Biogen; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Perception; Medicine; Family medicine; Disease; Psoriasis; Physical therapy; Psychology; Dermatology; Internal medicine","score_opus":0.024416752956582525,"score_gpt":0.305439583707307,"score_spread":0.2810228307507245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400297889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597571,0.03894475,0.0000117321415,0.00013385825,0.00015954848,0.00020912134,0.0005939596,0.000017377635,0.00017254778],"genre_scores_gemma":[0.93976974,0.059987612,0.00004142676,0.00003929854,0.000005784048,0.000028216775,0.00011338762,0.0000049987702,0.000009545811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931514,0.000072605566,0.00021001305,0.00022387759,0.000060086655,0.00011825296],"domain_scores_gemma":[0.99965763,0.00012830646,0.000035601563,0.00010186027,0.000016491547,0.000060091068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004059854,0.000110656634,0.00027583414,0.000059555146,0.00005054306,0.000013641955,0.000017364317,0.000028300647,0.000036780246],"category_scores_gemma":[0.0000148484,0.000082518454,0.00004294426,0.00011449726,0.00009356694,0.000050916286,0.00002110243,0.000058232334,0.0000042588536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095433224,0.000244638,0.85527307,0.000030664378,0.0005219502,0.000082152066,0.001056115,1.690519e-7,0.000003180468,0.0004275832,0.00012830325,0.14127785],"study_design_scores_gemma":[0.0028834683,0.00018715094,0.99315435,0.0004186195,0.000030054669,0.000024989371,0.0005278176,0.000086039334,0.0000012592908,0.0025518565,0.00007181139,0.000062597166],"about_ca_topic_score_codex":0.0014441637,"about_ca_topic_score_gemma":0.00063231407,"teacher_disagreement_score":0.14121525,"about_ca_system_score_codex":0.000020660775,"about_ca_system_score_gemma":0.000017746785,"threshold_uncertainty_score":0.3365005},"labels":[],"label_agreement":null},{"id":"W4400426358","doi":"10.1007/s40744-024-00696-9","title":"A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); University of Alberta","funders":"AbbVie Canada","keywords":"Medicine; Methotrexate; Rheumatoid arthritis; Internal medicine; Discontinuation; Tolerability; Rheumatology; Tapering; Infliximab; Antifolate; Prednisone; Concomitant; Surgery; Gastroenterology; Adverse effect; Tumor necrosis factor alpha; Antimetabolite","score_opus":0.015368373917730912,"score_gpt":0.28907250007372454,"score_spread":0.2737041261559936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400426358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8925897,0.104809836,0.000046873778,0.0011169097,0.000037975093,0.0011648966,0.000058423684,0.00009374151,0.00008164917],"genre_scores_gemma":[0.65146375,0.3479411,0.00015336437,0.0001688584,0.0000031066816,0.00013918606,0.00008381469,0.000030440273,0.000016392227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977521,0.0004714752,0.00040917858,0.0005148067,0.00024612516,0.0006063618],"domain_scores_gemma":[0.9989936,0.00022983058,0.00008839519,0.00023961636,0.00017257957,0.00027600577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078494474,0.0003050327,0.0008174343,0.00033806395,0.00015901712,0.000051097675,0.00007830382,0.00015499351,0.00057081453],"category_scores_gemma":[0.00017637512,0.00018270896,0.000054524622,0.00045883658,0.00019919912,0.00013993903,0.000012827959,0.00038919068,0.000015013194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015081976,0.000085635016,0.92195064,0.00021366942,0.00033780362,0.0002185065,0.00039396327,6.189835e-7,0.000061969935,0.00027715595,0.000056893074,0.074894965],"study_design_scores_gemma":[0.0103142895,0.0060211867,0.95213044,0.026615584,0.000013466867,0.0014567844,0.00016233507,0.0008784959,0.0002599915,0.00029485993,0.0013478443,0.00050473574],"about_ca_topic_score_codex":0.010615979,"about_ca_topic_score_gemma":0.017738223,"teacher_disagreement_score":0.24313128,"about_ca_system_score_codex":0.0002158481,"about_ca_system_score_gemma":0.00057516113,"threshold_uncertainty_score":0.9959724},"labels":[],"label_agreement":null},{"id":"W4400850096","doi":"10.1007/s40744-024-00694-x","title":"Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"AbbVie","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Adverse effect; Discontinuation; Safety profile; Refractory (planetary science); Surgery","score_opus":0.015729741154186416,"score_gpt":0.27883729372022265,"score_spread":0.26310755256603624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400850096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9395965,0.05743385,0.000020095664,0.0012403579,0.00010158767,0.0012806053,0.00011671243,0.00006741016,0.00014291608],"genre_scores_gemma":[0.8112827,0.18833312,0.00009492383,0.0001422376,0.000010094274,0.000040044062,0.000058587375,0.00002516695,0.000013151975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977464,0.00039710366,0.0006064301,0.0005827405,0.00026839034,0.00039895158],"domain_scores_gemma":[0.99735624,0.0019543888,0.00009327438,0.0003765153,0.00009779455,0.000121762554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050445495,0.00027452843,0.00072660425,0.0001350139,0.00016657171,0.00004750365,0.00014263985,0.0001375154,0.00006839483],"category_scores_gemma":[0.00035276188,0.00016204448,0.000048009337,0.00036995177,0.00040926808,0.00014955041,0.00006550459,0.00043012595,0.000013747145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016123759,0.0012594003,0.8047302,0.000025551584,0.0006567526,0.00004828585,0.010224377,0.0000013736985,0.00011577162,0.0005741066,0.0004714703,0.16576898],"study_design_scores_gemma":[0.022881469,0.0064734346,0.9281957,0.0013082168,0.0000036962215,0.00006163116,0.0010692717,0.000012422937,0.00010509245,0.0003787144,0.0392715,0.0002388366],"about_ca_topic_score_codex":0.0016248684,"about_ca_topic_score_gemma":0.0006195349,"teacher_disagreement_score":0.16553015,"about_ca_system_score_codex":0.000021423224,"about_ca_system_score_gemma":0.000114154886,"threshold_uncertainty_score":0.66079825},"labels":[],"label_agreement":null},{"id":"W4402454833","doi":"10.1007/s40744-024-00702-0","title":"Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; University of Saskatchewan; McGill University","funders":"Janssen Research and Development; National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriatic arthritis; Post-hoc analysis; Medicine; Post hoc; Phase (matter); Arthritis; Dermatology; Internal medicine; Chemistry","score_opus":0.02272486199969252,"score_gpt":0.3481809171652812,"score_spread":0.3254560551655887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402454833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392851,0.059312716,0.00015455157,0.00027083646,0.0000952053,0.00068410527,0.00011218444,0.000034350734,0.000050980376],"genre_scores_gemma":[0.98800135,0.011632454,0.00013311589,0.000061563594,0.0000147747205,0.000062300496,0.00002586401,0.000022847436,0.000045753677],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986751,0.00014393515,0.000519275,0.00024835434,0.00017769675,0.00023565064],"domain_scores_gemma":[0.99889964,0.0003648784,0.00026980927,0.00016517915,0.00023732417,0.0000631979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003386005,0.00020412516,0.0013049565,0.00014460535,0.00006838917,0.000013945737,0.00003874891,0.00007259987,0.000063328844],"category_scores_gemma":[0.00007594644,0.00012111537,0.00011312676,0.00018856153,0.00019700584,0.000068390116,0.00000868986,0.00009251522,0.000001684409],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10054145,0.004958041,0.22506742,0.0011443355,0.06714137,0.0016049976,0.0062857117,0.0000037981952,0.020213237,0.009727839,0.00020156262,0.56311023],"study_design_scores_gemma":[0.7812177,0.11139738,0.044231735,0.006561001,0.0051742196,0.0011176029,0.003976533,0.00027668956,0.040930547,0.0032414969,0.0008042441,0.0010708453],"about_ca_topic_score_codex":0.0004350619,"about_ca_topic_score_gemma":0.00006614824,"teacher_disagreement_score":0.6806763,"about_ca_system_score_codex":0.000018144323,"about_ca_system_score_gemma":0.00012538918,"threshold_uncertainty_score":0.49389413},"labels":[],"label_agreement":null},{"id":"W4402601491","doi":"10.1007/s40744-024-00715-9","title":"Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Observational study; Medicine; Internal medicine","score_opus":0.06738414713985798,"score_gpt":0.3545384091587891,"score_spread":0.28715426201893113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402601491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98267215,0.012287879,0.0000080152795,0.0008737164,0.00016721485,0.0022403733,0.00007535538,0.000049158945,0.0016261312],"genre_scores_gemma":[0.9834892,0.01583822,0.00013962263,0.00003318655,0.000014079047,0.00026453845,0.00008278322,0.000024201556,0.000114158705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800646,0.000614992,0.00044341295,0.00045796525,0.00022790254,0.00024925047],"domain_scores_gemma":[0.9970844,0.0023682658,0.000071865696,0.00031445277,0.000104201106,0.000056815585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012514895,0.00018244318,0.000574911,0.00013831281,0.00012962347,0.00007791252,0.00022104662,0.000080455546,0.00009243288],"category_scores_gemma":[0.00020641566,0.00011473018,0.000034635534,0.0004683462,0.00029176305,0.000185457,0.00010187672,0.0003312118,0.000009597139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015825357,0.0045500267,0.9106479,0.000102870385,0.00087554986,0.00011205369,0.0045009814,0.0000010912573,0.0055073653,0.03136843,0.00037062398,0.026137743],"study_design_scores_gemma":[0.022447763,0.0028532252,0.9549128,0.0013692108,0.0000056712447,0.000052608444,0.0005164921,0.00022621405,0.0026274824,0.013098346,0.0017273214,0.00016288216],"about_ca_topic_score_codex":0.0041487673,"about_ca_topic_score_gemma":0.0011750793,"teacher_disagreement_score":0.044264875,"about_ca_system_score_codex":0.000047466445,"about_ca_system_score_gemma":0.00022619893,"threshold_uncertainty_score":0.6271723},"labels":[],"label_agreement":null},{"id":"W4402851582","doi":"10.1007/s40744-024-00711-z","title":"Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Pfizer (Canada)","funders":"Pfizer; Eli Lilly and Company; Amgen","keywords":"Tofacitinib; Ankylosing spondylitis; Psoriatic arthritis; Medicine; Dermatology; Spondylitis; Internal medicine; Rheumatoid arthritis; Psoriasis; Physical therapy","score_opus":0.007827520775846628,"score_gpt":0.24537307695558855,"score_spread":0.23754555617974193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402851582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94563955,0.053288925,0.000008543276,0.00017779146,0.000101602294,0.00038884775,0.00028225948,0.000030143367,0.00008235304],"genre_scores_gemma":[0.95600086,0.043663703,0.00006564925,0.00006588301,0.00000445639,0.000017073939,0.00014452168,0.000019267203,0.000018602786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990085,0.000044761673,0.0002821459,0.00027986872,0.00011474058,0.00027000534],"domain_scores_gemma":[0.9995494,0.0001951933,0.000050296003,0.00010617979,0.00002847042,0.000070448616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007978037,0.00016481828,0.0004824949,0.00009942094,0.00007678598,0.000014769587,0.000019166067,0.00008912312,0.00018018336],"category_scores_gemma":[0.000026180234,0.00011560705,0.000023519244,0.00015640829,0.00017477079,0.00006931308,0.00001713357,0.00013094611,5.7186486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045899968,0.00017849679,0.68767536,0.00010055143,0.0004189018,0.00011249052,0.0009945041,9.135971e-8,0.000006429808,0.00049450883,0.000057872803,0.3053708],"study_design_scores_gemma":[0.041610494,0.0027384965,0.9369905,0.0029933446,0.00006979911,0.00029226844,0.00024075573,0.000015218738,0.00016658416,0.00020655176,0.014435439,0.00024052129],"about_ca_topic_score_codex":0.00011211233,"about_ca_topic_score_gemma":0.000035960755,"teacher_disagreement_score":0.3051303,"about_ca_system_score_codex":0.000020635269,"about_ca_system_score_gemma":0.00003733805,"threshold_uncertainty_score":0.47143188},"labels":[],"label_agreement":null},{"id":"W4403706766","doi":"10.1007/s40744-024-00714-w","title":"Disease Overlap, Healthcare Resource Utilization, and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A REVEAL Sub-study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Saint-Laurent","funders":"AstraZeneca","keywords":"Granulomatosis with polyangiitis; Eosinophilic; Disease; Medicine; Health care; Intensive care medicine; Dermatology; Internal medicine; Pathology; Vasculitis; Political science","score_opus":0.008011648819201663,"score_gpt":0.2404527020619614,"score_spread":0.23244105324275974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403706766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710924,0.02567198,0.0000073351075,0.002334165,0.0000317302,0.00072645966,0.00002994681,0.00006755016,0.000038433293],"genre_scores_gemma":[0.9949177,0.004586159,0.000009723339,0.00026153552,0.000005215466,0.00006092521,0.000112367285,0.000024010715,0.000022384404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990985,0.00009689046,0.00017748756,0.00031416153,0.00012514742,0.00018781121],"domain_scores_gemma":[0.9995509,0.000058861166,0.00003034702,0.00015638507,0.000043021697,0.00016048466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006726747,0.00014591984,0.000271397,0.00016365382,0.00013118629,0.000023769047,0.00002510438,0.00008493761,0.00001152178],"category_scores_gemma":[0.000008983747,0.00009569351,0.000021104677,0.0002652489,0.00013435542,0.0000659451,0.000010101357,0.0001794248,0.0000021273863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008501624,0.00029833653,0.986895,0.00009327144,0.00018237432,0.00013156747,0.0008458192,2.381239e-7,0.0000012325534,0.0018580385,0.000094045485,0.0087499],"study_design_scores_gemma":[0.005774789,0.0011023257,0.99068356,0.0011775873,0.00006110515,0.00019683118,0.00040992655,0.000029032775,0.0000036904025,0.00015508683,0.00028325059,0.00012279456],"about_ca_topic_score_codex":0.00018654738,"about_ca_topic_score_gemma":0.000102323604,"teacher_disagreement_score":0.02382528,"about_ca_system_score_codex":0.00002943117,"about_ca_system_score_gemma":0.000073359675,"threshold_uncertainty_score":0.3902268},"labels":[],"label_agreement":null},{"id":"W4403988753","doi":"10.1007/s40744-024-00719-5","title":"Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study","year":2024,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Université de Montréal; Pfizer (Canada); Université du Québec à Rimouski; McGill University; Memorial University of Newfoundland","funders":"Pfizer","keywords":"Tofacitinib; Rheumatoid arthritis; Medicine; Internal medicine; Physical therapy","score_opus":0.0038681404880064976,"score_gpt":0.22067613574712291,"score_spread":0.21680799525911643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403988753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8556247,0.1432206,0.000015730966,0.00009609099,0.00005880406,0.0008204132,0.000112105474,0.000016855513,0.00003470978],"genre_scores_gemma":[0.81053686,0.18935542,0.000004558593,0.00001156078,0.0000015918138,0.00004786398,0.000020523516,0.000018172383,0.000003452872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807304,0.0005733134,0.00030603877,0.00037952967,0.00027951272,0.00038859193],"domain_scores_gemma":[0.99917054,0.00020569851,0.000048211026,0.00030789227,0.00007151937,0.00019612456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077629887,0.00020313638,0.00072252366,0.00023434729,0.00019665655,0.000035434125,0.00008586583,0.00009378755,0.000042982498],"category_scores_gemma":[0.000055457338,0.00012911804,0.00011304662,0.000391584,0.00032544218,0.00009245253,0.00002705329,0.00028710597,0.0000014611195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005767301,0.00014667203,0.9471878,0.000045336503,0.0017937144,0.000035747627,0.0012293622,0.000002647352,0.000007062635,0.00031962604,0.0000144924215,0.048640855],"study_design_scores_gemma":[0.008548438,0.00064694526,0.98274773,0.000589592,0.00001783011,0.000117391864,0.0003435111,0.000059763024,0.000114200644,0.00018070608,0.006460279,0.00017359601],"about_ca_topic_score_codex":0.19025683,"about_ca_topic_score_gemma":0.08229448,"teacher_disagreement_score":0.10796235,"about_ca_system_score_codex":0.000054153752,"about_ca_system_score_gemma":0.00022353555,"threshold_uncertainty_score":0.9344512},"labels":[],"label_agreement":null},{"id":"W4406065091","doi":"10.1007/s40744-024-00731-9","title":"Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Observational study; Post-hoc analysis; Osteoarthritis; Adverse effect; Incidence (geometry); Placebo; WOMAC; Physical therapy; Internal medicine; Clinical trial; Alternative medicine; Pathology","score_opus":0.02623296896397935,"score_gpt":0.2799841190166003,"score_spread":0.25375115005262094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406065091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968627,0.0016898043,0.000030279904,0.000051272276,0.00012749647,0.0011615342,0.000004179444,0.0000071095164,0.0000655942],"genre_scores_gemma":[0.9995075,0.0002258094,0.00016262056,0.000021023277,0.0000027300002,0.000025594698,0.00004079482,0.0000046642886,0.000009291871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99921787,0.00011741104,0.00026952804,0.00015138196,0.00016825527,0.00007555141],"domain_scores_gemma":[0.99946296,0.00011100284,0.00010495163,0.0000852629,0.0002173263,0.000018514238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002774301,0.00008076562,0.00029009904,0.00012683126,0.00002826238,0.0000022715612,0.0000117523105,0.00008074577,0.000013945825],"category_scores_gemma":[0.00010233163,0.000064170614,0.000021344502,0.00010248297,0.00007268256,0.00005106303,0.000009347267,0.00004800912,1.6319112e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11183336,0.0015034688,0.36163443,0.000039181523,0.00008703494,8.2180617e-7,0.0004314286,0.0000047719413,0.0016744286,0.0006946742,0.0000013944119,0.522095],"study_design_scores_gemma":[0.3503751,0.013527517,0.6322757,0.00080704433,0.00009711407,0.000008379229,0.0000814094,0.0001267636,0.0021484557,0.00046899487,0.000020654013,0.00006290225],"about_ca_topic_score_codex":0.0000248712,"about_ca_topic_score_gemma":0.00006058691,"teacher_disagreement_score":0.5220321,"about_ca_system_score_codex":0.000022296073,"about_ca_system_score_gemma":0.00006813739,"threshold_uncertainty_score":0.26168016},"labels":[],"label_agreement":null},{"id":"W4408536924","doi":"10.1007/s40744-025-00751-z","title":"A Response to: Letter to the Editor Regarding Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials","year":2025,"lang":"en","type":"letter","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Tofacitinib; Post-hoc analysis; Rheumatoid arthritis; Post hoc; Medicine; Race (biology); Clinical trial; Internal medicine; Physical therapy; Gender studies; Sociology","score_opus":0.034747275011154606,"score_gpt":0.37721453177436554,"score_spread":0.34246725676321094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408536924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69182366,0.010432973,0.00002329208,0.2954183,0.00034325884,0.0014718414,0.00045381367,0.0000116336705,0.000021219752],"genre_scores_gemma":[0.7242274,0.21216074,0.000060472208,0.062885426,0.00030426457,0.0001314409,0.000111892456,0.000045216122,0.0000731144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9896563,0.006340386,0.0023628438,0.0006077331,0.00052107853,0.0005116108],"domain_scores_gemma":[0.9723288,0.025471997,0.0007748588,0.00096242956,0.00031808057,0.00014382887],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011215564,0.00044587138,0.003946422,0.0012716377,0.0001297864,0.000031435462,0.00039137475,0.00075732684,0.00021615083],"category_scores_gemma":[0.009770239,0.00024385538,0.00089541596,0.0010217547,0.00068855315,0.000046267778,0.00012728194,0.0015004765,0.0000037664026],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18272884,0.0004995925,0.031724826,0.00016027909,0.01864026,0.0001028164,0.0040143337,0.000025141162,0.0017846004,0.00034658663,0.6951185,0.064854234],"study_design_scores_gemma":[0.03849163,0.013118826,0.112987466,0.011966154,0.0002599758,0.00020079289,0.000693226,0.00009696732,0.0010137509,0.00025481777,0.820061,0.0008553626],"about_ca_topic_score_codex":0.00028893913,"about_ca_topic_score_gemma":0.00006366071,"teacher_disagreement_score":0.23253286,"about_ca_system_score_codex":0.00003302334,"about_ca_system_score_gemma":0.00041981088,"threshold_uncertainty_score":0.99857086},"labels":[],"label_agreement":null},{"id":"W4409190435","doi":"10.1007/s40744-025-00752-y","title":"Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents","year":2025,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Lupus nephritis; Disease; Medicine; Narrative review; Systemic lupus erythematosus; Intensive care medicine; Immunology; Internal medicine","score_opus":0.14399775121294558,"score_gpt":0.48083993668567243,"score_spread":0.3368421854727268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409190435","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059316372,0.9868387,0.000004114762,0.00042422762,0.0007115835,0.0058267075,0.000026792448,0.0000917024,0.00014453668],"genre_scores_gemma":[0.0003810885,0.9962423,0.00004393482,0.00040357796,0.000032360935,0.0021955923,0.00013162287,0.000057143716,0.00051238557],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942593,0.0023783294,0.0013414305,0.0009009031,0.00046287882,0.00065717456],"domain_scores_gemma":[0.9971208,0.0014562533,0.00051815296,0.0005318252,0.00014178967,0.0002311642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015922382,0.0007026654,0.004321878,0.00058305776,0.00020082368,0.000033457258,0.00034404185,0.00042346574,0.00036454864],"category_scores_gemma":[0.0005691222,0.00050104345,0.0004930498,0.0007744649,0.000246013,0.0000901621,0.00013349418,0.0010273682,0.00003609124],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017434529,0.00020061704,0.010130567,0.27264112,0.0008669517,0.00020673488,0.0015786012,4.8351257e-8,7.3778557e-7,0.000116474876,0.0018708431,0.712213],"study_design_scores_gemma":[0.005095814,0.0001996133,0.00003704018,0.59506184,0.00061399746,0.006304464,0.00033964822,0.000042333726,2.6019333e-7,0.00023848028,0.39156285,0.0005036676],"about_ca_topic_score_codex":0.00001944154,"about_ca_topic_score_gemma":0.000004326804,"teacher_disagreement_score":0.71170926,"about_ca_system_score_codex":0.0001884007,"about_ca_system_score_gemma":0.0012966398,"threshold_uncertainty_score":0.9997441},"labels":[],"label_agreement":null},{"id":"W4409255207","doi":"10.1007/s40744-025-00763-9","title":"Burden of Glucocorticoid Use and Risk of Toxicities Among Patients with Immunoglobulin-G4-Related Disease: A Retrospective US-Based Claims Study","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Amgen","keywords":"Glucocorticoid; Medicine; Retrospective cohort study; Disease; Antibody; Internal medicine; Immunology","score_opus":0.00373205175249349,"score_gpt":0.21559729271938205,"score_spread":0.21186524096688855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409255207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519324,0.0035590907,0.000007914904,0.000033799144,0.00006591801,0.0010046682,0.00005634943,0.000035564764,0.000043474647],"genre_scores_gemma":[0.9977358,0.0020879037,0.000014405394,0.00002612926,0.000001779617,0.000024418114,0.000026971658,0.000015331296,0.000067278954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881583,0.00015391492,0.00044016028,0.00026947164,0.00015419362,0.00016639587],"domain_scores_gemma":[0.998945,0.00017543786,0.0002805488,0.00029618197,0.00022229481,0.00008051461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100372694,0.00019542855,0.00062580826,0.00017031586,0.000092411356,0.000010087132,0.000055732646,0.00012275895,0.00004004051],"category_scores_gemma":[0.00009351215,0.00014170195,0.00006634249,0.00019556688,0.00052279374,0.00010823945,0.000023814691,0.00018137209,7.036706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057147145,0.0007045342,0.990275,0.0001409804,0.001366556,0.000011223934,0.0006639213,0.000030738945,0.00004928226,0.00050802744,0.000011969862,0.0005230337],"study_design_scores_gemma":[0.011172872,0.0013118199,0.9852841,0.00051459006,0.00037585705,0.0000017215734,0.00038837863,0.0002688589,0.00030076702,0.00024437933,0.000015445858,0.00012120061],"about_ca_topic_score_codex":0.0003432491,"about_ca_topic_score_gemma":0.000010544171,"teacher_disagreement_score":0.0054581575,"about_ca_system_score_codex":0.000017580593,"about_ca_system_score_gemma":0.0001348257,"threshold_uncertainty_score":0.5778438},"labels":[],"label_agreement":null},{"id":"W4410206040","doi":"10.1007/s40744-025-00768-4","title":"In-Person and Virtual Clinic Visit Frequency to Rheumatologists for Rheumatoid Arthritis at an Academic Medical Center Before, During, and After COVID Lockdown","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Rheumatology Research Foundation","keywords":"Coronavirus disease 2019 (COVID-19); Rheumatoid arthritis; Center (category theory); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Medicine; Family medicine; Physical therapy; Medical education; Internal medicine; Virology","score_opus":0.012851642142652499,"score_gpt":0.3207925192025876,"score_spread":0.3079408770599351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410206040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428162,0.050391197,0.00007343778,0.005247666,0.00021702606,0.0010542884,0.000043760905,0.00007812039,0.000078315825],"genre_scores_gemma":[0.7131672,0.28467587,0.00013275495,0.0015310948,0.00001043716,0.00029191992,0.000025016374,0.000028197604,0.00013751407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716496,0.0002200727,0.000709973,0.0008473092,0.00028271024,0.0007749878],"domain_scores_gemma":[0.9984057,0.00037010427,0.00009701966,0.00033689037,0.00007647142,0.0007138013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006920705,0.0003889658,0.0010191633,0.00048052307,0.00032112107,0.000045614823,0.00017614223,0.00060364755,0.0005140728],"category_scores_gemma":[0.000428241,0.00033636528,0.00008438343,0.0001986576,0.00083417265,0.00026023827,0.00014093934,0.0005928323,0.000021297163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005020551,0.00020638909,0.9517787,0.0001677608,0.00019161642,0.0001747842,0.0017758036,6.0116555e-8,0.00044727259,0.0053660385,0.0005222335,0.034348786],"study_design_scores_gemma":[0.05610224,0.0048977286,0.8877052,0.004653554,0.0000063711905,0.010639146,0.0010582205,0.00015411722,0.0011871273,0.009562672,0.02298804,0.0010455969],"about_ca_topic_score_codex":0.00019363358,"about_ca_topic_score_gemma":0.001068845,"teacher_disagreement_score":0.23428467,"about_ca_system_score_codex":0.00005684187,"about_ca_system_score_gemma":0.00019034804,"threshold_uncertainty_score":0.99990886},"labels":[],"label_agreement":null},{"id":"W4410928453","doi":"10.1007/s40744-025-00771-9","title":"A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Research and Development","keywords":"Secukinumab; Psoriatic arthritis; Medicine; Dermatology; Matching (statistics); Arthritis; Psoriasis; Internal medicine; Pathology","score_opus":0.007757000574110243,"score_gpt":0.25900967527913876,"score_spread":0.25125267470502854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410928453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819393,0.017194876,0.000007657642,0.00012285073,0.000086039014,0.00039091238,0.000008954316,0.000018857094,0.0002305548],"genre_scores_gemma":[0.9940992,0.0056505534,0.000096119846,0.00007725486,0.0000018990597,0.000026320291,0.000017949873,0.000009751484,0.000020943595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991965,0.00004953836,0.0002756107,0.000214343,0.00008929823,0.00017466715],"domain_scores_gemma":[0.9996129,0.00009396037,0.00009277679,0.00012815728,0.00003725048,0.00003492526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005464305,0.00014966792,0.00069685094,0.00015205092,0.00007481778,0.000005899018,0.000027284976,0.00010292502,0.000032010223],"category_scores_gemma":[0.000010646808,0.000114504684,0.000024700683,0.00016200637,0.00012941491,0.000036537866,0.000023807721,0.00012344451,8.7027274e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001647447,0.00050275854,0.93571895,0.000067976434,0.00037888144,0.000010557018,0.0015498424,3.2922003e-7,0.000004631549,0.00087083864,0.000038894104,0.05920891],"study_design_scores_gemma":[0.027544072,0.001010465,0.96927863,0.00059761957,0.000034914705,0.0000206141,0.00032794254,0.000012307382,0.000103319275,0.0007957778,0.00018177975,0.00009254033],"about_ca_topic_score_codex":0.00034454415,"about_ca_topic_score_gemma":0.0004567792,"teacher_disagreement_score":0.05911637,"about_ca_system_score_codex":0.000016358164,"about_ca_system_score_gemma":0.000030494577,"threshold_uncertainty_score":0.46693656},"labels":[],"label_agreement":null},{"id":"W4411959730","doi":"10.1007/s40744-025-00780-8","title":"The Efficacy and Safety of Single Injections of Hybrid HA in the Treatment of Symptomatic Knee Osteoarthritis: A Case Series","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Osteoarthritis; Medicine; Series (stratigraphy); Surgery; Alternative medicine; Pathology; Biology","score_opus":0.00967497359764782,"score_gpt":0.25288295560163165,"score_spread":0.24320798200398383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411959730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97410554,0.024563551,0.000005738661,0.00040111385,0.00007014286,0.00059719785,0.000011606295,0.0000075738167,0.00023755924],"genre_scores_gemma":[0.9885041,0.011290807,0.000051838655,0.000016731943,0.0000020023506,0.000047895992,0.000004415779,0.0000042855463,0.00007789993],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993693,0.00010071055,0.00028733845,0.00009834319,0.000044925593,0.0000993395],"domain_scores_gemma":[0.99923176,0.00046090066,0.00008537657,0.00017653026,0.000029645087,0.000015762784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010230811,0.00009473351,0.00034534594,0.000073132745,0.00010582489,0.000004053829,0.000025842754,0.00003531882,0.000005213877],"category_scores_gemma":[0.000022126904,0.00005290413,0.00004317676,0.00010746957,0.00029609757,0.000025680409,0.000007040613,0.00003611444,1.7381778e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055472488,0.002752523,0.06554249,0.00027378477,0.0006080156,0.00047367674,0.011846152,0.0000013788537,0.007733072,0.03509276,0.000018594083,0.87011033],"study_design_scores_gemma":[0.20180267,0.19293016,0.045282554,0.006238946,0.0012743182,0.1294506,0.040325783,0.00008260955,0.34097913,0.02825361,0.012579863,0.0007997663],"about_ca_topic_score_codex":0.0000653771,"about_ca_topic_score_gemma":0.00022435459,"teacher_disagreement_score":0.86931056,"about_ca_system_score_codex":0.000008417854,"about_ca_system_score_gemma":0.000036563604,"threshold_uncertainty_score":0.21573679},"labels":[],"label_agreement":null},{"id":"W4412505388","doi":"10.1007/s40744-025-00777-3","title":"Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Johnson and Johnson; Gilead Sciences; Yale University; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Psoriatic arthritis; Post-hoc analysis; Medicine; Disease; Post hoc; Psoriasis; Dermatology; Internal medicine","score_opus":0.019156977982540794,"score_gpt":0.32475580562745837,"score_spread":0.3055988276449176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412505388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805944,0.018269088,0.0000038712274,0.00038395514,0.00003173277,0.0006406042,0.00003540158,0.000018354067,0.000022625058],"genre_scores_gemma":[0.98070997,0.019082356,0.000016729144,0.0000772308,0.0000016586581,0.00007555864,0.000016056287,0.000006193323,0.000014263796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990262,0.000120460245,0.00023154382,0.00032126857,0.00007254865,0.00022799148],"domain_scores_gemma":[0.99936646,0.0002138856,0.000082681836,0.00020568246,0.000045427736,0.00008585999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001100888,0.00016818765,0.0008445601,0.00029042174,0.000090534675,0.0000074114178,0.00003119302,0.000058297162,0.000031643693],"category_scores_gemma":[0.00005624327,0.00011722886,0.000054095,0.00050371344,0.00017567024,0.000037985767,0.000028699951,0.0000841039,6.2631403e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013648209,0.0046746396,0.82913226,0.000029944189,0.0047468785,0.00022736726,0.0011922941,0.000001556345,0.00003674827,0.00016072912,0.0000035130709,0.14614584],"study_design_scores_gemma":[0.04134706,0.0045079915,0.9518205,0.00021615629,0.00087536837,0.000023353183,0.0008892211,0.00008347845,0.000037925292,0.00006852007,0.000022199516,0.00010821558],"about_ca_topic_score_codex":0.0002636742,"about_ca_topic_score_gemma":0.0007473494,"teacher_disagreement_score":0.14603762,"about_ca_system_score_codex":0.000012717304,"about_ca_system_score_gemma":0.00005492911,"threshold_uncertainty_score":0.4780454},"labels":[],"label_agreement":null},{"id":"W4414358510","doi":"10.1007/s40744-025-00788-0","title":"Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Bioinformatics Solutions (Canada); Memorial University of Newfoundland; NOSM University; University of Alberta; Université Laval; University of Saskatchewan","funders":"Johnson and Johnson","keywords":"Golimumab; Rheumatoid arthritis; Psoriatic arthritis; MEDLINE; Clinical trial","score_opus":0.004615602569895753,"score_gpt":0.22349841932752182,"score_spread":0.21888281675762605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414358510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95568675,0.03988189,0.0000018465179,0.0006908503,0.00019435724,0.00072165526,0.00043509758,0.000032860506,0.0023546878],"genre_scores_gemma":[0.87023246,0.12891963,0.00027659972,0.00022622492,0.000008058896,0.000037836056,0.00025271723,0.000021285212,0.000025170704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979725,0.000117462616,0.00073969376,0.00053300185,0.00015567124,0.00048167966],"domain_scores_gemma":[0.998945,0.0002935968,0.00017400272,0.00030523597,0.00009738299,0.00018475644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019892301,0.0003041283,0.0009804978,0.00036037184,0.00025642224,0.00002101429,0.0000640619,0.00017734378,0.000040610215],"category_scores_gemma":[0.000070782815,0.0002750913,0.000051082487,0.00031831543,0.000376788,0.00010129729,0.000038825696,0.00023927604,0.0000029140012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006176019,0.00024231718,0.76894754,0.000030123068,0.00044113194,0.00012306012,0.00085196894,5.7875e-7,0.000003772532,0.0076070162,0.00010439295,0.21547207],"study_design_scores_gemma":[0.06796084,0.0006896071,0.92139643,0.0042262734,0.000023141034,0.000057937643,0.00027568973,0.00001075983,0.00006903396,0.0016831636,0.0033419102,0.00026522376],"about_ca_topic_score_codex":0.15334696,"about_ca_topic_score_gemma":0.43930286,"teacher_disagreement_score":0.2859559,"about_ca_system_score_codex":0.00006729376,"about_ca_system_score_gemma":0.00023999532,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W4414651921","doi":"10.1007/s40744-025-00793-3","title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"AbbVie","keywords":"Randomized controlled trial; Clinical trial; Psoriasis; Adverse effect; MEDLINE","score_opus":0.0501710238633082,"score_gpt":0.3756606611824898,"score_spread":0.3254896373191816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414651921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9013587,0.09126388,0.00018078343,0.0036954824,0.00042875446,0.0025350337,0.00029165938,0.000022724556,0.00022295401],"genre_scores_gemma":[0.76689076,0.23218645,0.00031784197,0.0003197757,0.00003289463,0.00013248902,0.00006175247,0.000010095002,0.00004797159],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698037,0.0010889166,0.0012278832,0.00041376599,0.00008352321,0.00020556814],"domain_scores_gemma":[0.97517234,0.024041714,0.0003945507,0.0002498182,0.0000732063,0.00006835185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026683505,0.00021603891,0.002235401,0.000051748706,0.00025994098,0.000014690308,0.000053801738,0.00021672531,0.00001807324],"category_scores_gemma":[0.0045400243,0.00012925189,0.00021417237,0.00007733431,0.0007832343,0.000032070755,0.00004348305,0.00017529899,7.9511733e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43303654,0.0003761029,0.0039047755,0.00002595502,0.0034607423,0.0000069523257,0.0012016995,8.2431626e-8,0.0000082206925,0.0033001287,0.00045587262,0.55422294],"study_design_scores_gemma":[0.9113707,0.0011018305,0.06727076,0.0007655535,0.0006236143,0.00005743829,0.00063201564,0.00007032831,0.00013839753,0.010314367,0.007504365,0.00015065286],"about_ca_topic_score_codex":0.00024123598,"about_ca_topic_score_gemma":0.000084276355,"teacher_disagreement_score":0.5540723,"about_ca_system_score_codex":0.0000075002968,"about_ca_system_score_gemma":0.00007169276,"threshold_uncertainty_score":0.54351616},"labels":[],"label_agreement":null},{"id":"W4415614649","doi":"10.1007/s40744-025-00800-7","title":"Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Post-hoc analysis; Psoriatic arthritis; Post hoc; Clinical trial; Rheumatoid arthritis; Phases of clinical research","score_opus":0.00871651732288529,"score_gpt":0.2905204589120947,"score_spread":0.2818039415892094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415614649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144007,0.01668789,0.000023635832,0.0007140423,0.00003615266,0.00092559605,0.00012106307,0.000011639766,0.00003992754],"genre_scores_gemma":[0.9847094,0.01473926,0.00014411923,0.00019711432,0.000001040204,0.000118615186,0.000053635114,0.000007025195,0.000029791756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988315,0.00021528444,0.00039851604,0.0002820296,0.0000889575,0.00018372794],"domain_scores_gemma":[0.9992171,0.0003289997,0.000122054254,0.00017278819,0.000099313205,0.000059764592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030543742,0.00015201478,0.0011047673,0.0004063908,0.00008182669,0.000008383941,0.000029933615,0.00007915346,0.000044439956],"category_scores_gemma":[0.00023204902,0.00010970469,0.0000665333,0.00057211984,0.00010382903,0.000039010007,0.000024146908,0.00006135141,6.0334463e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046396643,0.00083012733,0.79067177,0.000024113711,0.0023236568,0.000013016094,0.0008220082,0.0000016497474,0.000042379572,0.00026283422,0.000020678935,0.15859112],"study_design_scores_gemma":[0.09342707,0.0051117595,0.89814794,0.0005375402,0.00049889495,0.000012789528,0.00037219498,0.000018439272,0.00016651725,0.00017482592,0.0013825239,0.00014950399],"about_ca_topic_score_codex":0.00014186434,"about_ca_topic_score_gemma":0.00033280786,"teacher_disagreement_score":0.15844162,"about_ca_system_score_codex":0.000011695926,"about_ca_system_score_gemma":0.000048287227,"threshold_uncertainty_score":0.44736275},"labels":[],"label_agreement":null},{"id":"W4415928440","doi":"10.1007/s40744-025-00802-5","title":"Effectiveness and Safety of Upadacitinib in Treating Oligoarticular and Polyarticular Psoriatic Arthritis: Primary Analysis from the UPJOINT-Study","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; ABB (Canada)","funders":"AbbVie","keywords":"Clinical trial; MEDLINE; Psoriatic arthritis; Disease; Rheumatoid arthritis","score_opus":0.005525044665966135,"score_gpt":0.2539336185536883,"score_spread":0.24840857388772217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415928440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93008125,0.068917625,0.00004843073,0.00027771294,0.00003334476,0.0005667439,0.000009903091,0.000010638316,0.00005436745],"genre_scores_gemma":[0.98172295,0.018030822,0.000079330894,0.00008331289,0.0000029325365,0.00006148342,0.000009460324,0.0000057501165,0.000003942349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989569,0.0002495399,0.0003008375,0.00027020441,0.00007119546,0.00015130767],"domain_scores_gemma":[0.9990832,0.0006142023,0.000066384135,0.00017680675,0.000026485659,0.000032916967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002689218,0.00014050664,0.00072194886,0.00010421425,0.00014228301,0.000010128226,0.00002578095,0.000064424814,0.000012039547],"category_scores_gemma":[0.000058919995,0.00009506923,0.000056671164,0.00030339582,0.00019069773,0.000031217704,0.00004094532,0.00008860607,3.2653998e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008060496,0.00026695695,0.9291405,0.000038256956,0.0023870324,0.000041286024,0.0013229263,0.0000010608701,0.00016481847,0.000349657,0.000001245557,0.065480195],"study_design_scores_gemma":[0.011850826,0.0003112109,0.984958,0.00032491016,0.00043104158,0.000028724651,0.0011769555,0.000050892962,0.00027715313,0.0004933177,0.000029374429,0.000067616405],"about_ca_topic_score_codex":0.0012737794,"about_ca_topic_score_gemma":0.00030185413,"teacher_disagreement_score":0.06541258,"about_ca_system_score_codex":0.000012681466,"about_ca_system_score_gemma":0.00002060797,"threshold_uncertainty_score":0.38768104},"labels":[],"label_agreement":null},{"id":"W4416994387","doi":"10.1007/s40744-025-00811-4","title":"Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; LEO Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Genentech; Children's Hospital of Philadelphia; Chugai Pharmaceutical; Amgen; Pfizer; Rheumatology Research Foundation","keywords":"Tofacitinib; Psoriatic arthritis; Rheumatoid arthritis; Clinical trial; Psoriasis","score_opus":0.011150234441843463,"score_gpt":0.2540121528060775,"score_spread":0.24286191836423401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416994387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95371145,0.043250583,0.00002498943,0.00046499044,0.0004865153,0.0014587191,0.0002797388,0.000041941294,0.00028108264],"genre_scores_gemma":[0.93018955,0.06886491,0.00012614416,0.00017095204,0.000012648787,0.00018787775,0.00041250204,0.00002828975,0.000007116411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766564,0.00049068395,0.0007097171,0.00052852824,0.0002527324,0.00035272073],"domain_scores_gemma":[0.99682856,0.0021103944,0.00034674123,0.00047536788,0.0001823612,0.000056568453],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046082216,0.00035001285,0.0009924013,0.00014458122,0.00025073378,0.000029509874,0.00012712379,0.00021061374,0.00003754114],"category_scores_gemma":[0.00027369,0.00025759096,0.00010121992,0.0004205585,0.00036553043,0.00012744367,0.000032750693,0.00028813852,0.000003037862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036133636,0.0010141538,0.52016544,0.00007493461,0.0011245271,0.000042127278,0.0010308648,0.0000022979063,0.00003095721,0.003991276,0.000059035214,0.43633074],"study_design_scores_gemma":[0.16726625,0.0026616089,0.82172036,0.0038101685,0.000039096223,0.00001636274,0.000341863,0.000015782134,0.0007003923,0.0024750794,0.00070360815,0.0002494073],"about_ca_topic_score_codex":0.0007095376,"about_ca_topic_score_gemma":0.0002017026,"teacher_disagreement_score":0.43608135,"about_ca_system_score_codex":0.00005224027,"about_ca_system_score_gemma":0.00011273316,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W4417329339","doi":"10.1007/s40744-025-00812-3","title":"Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Women's College Hospital; Toronto Western Hospital","funders":"Johnson and Johnson; Swedish Orphan Biovitrum; University of Pennsylvania; Biogen; Gilead Sciences; Amgen; Pfizer; Yale University; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Post-hoc analysis; Post hoc; Randomized controlled trial; Clinical trial; Cohort study; Placebo","score_opus":0.039729753033510104,"score_gpt":0.34537721506629826,"score_spread":0.30564746203278814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97293234,0.025786068,0.000005503234,0.00024009639,0.000039960785,0.00094152975,0.000030168529,0.000011684534,0.000012624726],"genre_scores_gemma":[0.88949525,0.11028442,0.000038848546,0.000050436916,0.0000022971244,0.00010084554,0.000022657296,0.0000038936137,0.0000013746064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817806,0.00048813937,0.00081637205,0.00026039686,0.00008391032,0.00017311513],"domain_scores_gemma":[0.9973042,0.0020621058,0.00035714326,0.00015978863,0.0000748543,0.00004188104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081447803,0.0001651648,0.0027763874,0.00047136156,0.00005557241,0.0000041623216,0.000037762016,0.00014371405,0.000013568376],"category_scores_gemma":[0.0009887266,0.00010337526,0.00018372312,0.0004438539,0.0005155504,0.000022357126,0.000022232221,0.00010239203,2.3949084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20272797,0.0010522085,0.51386976,0.000065871245,0.009314681,0.000029890076,0.0011499614,0.000003862293,0.00035265132,0.002372206,0.0000018464632,0.2690591],"study_design_scores_gemma":[0.14632432,0.0014948585,0.8492427,0.00079905416,0.00079388823,0.0000097219945,0.00010493397,0.00005884939,0.0005388646,0.00054847245,0.0000073925157,0.00007692747],"about_ca_topic_score_codex":0.000091153604,"about_ca_topic_score_gemma":0.000042187567,"teacher_disagreement_score":0.33537298,"about_ca_system_score_codex":0.0000066241087,"about_ca_system_score_gemma":0.000032011623,"threshold_uncertainty_score":0.4215521},"labels":[],"label_agreement":null},{"id":"W4417501165","doi":"10.1007/s40744-025-00810-5","title":"Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Ixekizumab; Clinical trial; Placebo; Action (physics); MEDLINE","score_opus":0.018256243702722115,"score_gpt":0.3018775763154586,"score_spread":0.2836213326127365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417501165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96493304,0.02917496,0.0000053907584,0.0038223881,0.000530727,0.0009163362,0.0004198772,0.00005333172,0.00014396917],"genre_scores_gemma":[0.92162126,0.07714812,0.00007541094,0.0007870917,0.00003266955,0.00008048966,0.00011104767,0.000016767319,0.00012716373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975015,0.00044331935,0.00081593636,0.00058335974,0.00016529659,0.0004905835],"domain_scores_gemma":[0.99634165,0.0028627245,0.00020539066,0.00039199844,0.00008112008,0.00011714742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064631173,0.0003298685,0.0011725472,0.00012303649,0.00034315835,0.000050099465,0.00010674455,0.00023662651,0.000042500393],"category_scores_gemma":[0.0010746587,0.00018020046,0.00009963133,0.00023746835,0.0005325328,0.00009020025,0.000113648515,0.00033004902,0.0000075321336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021374902,0.0007322254,0.6209311,0.00003836678,0.000939863,0.00032330886,0.0060375007,0.0000029535995,0.0003184825,0.0019037776,0.0016808135,0.3457167],"study_design_scores_gemma":[0.07332801,0.00071611913,0.8901518,0.0008982886,0.00010250848,0.0001409571,0.0021588912,0.000014164035,0.00047979792,0.0026606186,0.029071942,0.00027688366],"about_ca_topic_score_codex":0.0060408,"about_ca_topic_score_gemma":0.007228681,"teacher_disagreement_score":0.34543982,"about_ca_system_score_codex":0.000028853558,"about_ca_system_score_gemma":0.00013983749,"threshold_uncertainty_score":0.9131923},"labels":[],"label_agreement":null},{"id":"W7117152485","doi":"10.1007/s40744-025-00817-y","title":"Treatment Patterns and Clinical Outcomes for Patients Living with Active Giant Cell Arteritis in Canada","year":2025,"lang":"en","type":"article","venue":"Rheumatology and Therapy","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"AbbVie Canada","keywords":"Giant cell arteritis; Adverse effect; Disease; Inflammatory bowel disease; Vasculitis; Epidemiology","score_opus":0.0079639979188784,"score_gpt":0.2647403501134255,"score_spread":0.2567763521945471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117152485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981192,0.00033783686,0.000038600705,0.0009570091,0.00009691712,0.00031900514,0.000030292347,0.000005176257,0.00009598709],"genre_scores_gemma":[0.99124044,0.0083343955,0.00004509001,0.00022691271,0.0000016163132,0.000046276196,0.000019529312,0.000004520293,0.000081197024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954146,0.000030238356,0.00015085812,0.00014197749,0.000024996052,0.00011048747],"domain_scores_gemma":[0.99953,0.00031517027,0.000030860192,0.00006473771,0.000018834648,0.000040396983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000020232363,0.00007729853,0.00027569832,0.000034840832,0.00005334466,0.0000035146522,0.000012851526,0.00006282178,0.000015090459],"category_scores_gemma":[0.00001070027,0.00004910416,0.00002819147,0.000024259338,0.0000351375,0.000015637284,0.0000047550325,0.00006536598,1.5980768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007931802,0.00018506867,0.95542043,0.000015344245,0.00022457106,0.000011843427,0.00014473587,7.826668e-8,5.017058e-7,0.00011042276,0.000024200044,0.04378346],"study_design_scores_gemma":[0.0064393277,0.0005741018,0.99213535,0.00017371957,0.000030955303,0.000025403879,0.0002509031,0.00003488517,0.000010822851,0.000055655237,0.00021941151,0.00004948224],"about_ca_topic_score_codex":0.14083348,"about_ca_topic_score_gemma":0.3061497,"teacher_disagreement_score":0.1653162,"about_ca_system_score_codex":0.000042898548,"about_ca_system_score_gemma":0.00018981558,"threshold_uncertainty_score":0.8648878},"labels":[],"label_agreement":null},{"id":"W764221726","doi":"10.1007/s40744-015-0013-z","title":"The Tissue-Selective Estrogen Complex: A Review of Current Evidence","year":2015,"lang":"en","type":"review","venue":"Rheumatology and Therapy","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Raloxifene; Medicine; Placebo; Vasomotor; Osteoporosis; Estrogen; Internal medicine; Hormone therapy; Oncology; Breast cancer; Tamoxifen; Cancer; Alternative medicine; Pathology","score_opus":0.07359831280667199,"score_gpt":0.3990371314819447,"score_spread":0.3254388186752727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W764221726","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000088426015,0.99867386,0.000012823324,0.000044667246,0.00020181586,0.00086233625,0.000013170464,0.000008757241,0.00009416138],"genre_scores_gemma":[0.000051976604,0.99956876,0.000022411612,0.00003123988,0.000030128856,0.00011973683,0.0001051735,0.000029248373,0.000041350937],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981532,0.00062184973,0.0004945544,0.00036252989,0.00011800065,0.0002498461],"domain_scores_gemma":[0.99871624,0.00018045008,0.00044444113,0.00043064344,0.00014080812,0.0000874347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006322997,0.00032773332,0.0011592318,0.00003285585,0.00012129464,0.000009699918,0.00033691063,0.00035909773,0.0000055836763],"category_scores_gemma":[0.00015829099,0.00018873242,0.00024279114,0.0001362229,0.0003178487,0.0000026347361,0.00010144588,0.00030795566,0.000014168402],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000387989,0.00002997166,0.000013976006,0.012634991,0.0003879107,0.0000015398286,0.000010876229,1.664688e-8,0.000032957905,0.00042962187,0.0057966583,0.9806227],"study_design_scores_gemma":[0.00017869256,0.00036320338,9.820733e-7,0.027100267,0.0001578432,0.00038149633,0.0000019802371,2.8380273e-7,0.00012898173,0.00007516176,0.9714258,0.00018534959],"about_ca_topic_score_codex":0.0000051957186,"about_ca_topic_score_gemma":7.3648147e-7,"teacher_disagreement_score":0.98043734,"about_ca_system_score_codex":0.00001113122,"about_ca_system_score_gemma":0.00039356446,"threshold_uncertainty_score":0.76962847},"labels":[],"label_agreement":null}]}